Newsroom

austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq:hyft) (“mindwalk” or the “company”), a bio-native ai therapeutic research and technology company, today announced an application of its proprietary hyft® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequence-alignment-based analysis often fails to capture. using hyft® technology, mindwalk found a shared biological “signature” in influenza that stays consistent even when the virus’s genetic code changes a lot. this supports mindwalk’s approach to designing vaccine targets aimed at broader protection across strains and shows how hyft identifies meaningful similarities in biology even when molecules do not look alike at first glance. “functional adjacency is now one of the most under-appreciated risks in pharmaceutical r&d,” said jennifer bath, ph.d., chief executive officer of mindwalk. “if two molecules deliver the same biological effect, they may compete for the same patient, pursue similar regulatory labels, and undermine perceived differentiation even if their sequences appear unrelated. as ai accelerates protein design, teams can generate many distinct sequences that converge on the same functional outcome, increasing the likelihood of competitive overlap, ip vulnerability, and valuation compression. hyft is intended to help identify this convergence early by evaluating similarity at the functional level, not only at the sequence level.” the functional adjacency problem: an emerging ip risk for pharma functional adjacency, where distinct molecular entities produce the same biological effect despite limited or no sequence similarity, has emerged as a material legal, competitive, and valuation risk in pharmaceutical development. recent u.s. patent decisions have increased scrutiny on broadly drafted, functionally defined claim scope and underscore the need for disclosure and support proportional to what a patent claims. in amgen v. sanofi, the u.s. supreme court found certain broad, functionally defined antibody claims directed to pcsk9 inhibition invalid for lack of enablement, meaning the patent did not teach others how to make and use the full claimed scope without undue experimentation. the decision reinforced a critical reality for biologics, competitive overlap often follows functional equivalence, not sequence similarity, and durable patent protection requires enabling disclosure consistent with the breadth of the claim. similarly, in juno therapeutics v. kite pharma, the federal circuit found certain car-t claims invalid for lack of written description, meaning the patent did not adequately describe the full claimed class of binding elements. the court’s analysis highlighted the risk of claiming broad functional territory without sufficient support, such as representative examples and shared defining features, across the claimed range. together, these decisions reflect an industry shift: multiple molecules achieve the same therapeutic effect through different sequences sequence novelty alone often proves insufficient as a proxy for competitive or legal differentiation competitive landscapes, deal valuations, and ip strategies built primarily on sequence similarity may face increasing fragility as ai-driven protein design accelerates, this challenge intensifies. high-throughput platforms rapidly explore functional space and produce diverse sequences that converge on similar activity, creating blind spots in competitive intelligence and asset valuation when evaluation relies heavily on sequence similarity alone. functional adjacency is no longer theoretical; it is increasingly recognized as an economically material risk, and recent case law underscores its ip implications. hyft technology: functional intelligence beyond sequence alignment hyft technology is designed to help close this gap by identifying conserved functional patterns shaped by biophysical constraints such as structure, charge, and binding interactions, even when evolutionary relationships are unclear and sequence similarity is low. “hyft technology lets us step outside sequence thinking and identify a functional constraint influenza appears to preserve for infection,” said dirk van hyfte, md, ph.d., chief technology officer of mindwalk. in mindwalk’s influenza study, hyft-based analysis identified functional architecture that persisted despite viral mutation, showing how influenza can change its sequence while preserving features required for infection. the same principle applies to ai-designed therapeutics, where optimization can generate diverse sequences that converge on similar functional outcomes. hyft technology is designed to help organizations evaluate competition, ip exposure, and portfolio risk based on functional similarity, where clinical and commercial overlap often occurs. strategic implications for pharma and investors the influenza observation, together with mindwalk’s previously disclosed hyft-enabled dengue epitope program, shows hyft as a cross-pathogen platform for identifying conserved functional design rules in biology, even when targets look different at the sequence level. taken together, these programs support the view that hyft is not a single-asset discovery tool. it is positioned as a scalable strategic intelligence capability within mindwalk’s broader data management and biological reasoning platform. as deployed, hyft is intended to help pharmaceutical and biotechnology organizations: identify potential functional competitors earlier, including ai-designed or convergently evolved assets that sequence-based comparisons may miss strengthen in-licensing and m&a diligence efforts by assessing functional overlap, not only sequence similarity inform patent strategy under heightened scrutiny of function-based claims by grounding how functional space is characterized and supported improve r&d portfolio choices and capital allocation by prioritizing differentiated opportunities and identifying crowded functional areas earlier mindwalk plans to engage pharmaceutical, biotechnology, and other organizations to explore collaborations and commercial arrangements that deploy hyft-based functional intelligence across discovery, diligence, and portfolio decision workflows. this is designed to integrate with mindwalk’s end-to-end data platform, which unifies sequence, structure, function, and literature within a single operational framework. this approach is designed to shift organizations from backward-looking analysis to forward-looking functional decision-making, aligning scientific discovery, competitive intelligence, ip strategy, and capital deployment as ai accelerates therapeutic design. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “seeks,” “potential,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding: the interpretation and significance of observations derived from the application of the company’s hyft® technology; the identification, characterization, and relevance of conserved functional patterns and functional adjacency; the hypothesis that such patterns may support rational design toward broadly protective influenza immunogens; the relevance of functional adjacency to competitive intelligence, intellectual property strategy, business development, and portfolio decision-making; the intended role of hyft-based analysis in evaluating functional competition, ip exposure, or portfolio risk; the integration of hyft within the company’s broader data management and biological reasoning platform; the scope, timing, and outcome of potential future validation activities; and the company’s ability to pursue, structure, or complete strategic investments, collaborations, commercial arrangements, partnering transactions, or licensing opportunities related to hyft-based technologies or programs. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. forward-looking statements involve known and unknown risks, uncertainties, and other factors that cause actual results, performance, or achievements to differ materially from those expressed or implied. these factors include, among others: the preliminary and exploratory nature of computational analyses and in silico observations; limitations in available data, inputs, or analytical assumptions; the risk that subsequent laboratory, experimental, or validation studies do not replicate or support the reported observations; uncertainty regarding the biological relevance, robustness, or generalizability of identified functional patterns; risks inherent in therapeutic research and development, including challenges related to translation, validation, manufacturability, safety, immunogenicity, breadth, durability, or efficacy; the risk that future development decisions are delayed, modified, or discontinued; regulatory requirements and uncertainties; dependence on third-party collaborators, laboratories, service providers, and data sources; intellectual property risks, including the ability to obtain, maintain, defend, and enforce patent and other proprietary rights; competitive developments; the availability, timing, and terms of strategic investments or other financing alternatives; the ability to enter into, maintain, or enforce collaborations, partnering arrangements, or commercial agreements on acceptable terms; and broader economic, market, geopolitical, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

study demonstrates selective targeting of misfolded tdp-43 with relevance to amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease victoria, british columbia--(business wire)-- mindwalk holdings corp. (“mindwalk” or the “company”) (nasdaq: hyft) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic tdp-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease. this achievement, generated through mindwalk’s integrated discovery engines and research ecosystem, demonstrates the company’s ability to discriminate with structural precision between toxic protein conformations and their essential, healthy counterparts, a long-standing challenge in neurodegenerative disease drug development. by defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, mindwalk is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets. “this discovery is a direct validation of our platform strategy,” said dr. jennifer bath, president and chief executive officer of mindwalk. “we are not just discovering antibodies. we are identifying the disease-defining protein state and translating that insight into selective, validated assets with traceable biological evidence behind them. this is what platform-driven execution looks like in debilitating, life-threatening disease.” mindwalk has demonstrated its ability to generate disease-defining biological assets through the creation of monoclonal antibodies and intrabodies that selectively recognize misfolded, pathogenic tdp-43, a protein implicated in nearly all als cases and a significant portion of ftd and alzheimer’s disease cases. the defining feature of this work is selectivity: the ability to distinguish toxic protein conformations from their healthy counterparts, a key determinant of downstream development risk in neurodegenerative drug programs. beyond the specific biology, this work provides external validation of mindwalk’s platform capabilities in a client-driven setting. it demonstrates the company’s ability to systematically identify and characterize disease-driving protein states and translate that understanding into selective, evidence-linked biological assets. strategically, this strengthens mindwalk’s position as a trusted discovery partner for complex neurodegenerative programs and supports expanded opportunities for future collaborations, repeat engagements, and broader application of its platform across similarly challenging disease areas. “every molecule we characterize today strengthens our evidence base for what defines disease and what distinguishes healthy biology,” added dr. bath. “that compounding, evidence-linked learning is what defines a truly bio-native platform.” the full scientific study, “rational generation of monoclonal antibodies and intrabodies selective for pathogenic tdp-43,” is available on biorxiv (doi: 10.1101/2025.06.10.658846). about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by its patented hyft® technology and lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with a fully integrated wet-lab. the platform enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics to convert insight into validated candidates with speed and precision. forward looking statement this press release contains forward-looking statements within the meaning of applicable securities laws. forward-looking statements include statements regarding the significance of the discovery and validation described in this release, the company’s discovery capabilities and platform performance, the potential relevance or application of the monoclonal antibodies and intrabodies referenced, the ability to identify and characterize disease-driving protein states, the potential translation of preclinical findings into future research or development programs, and potential future collaboration, partnering, licensing, or commercialization opportunities. forward-looking statements are based on management’s current expectations and assumptions as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. these risks and uncertainties include, but are not limited to, the preliminary nature of scientific findings reported in a preprint that has not undergone peer review; the possibility that subsequent peer review, additional experiments, or further analysis may produce different or contrary results; scientific and technical challenges inherent in drug discovery and development; uncertainties regarding reproducibility, selectivity, safety, pharmacology, and manufacturability; uncertainties regarding the translation of preclinical findings into clinical outcomes; regulatory requirements and approval processes; the company’s reliance on third-party collaborators, clients, and partners; intellectual property risks and uncertainties; competitive developments; market and macroeconomic conditions; and the company’s ability to execute its strategy, secure resources, and manage growth. except as required by law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

validated across influenza a and influenza b, including h3n2 subclade k and zoonotic influenza a subtypes h5, h7, h9 austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq:hyft) (“mindwalk” or the “company”), a bio-native ai therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. using its patented hyft® deep data technology, mindwalk identified a functional pattern embedded in influenza biology that remains intact beneath surface-level genetic change. when mindwalk examines what does not change, it is not referring to conserved genetic sequences. it refers to preserved biological constraints; the biophysical requirements influenza must satisfy for infection. influenza remains a major global health threat because influenza viruses continually alter immune-exposed regions of surface proteins, eroding durable protection and forcing reactive vaccine redesign. current u.s. surveillance reflects unusually high influenza activity, described in public reporting as the highest level in approximately 25 years. why influenza keeps beating conventional vaccines most influenza research relies on tracking genetic variation. researchers align sequences, score similarity, and catalog mutations. these methods support surveillance, yet they often miss deeper functional constraints because they operate at the level influenza changes readily. mindwalk’s hyft® pattern technology works without sequence alignment, capturing multi-dimensional functional fingerprints that encode geometry, stability, and biophysical constraints. this reveals functional logic that remains stable even when sequence variation obscures it. this is a layer influenza is constrained from altering without loss of core function required for infection. validation across influenza a subtypes and influenza b lineages using its proprietary hyft pattern framework, mindwalk evaluated the identified functional constraint across influenza a and influenza b datasets spanning multiple hosts. the hyft-defined pattern was confirmed across currently circulating influenza a viruses, including viruses classified within h3n2 subclade k, a genetic subgroup under active global surveillance. the same strict functional pattern was also observed across avian influenza a datasets spanning subtypes h5, h7, and h9, indicating preservation of this constraint across both human and avian influenza backgrounds. mindwalk expanded this analysis beyond influenza a to include influenza b, evaluating representative references from both influenza b lineages, victoria and yamagata, and again observed the same strict hyft-defined functional pattern. in addition, assessment of a representative swine-origin influenza a h1n1 dataset yielded the same result. taken together, mindwalk has now identified this conserved hyft pattern across: influenza a in human datasets, including h3n2 and h3n2 subclade k influenza a in avian datasets, spanning subtypes h5, h7, and h9 influenza a in swine-associated datasets, including h1n1 influenza b across both victoria and yamagata lineages across the influenza datasets evaluated to date, mindwalk has not observed a different way for influenza to meet this functional requirement within the constraints analyzed. these results support the conclusion that the identified pattern reflects an evolutionary constraint shared across influenza a and influenza b, rather than a strain-specific or sequence-dependent feature. “influenza constantly rewrites its genetic script, but it remains tightly constrained by the physics required for infection,” said jennifer bath, ph.d., ceo of mindwalk. “our hyft technology allows us to identify those constraints and design directly against them.” from discovery to biological reasoning and rational vaccine design this advance builds directly on mindwalk’s prior work in rational vaccine design and further supports its bio-native ai and deep data approach. rather than predicting outcomes from incomplete inputs, mindwalk’s lensai™ platform, using the core hyft technology, captures and reasons over biological context, linking sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system. by reasoning directly from biological constraints, mindwalk aims to improve decision quality, reduce downstream failure, and increase the expected value of drug discovery programs. “influenza has been studied for decades, yet researchers kept looking at what changes instead of what does not,” said dirk van hyfte md, phd, chief technology officer of mindwalk. “hyft technology let us step outside sequence thinking and identify a functional constraint influenza must preserve for infection. once you see that layer, the problem stops being about prediction and starts being about design.” influenza program development and out-licensing strategy mindwalk intends to advance its influenza program through a phased, capital-efficient development pathway built around program-level segregation. platform-derived programs are structured as standalone development portfolios, allowing capital, risk, and decision-making to align with each individual asset while preserving the integrity of mindwalk’s core discovery platform. under this approach, the influenza program will progress through additional pre-clinical validation and ind-enabling work within its own dedicated portfolio. this structure is designed to support focused investment, clear value inflection points, and efficient governance as the program advances. following ind-enabling activities and sufficient pre-clinical de-risking, mindwalk plans to out-license the influenza program or enter into strategic development partnerships with global pharmaceutical companies with the scale and infrastructure to advance late-stage development and commercialization. mindwalk also expects to support discussions regarding potential strategic investments and other financing alternatives for the program. about mindwalk mindwalk is a bio-native ai therapeutic research and technology company. through its lensai platform and patented hyft technology, mindwalk generates proprietary biological pattern intelligence designed to support rational vaccine and therapeutic discovery. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “seeks,” “potential,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding the company’s influenza research findings and their interpretation; the identification, characterization, and relevance of hyft patterns; the scope of the company’s universal influenza program, including intended breadth across influenza a and influenza b and across seasonal and zoonotic strains; the initiation, design, timing, and results of planned wet-lab validation activities; the ability to translate the reported findings into immunogens, vaccine candidates, or other development assets; the ability to demonstrate immune accessibility, immunogenicity, safety, breadth, and durability in preclinical studies and, if pursued, clinical settings; the timing and outcome of future development decisions; and the company’s ability to pursue, structure, or complete strategic investments, financing alternatives, collaborations, partnering arrangements, or licensing transactions related to the program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. forward-looking statements involve known and unknown risks, uncertainties, and other factors that cause actual results, performance, or achievements to differ materially from those expressed or implied. these factors include, among others: the preliminary nature of computational analyses and in silico observations; limitations in available data, sampling, and surveillance inputs; the risk that laboratory studies do not replicate or validate the reported findings; uncertainty regarding whether the identified pattern is immune accessible or yields protective immune responses; risks inherent in vaccine discovery and development, including antigen design, formulation, delivery, manufacturability, stability, and scale-up; the risk that a candidate does not demonstrate acceptable safety, tolerability, immunogenicity, breadth, or durability in preclinical studies or clinical settings; the risk of viral evolution and immune escape that reduces effectiveness; regulatory requirements and uncertainties, including requirements for preclinical packages and clinical trial design; dependence on third-party manufacturers, laboratories, collaborators, suppliers, and other service providers; the need for additional capital and the availability, terms, and timing of strategic investments or other financing alternatives; the ability to enter, maintain, and enforce collaborations, partnering arrangements, or licensing transactions on acceptable terms; intellectual property risks, including the ability to obtain, maintain, defend, and enforce patent and other proprietary rights; competitive developments; and broader economic, market, geopolitical, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), bio-native ai company today announces the appointment of industry veteran r. scott areglado as chief financial officer (cfo), effective october 20, 2025. “scott’s extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team,” said dr. jennifer bath, mindwalk ceo. “his proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our bio-native ai platform globally.” mr. areglado brings more than 25 years of financial leadership experience across the healthcare, life sciences, and technology sectors, including extensive expertise in corporate finance, strategic planning, capital markets, and investor relations for publicly traded companies. he has a consistent record of strengthening financial operations, driving revenue growth, and supporting transformative transactions that deliver shareholder value. most recently, mr. areglado served as chief financial officer of brainsway ltd. (nasdaq: bway), a global medical device leader in interventional psychiatry. there, he helped redefine corporate strategy and led eight consecutive quarters of revenue growth while enhancing financial discipline and transparency. he also expanded analyst coverage and investor engagement, strengthening the company’s capital market presence. before joining brainsway, mr. areglado was chief financial officer at icad, inc. (nasdaq: icad), a medical technology company specializing in ai-driven cancer detection and therapy solutions. during his tenure, he successfully led multiple financings totaling more than $50 million, executed strategic partnerships, and supported a series of acquisitions that advanced the company’s product portfolio and market position. earlier in his career, mr. areglado held senior financial roles at amicas, inc. (nasdaq: amcs) and several emerging growth technology companies, where he developed deep expertise in sec reporting, m&a integration, and operational transformation. he began his career in public accounting and holds an mba from babson college and a bba in accounting from the university of massachusetts amherst. mr. areglado added, “mindwalk represents a unique opportunity to apply data-driven financial leadership in support of an organization poised to redefine how ai is applied in life sciences. i am excited to join the team and help advance both our strategic and financial goals as we build long-term value for shareholders.” annual general meeting results and board update mindwalk also announced the results of its 2025 annual general meeting of shareholders, held on october 9, 2025. each of dr. jennifer bath, jon lieber, and dirk witters was elected to the company’s board of directors, and davidson & company llp was re-appointed as auditor for the ensuing fiscal year. in accordance with the company’s majority voting policy, mr. kamil isaev, having received approximately 32% of votes in favor and 68% withheld for his re-election, has tendered his resignation to the board. the board has accepted mr. isaev’s resignation, effective immediately, and wishes to thank him for his valuable contributions to mindwalk’s transformation into a bio-native ai leader. mindwalk will file the complete voting results of the 2025 agm on sedar+ and on form 6-k with the u.s. securities and exchange commission. the board is initiating a search process to fill the resulting vacancy and will provide an update once a successor has been appointed, consistent with the company’s governance framework about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company today announced the appointment of industry veteran thomas w. lynch, ph.d. as chief business officer (cbo), effective october 20, 2025. “tom’s combination of biotech depth and software commercialization expertise directly supports mindwalk’s next path of growth,” said dr. jennifer bath ceo of mindwalk. “as we expand the reach of our hyft-powered deep data platform across pharma and biotech markets worldwide, tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value.” dr. lynch is an accomplished industry leader with over two decades of experience focused at the intersection of biotechnology and software innovation. dr. lynch has a strong track record in scaling global commercial organizations, launching high-impact products, and driving market adoption of advanced software and data platforms. his career spans technical sales, client services, and business development, where he has consistently delivered growth by combining deep scientific understanding with disciplined commercial execution. most recently, dr. lynch served as director of technical sales & scientific support at aldevron, where he built and led a new global commercial team, aligning strategies with scientific innovation and client needs. prior to that, as vice president of global sales and client services, dr. lynch spearheaded key initiatives including the introduction of clinical mrna manufacturing services and strategic account expansion that materially advanced aldevron’s market position. these efforts were instrumental in accelerating growth and positioning aldevron for its $9.6b acquisition by danaher life sciences in 2021. earlier in his career, dr. lynch led global commercial operations at dnastar, overseeing sales, distribution, and technical support while successfully launching software products that advanced protein structure prediction and analysis, such as novafold powered by i-tasser. his achievements underscore a proven ability to successfully bring complex scientific software and data platforms to market. dr. lynch also serves on the board of bioforward, wisconsin’s leading biohealth association, where he helped drive industry collaboration, education, and legislative initiatives across wisconsin’s biohealth sector. dr. lynch added: “mindwalk sits at the frontier of ai-native data intelligence in life sciences. i am excited to help accelerate the company’s growth trajectory by translating its powerful technology into solutions that drive measurable value for customers, partners, and investors alike.” mindwalk’s appointment of dr. lynch marks another step in executing its commercial strategy to broaden adoption of its bio-native ai platform, positioning the company to capture a growing share of the multibillion-dollar life sciences data analytics market. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding mindwalk’s appointment of dr. thomas w. lynch as chief business officer; the expected impact of this appointment on the company’s commercial strategy and growth trajectory; the scalability and adoption of mindwalk’s hyft® technology and lensai™ platform; and the company’s ability to expand its bio-native ai solutions across pharmaceutical and biotechnology markets. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks related to the execution of commercial and strategic initiatives; challenges in scaling ai-enabled software adoption in complex enterprise environments; scientific or technical development risks; market acceptance of the company’s technologies; competitive pressures; intellectual property protection; and general economic, regulatory, or geopolitical conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f for the fiscal year ended april 30, 2025, available on the company’s profiles at www.sedarplus.ca and www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

company builds on earlier glp-1 success with breakthrough ai-led insights into aging biology -- targeting the widely projected $60b longevity therapeutics market hyft®-driven discovery supports co-administration of mindwalk’s proprietary companion therapeutic with the company’s glp-1 receptor agonist austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company, today announced a major advancement of its ai-designed glp-1 therapeutics program. new insights from the company’s lensai™ platform reveal a previously unrecognized connection between glp-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. the findings support a first-in-class dual-pathway regimen in which mindwalk’s proprietary companion therapeutic is co-administered with its glp-1 receptor agonists (glp-1ras) to engage both mechanisms in concert. to the company’s knowledge, no approved or marketed drugs use this regimen. the companion therapeutic is a mindwalk-exclusive asset and is not a repurposed or co-branded product. this strategic evolution builds directly on mindwalk’s earlier success designing glp-1ras entirely in silico and positions the company to address the high-growth longevity therapeutics market, widely projected to exceed $60 billion by 2030. key takeaways expansion builds directly on mindwalk’s previously announced glp-1ra success. lensai™ identifies a complementary longevity-linked pathway and guides a proprietary companion therapeutic designed to be administered alongside mindwalk’s glp-1ras. regimen is first-in-class to the company’s knowledge and engineered for preventive, chronic use. strategy aims to enhance efficacy, durability, and long-term adherence. platform enables repeatable, in silico design and optimization of combination therapeutics in high-growth markets. redefining the scope of glp-1 therapeutics with bio-native ai using hyft®, mindwalk’s patented first-principles discovery engine, lensai™ mapped conserved biological patterns that link glp-1 signaling to adaptive resilience in metabolism, inflammation balance, and cellular stress response. in parallel, lensai™ identified a complementary regulatory node—kept undisclosed while validation and protection activities proceed—that interfaces with these same longevity-relevant processes. together, these insights form the basis of a novel dual-pathway regimen designed to maintain the benefits of glp-1 while broadening impact on healthspan outcomes. unlike traditional black-box ai tools, lensai™ provides explainability, biological traceability, and full lineage tracking designed to support regulatory review of ai-informed decisions throughout discovery and development. “glp-1 drugs have already transformed diabetes and obesity care, but their potential as healthspan medicines is only beginning to be recognized,” said dr. jennifer bath, ceo of mindwalk. “by applying hyft® and lensai™, we are not simply iterating on existing drugs—we are uncovering first principles that enable the design of safe, durable glp-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway. to our knowledge, this represents a new route in longevity medicine and a direct evolution of our earlier success, showing how our bio-native ai platform creates repeatable, high-impact programs in preventive health.” scientific foundation: a confidential, complementary longevity pathway leveraging mindwalk’s patented hyft® patterns—universal biological fingerprints that encode conserved sequence-structure-function relationships—lensai™ integrated sequence models, structural predictions, and knowledge-graph reasoning to highlight a second, non-overlapping pathway that operates alongside glp-1 in maintaining cellular robustness. while specific target details remain undisclosed, this hyft-anchored analysis indicates that coordinated engagement of both mechanisms may help sustain high-quality signaling, moderate stress responses, and reinforce metabolic balance over time—key aims for healthspan-oriented, chronic therapies. the regimen is engineered to sustain high-quality glp-1 signaling while engaging complementary resilience processes implicated in healthy aging. mindwalk has initiated intellectual-property protection around the companion therapeutic and regimen design. recent progress and forward strategy earlier this year, mindwalk reported that its ai-designed glp-1 peptides matched or exceeded semaglutide—a global market leader—in receptor activation assays. those sequences were discovered, selected, and optimized entirely in silico using lensai™, marking a major milestone in scalable, data-driven drug discovery. building on that foundation, the company is now advancing a dual-pathway program that includes: ai-optimized, long-acting glp-1 analogs for durable, patient-friendly dosing; a mindwalk-exclusive companion therapeutic directed at a longevity-linked, non-overlapping pathway for regimen-level co-administration; in silico exploration of dose, schedule, and sequence design to inform preclinical evaluation of the proprietary combination; incorporation of aging biomarkers and healthspan endpoints into discovery and preclinical prioritization; and mindwalk expects to provide updates on lead selection for the companion therapeutic, preclinical combination design parameters, and potential development paths for the regimen in the coming quarters. “this announcement reflects the scalability of mindwalk’s bio-native ai platform and its ability to address high-value therapeutic categories with speed and scientific rigor,” said dr. dirk van hyfte, cto of mindwalk bv. platform scalability: beyond a single mechanism the dual-pathway glp-1 program exemplifies the scalability and repeatability of mindwalk’s approach. the same hyft®-driven framework is being applied across additional therapeutic areas—including oncology, immunology, and vaccine design—enabling a multi-program pipeline built from a single, explainable ai foundation. mindwalk’s platform is used by leading biopharma partners and supports multi-program discovery across modalities. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s expansion of its glp-1 receptor agonist program toward longevity and healthspan medicine; the anticipated benefits of applying hyft® technology and the lensai™ platform to metabolic and aging biology; the development and potential of a co-administered proprietary companion therapeutic engaging a complementary longevity pathway; the potential for next-generation glp-1 therapeutics to achieve outcomes beyond glycemic control; and the scalability and repeatability of the company’s bio-native ai approach across therapeutic areas. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks inherent in drug discovery and development; challenges in validating preclinical findings in clinical settings; regulatory approval requirements and uncertainties; market adoption dynamics in longevity and metabolic medicine; competitive developments in glp-1 and adjacent therapeutic classes; intellectual property protection; reliance on third-party partners; and broader economic, geopolitical, or regulatory shifts. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

an evolution in name, structure, and strategy reflecting the company’s ai-driven platform and bio-native discovery vision austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), immunoprecise antibodies ltd. and its subsidiaries (biostrand and talem) today announced a unification under a single corporate brand, mindwalk, and a change of its nasdaq ticker symbol to hyft. the new identity conveys the company’s evolution into a bio-native ai platform business built at the intersection of ai, multi-omics data, and advanced laboratory research. “today is an evolutionary step forward,” said dr. jennifer bath, president and chief executive officer of mindwalk. “inspired by darwin’s thinking path, mindwalk is about seeing what others can’t—patterns hidden in biology that point to better medicines. our role is to convert that insight into impact, uniting science, computation, and responsible experimentation to change the pace of care.” mindwalk: a new era in bio-native ai-powered discovery inspired by charles darwin’s daily walks along his “thinking path” — where he questioned convention and advanced new theories — mindwalk carries that spirit forward. it represents a modern extension of that philosophy: a transformative, pattern-seeking journey through the complexity of biology, powered by the combined strengths of ai, data and advanced lab research. now operating as a bio-native ai company, mindwalk reimagines discovery by intelligently integrating data across formats and disciplines—turning information into dynamic biological meaning. by making biological diversity computable, mindwalk unifies this data into a single, structured system that accelerates discovery with depth and direction. at the core of this transformation is the company’s lensai™ platform powered by hyft® technology, built to redefine how biologics are discovered and developed. drug discovery, unified—from idea to impact. this brand evolution is also a business transformation. mindwalk is expanding beyond specialized wet-lab services to commercialize an intelligence-platform model—amplifying discovery, enabling recurring saas offerings, creating generative asset opportunities, and supporting scalable partnerships across the pharmaceutical ecosystem. key business highlights: unified brand identity: immunoprecise antibodies (ipa) together with its subsidiaries biostrand and talem are now unified as mindwalk, a single brand under the umbrella of mindwalk holdings corp. business model shift: transitioning from standalone wet-lab services to an integrated, scalable platform company model — launching daas, saas offerings, enhancing asset generation, and enabling large-scale partnerships new nasdaq ticker: “hyft” — replacing “ipa” to reflect the foundational role of hyft ® technology in the company’s ai stack “mindwalk is the first to make biological diversity truly computable — integrating multi-modal data into a structured system that drives insight with clarity, speed, and depth,” added dr. bath. for more information visit: mindwalkai.com about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s name change and ticker symbol transition to “hyft,” the anticipated benefits of rebranding under the mindwalk ai identity, projected scalability and adoption of the hyft® technology and lenai™ platform, and the company’s strategic shift toward a unified, ai-native discovery model. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: operational challenges in executing the rebrand and technology consolidation; risks associated with platform scalability and ai integration; scientific or technical validation hurdles; evolving market adoption dynamics in the saas and biologics r&d sectors; economic, geopolitical, or regulatory shifts; and customer or partner response to the new corporate structure. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mab) responses. austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. building on its june announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its lensai™ platform powered by patented hyft® technology, the company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralization analysis. the manufactured product will be used in proprietary immunization protocols at ipa’s canadian facility. these studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mab) responses—a crucial step toward translational development. “this is the natural next step in our journey from ai discovery to real-world validation,” said dr. jennifer bath, ceo of immunoprecise. “we’ve shown that hyft technology can identify vaccine targets that others miss — unique targets that are conserved, specific, and immunologically relevant. now we’re now moving into manufacturing and live immunization studies, where the question becomes: can this target elicit a powerful and protective antibody response? this is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases.” the science behind the step: ai discovery → manufacturing: hyft-guided analysis revealed a discontiguous dengue epitope conserved across all four virus serotypes. validated safety & immunogenicity: in silico screens confirmed immune activation potential (b- and t-cell responses), structural stability, and comprehensive safety against host proteomes. now entering immunization studies: the product is being synthesized and will be used in rabbit models to assess whether it elicits specific monoclonal antibodies — an essential proof point for vaccine development. a platform approach, not just a vaccine: this progression highlights ipa’s end-to-end advantage: combining ai-native discovery with in-house wet-lab validation. with regulators like the u.s. fda encouraging predictive, human-relevant approaches that reduce reliance on animal testing, immunoprecise’s in silico-to-in vivo workflow represents a forward-looking model for next-generation vaccine r&d. by applying the same methodology across pathogens, ipa is positioning its lensai/hyft platform as a versatile discovery engine — not only for dengue, but also for other infectious diseases and immuno-oncology targets. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutics company focused on the discovery and development of next-generation biologics. the company combines scientific expertise with proprietary technologies—such as its lensai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. ipa supports global partners in advancing novel therapeutics, diagnostics, and translational research. for more information, visit www.ipatherapeutics.com. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the company’s advancement of its universal dengue vaccine initiative, the anticipated benefits of its proprietary hyft® and lensai™ platforms, the potential for its vaccine candidate to generate protective monoclonal antibody responses, and the broader applicability of its ai-native discovery platforms to infectious diseases and immuno-oncology. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks inherent in preclinical studies and vaccine development; uncertainties in manufacturing, immunization, and virus neutralization testing; execution risks related to ai-driven discovery and translational validation; the pace and accuracy of scientific and technological innovation; competitive dynamics in biologics and vaccine r&d; customer and partner adoption rates; and shifts in economic, market, or regulatory conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its netherlands-based subsidiary, immunoprecise antibodies (europe) b.v. (“ipa europe”), to avs bio for a total enterprise value of $12 million usd. avs bio, a portfolio company of arlington capital partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. the transaction generated $11.7 million usd in net proceeds on a cash-free, debt-free basis. this transaction marks a meaningful step in ipa’s strategic refinement—streamlining its operational footprint, strengthening its balance sheet, and allowing the company to concentrate resources on its most impactful growth areas. the proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs. “this transaction delivers strong value to ipa and our investors,” said dr. jennifer bath, president and ceo of immunoprecise antibodies ltd. “it reflects our disciplined strategy to focus resources on our ai-based software as a service (saas) platform—where we’re combining scientific expertise with advanced technologies to accelerate modern biologics discovery. we’re proud of the business we’ve built in the netherlands and confident it will continue to thrive under avs bio’s ownership.” ipa’s global operations span biologics discovery, engineering, and characterization, supported by lensai™, the company’s proprietary platform powered by hyft® multi-omics technology. lensai helps unify and interpret complex biological data, enabling more integrated insights and smarter decisions across the discovery and development process. by harmonizing data across modalities, the platform supports faster identification of opportunities and reduces inefficiencies that typically slow biologics innovation. the sale was conducted through a competitive, arm’s-length process. a 12-month transition services agreement (tsa) will provide continuity across key functions during the transition. ipa holds no material ongoing relationship with avs bio or its affiliates beyond the scope of the transaction. edgemont partners served as exclusive financial advisor to ipa. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutics company focused on the discovery and development of next-generation biologics. the company combines scientific expertise with proprietary technologies—such as its lensai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. ipa supports global partners in advancing novel therapeutics, diagnostics, and translational research. for more information, visit www.ipatherapeutics.com. about avs bio headquartered in norwich, ct, avs bio is a global provider of specific pathogen-free (spf) laboratory products and services that support the development and manufacture of vaccines, therapeutics, and biologics. the company supplies leading manufacturers with critical bioprocessing inputs including spf eggs, antigens, and antibodies, and also offers diagnostic testing and gmp support services. avs bio operates more than 20 facilities across north america and europe and is a portfolio company of arlington capital partners. for more information, visit www.avsbio.com. about arlington capital partners arlington capital partners is a washington, d.c.-area private investment firm specializing in government-regulated industries. the firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. since its inception in 1999, arlington has invested in over 175 companies and is currently investing out of its $3.8 billion fund vi. for more information, visit arlington’s website at www.arlingtoncap.com and follow arlington on linkedin. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding the anticipated benefits of the divestiture of ipa europe, the company’s strategic focus on its ai-native platforms, projected scalability and market adoption of its lensai™ platform, and the impact of reinvestment into data-driven, biologics discovery technologies. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: operational challenges in transitioning the divested business; execution risks related to ai-driven platform scaling; the pace and accuracy of scientific and technological innovation; changes in competitive dynamics within saas and biologics r&d markets; customer adoption rates; and shifts in economic, market, or regulatory conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@ipatherapeutics.com avs bio & arlington capital partners ryan fitzgibbon pro-arlington@prosek.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a bio-native ai pioneer operating where techbio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its lensai™ immunogenicity screening can reliably predict anti-drug-antibody (ada) risk for therapeutic proteins before they enter animal studies or human trials. “ada-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,” said dr. jennifer bath, president & ceo, ipa. “with lensai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.” late‑stage ada failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑mhc ii binding across a few dozen hla alleles—leaving large swaths of immune diversity untested and immunogenic “self/non‑self” checks largely unaddressed. lensai’s hyft‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. it evaluates nearly 900 hla variants and performs a whole‑proteome “humanness” scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. by revealing design‑level fixes before expensive animal studies or repeat gmp production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. study highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ada dataset to predict immunogenicity risk single composite score tracks clinical reality – enables reliable ada incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ada in patients). the discriminative capability is very powerful as indicated by an auc=0.92. alignment-free, hyft-powered engine – the proprietary screening algorithm combines state-of-the-art mhc ii binding with ipa’s proprietary hyft® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. detailed amino acid and epitope-level immunogenicity “self” scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. read the full case study: [link] about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward looking statements within the meaning of applicable united states and canadian securities laws. forward looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. examples include statements regarding the projected performance, scalability, and market adoption of the company’s lensai™ immunogenicity screening; the ability of its hyft® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ada prediction on biopharma r&d efficiency; and the company’s broader scientific, commercial, and capital markets objectives. forward looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results could differ materially from those expressed or implied because of factors beyond the company’s control, including the pace of scientific and technological innovation in ai driven drug discovery, the accuracy and regulatory acceptance of in-silico ada risk screening, competitive shifts as the industry transitions away from ms dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. if any of these risks materialize, the company’s actual results, performance, or achievements could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on forward looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a bio-native ai company operating at the intersection of techbio and next-generation drug discovery, today announced the appointment of jeff fried to its advisory board. a recognized leader in healthcare data infrastructure and ai innovation, jeff fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. he currently serves as director of platform strategy and innovations for intersystems, where he helps shape high-performance data solutions for some of the world’s most demanding healthcare and life sciences environments. he has served on advisory boards for industry, government, and academia, and served as cto for teloquent (acquired by syntellect), empirix (acquired by infovista), and ba insight (acquired by upland software), as well as product leadership roles at fast search and microsoft. mr. fried has been an enthusiastic advocate for ipa’s lensai™ platform, praising its ability to unify biological sequence, structure, function, and scientific literature into a searchable, ai-ready framework. he has played a pivotal role in supporting biostrand’s partnership with intersystems to integrate advanced vector search capabilities into lensai—helping unlock powerful new possibilities for ai-driven research, diagnostics, and therapeutic development. “we are excited to welcome jeff to our advisory board at a time when our vision for a scalable, bio-native ai infrastructure is rapidly becoming a reality,” said dr. jennifer bath, ceo of ipa. “jeff’s insights at the intersection of healthcare data architecture and ai-enabled discovery are invaluable as we continue to expand lensai’s capabilities and reach across life sciences.” “lensai is one of the most exciting ai platforms i’ve encountered in the life sciences space,” said fried. “it solves a foundational problem—making biological data interoperable and computationally accessible at scale. i’m thrilled to contribute to ipa’s vision and help shape the future of bio-native ai drug discovery.” fried’s appointment underscores ipa’s commitment to enabling discovery work at the speed of computation, not convention, by providing the bio-native ai infrastructure the life sciences industry truly needs—fast, scalable, and grounded in real biological data. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the company’s strategic direction, the company’s future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in ai and biotechnology; and other risks inherent to the company’s industry and business model. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a company operating at the convergence of techbio and biological intelligence, today announced that it has received formal notification from the nasdaq stock market llc (“nasdaq”) confirming that the company has regained compliance with nasdaq listing rule 5550(a)(2), concerning the minimum bid price requirement. the notice, dated july 11, 2025, stated that for the 10 consecutive business days from june 26, 2025, through july 10, 2025, the closing bid price of the company's common shares was at or above $1.00 per share. as a result, immunoprecise has satisfied the requirements for continued listing on the nasdaq capital market, and the matter is now closed. “this compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native ai,” said dr. jennifer bath, ceo of immunoprecise. “we’re building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. the recent momentum in our share price is a strong signal of support for that vision.” through its proprietary lensai™ platform powered by hyft® technology, immunoprecise is reimagining how biological data can be modeled and deployed at scale. the lensai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere. our integrated framework enables unprecedented zero-shot discovery scenarios where lensai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. this unique bio-native ai approach captures functional meaning rather than structural patterns, enabling new capabilities across r&d from drug and vaccine discovery to systems biology and positioning ipa at the frontier of techbio innovation. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is advancing bio-native™ ai at the intersection of biology and computation. the company’s lensai™ and hyft® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the company’s strategic direction, the company’s future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in ai and biotechnology; and other risks inherent to the company’s industry and business model. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2024, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

new benchmark confirms lensai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), an ai-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, lensai, powered by ipa’s patented hyft® technology. the newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. “it’s generally assumed that ai can only make accurate predictions if it has seen similar data before,” said dr. jennifer bath, ceo of immunoprecise. “but this benchmark proves otherwise: lensai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. not the antibodies. not the targets. not the complexes. and the predictions aligned with wet-lab results. this is a major breakthrough in generalizing ai for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. it shows that ai doesn’t always need massive data to be powerful and accurate - it just needs the right kind.” lensai epitope mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. unlike traditional methods that take months and require lab work, lensai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. in a new benchmark study, lensai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. despite having no prior exposure to these molecules, lensai achieved prediction scores nearly identical to those from its original training data. this score, known as auc (area under the curve), is a widely accepted measure of accuracy in computational biology. the consistent performance on entirely new, unseen complexes confirms that lensai’s artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. this breakthrough demonstrates lensai’s power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. why this benchmark matters in the new study, lensai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. what it means for partners and investors with lensai already embedded in collaborations across big pharma and biotech, immunoprecise is scaling access through secure apis and custom partnerships. the platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of ai-driven antibody therapeutics. for more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of lensai epitope mapping. the first highlights performance on a “seen” target, where the system was trained on related data. the second - featured in this press release - demonstrates lensai’s breakthrough ability to accurately map binding sites on a completely “unseen” target, with no prior exposure to the antibody, the antigen, or their structure. new case study:lensai epitope mapping on an “unseen” target[ link] previous case study:head-to-head benchmark on a “seen” target[ link] these examples underscore how lensai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the lensai™ and hyft® platforms; the generalizability of the company’s ai models to novel therapeutic targets; the role of ai in accelerating antibody discovery; and the company’s future scientific, commercial, and strategic developments. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for ai-driven therapeutic platforms. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

follow-up to june 5, 2025, announcement demonstrates validated vaccine candidate with strong translational potential austin, texas--(business wire)-- immunoprecise (nasdaq: ipa), a leader in ai-driven biotherapeutics, provides a significant update following its june 5, 2025, press release immunoprecise announces ai-driven breakthrough in universal dengue vaccine discovery. this new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. “this is a major step forward,” said dr. jennifer bath, ceo of immunoprecise. “our ai technology not only found a new target for a universal dengue vaccine, but we’ve now shown it’s safe and can trigger the right immune response. with this validation, we’re excited to move ahead and advance this candidate toward the next stages of vaccine development.” following the recent discovery of a unique “achilles’ heel” shared by all four types of dengue virus, immunoprecise has confirmed—using its patented hyft technology and lensai immunogenicity screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. this breakthrough may pave the way for a safer, more universal dengue vaccine. the new target was discovered using the company’s proprietary lensai platform. “our ability to move from computational discovery to ai-guided immunogenicity validation is unique to our methodology and drug development,” commented dr. jennifer bath, immunoprecise ceo. “further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.” for decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn’t guarantee protection from the others. many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. what makes this development so important is that immunoprecise’s target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both b cells and t cells, in a manner that appears safe and highly specific. immunoprecise’s latest ai-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body’s defenses in a very precise way, without the risks of traditional, broader approaches. a methodology that changes the game—far beyond dengue what sets immunoprecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. with lensai powered by hyft technology, ipa brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. by revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design. the findings for dengue showcase the platform’s versatility. because hyft technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping ipa to tackle a wide spectrum of infectious diseases, from hiv and influenza to emerging pathogens and oncology targets. with this approach, immunoprecise isn’t just keeping pace with the field; it’s setting a new standard for how next-generation therapeutics are discovered and validated. immunoprecise's patented hyft technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (denv-1 through denv-4). this target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine. this hyft-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3d shape. this advanced mapping process combines genetic similarity analysis with 3d structural modeling and functional annotation to identify the most promising vaccine targets. key technical findings complete immune response testing computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (b cells) and infection-fighting cells (t cells) would respond to the vaccine target. the target site showed strong predicted binding to multiple human immune system markers (hla class i and ii types). this suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment. safety verification against human proteins using immunoprecise's proprietary retrieve-and-relate technology at the core of hyft™ ( van hyfte et al., 2023, biorxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. this comprehensive safety check goes beyond standard comparison methods—hyft systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. this is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. no problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells. structural stability analysis advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. stability testing demonstrated that the target remains robust under normal physiological conditions. balanced immune response profile importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. this balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ade)—a serious complication that can worsen dengue infection. looking ahead this release is the second in a series of disclosures aimed at showcasing the power of immunoprecise’s end-to-end ai-native platform. the june 5th announcement introduced a promising target; today’s release provides the crucial next step: a rigorous validation of that target’s safety and immunological relevance. this validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation. these findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. ipa is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the lensai™ and hyft® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of ai-native approaches for dengue and other infectious diseases; and the company’s ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. these factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of ai designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

breakthrough in ai-powered drug discovery validates hyft™-driven peptide design, with broad potential across multiple therapeutic areas austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa), a leader in ai-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (ai)-designed glp-1 receptor agonist (glp-1ra) peptide sequences achieve comparable or superior receptor activation to semaglutide, a benchmark glp-1 therapy and one of the most commercially successful drugs in the world. the in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. the results validate the power of ipa’s lensai™ platform and its proprietary hyft™ technology, which enables first-principles-based in silico peptide discovery and optimization. five rationally engineered peptide sequences—ai-optimized for improved stability and peptidase resistance—were tested against benchmark glp-1 analogs in receptor activation assays. two lead candidates outperformed or matched semaglutide under controlled assay conditions. crucially, the sequences were not discovered by chance. they were designed using hyft-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. with glp-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that ai can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same hyft-driven approach. “this is not a one-off success,” said dr. jennifer bath, ceo of immunoprecise. “we’ve demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. hyft-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. it represents a foundational shift in how therapeutics are discovered. the same lensai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with glp-1.” ipa is now considering two complementary preclinical paths for its lead glp-1 candidates: injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. the sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. the significance of this breakthrough extends far beyond glp-1. the same ai framework and hyft-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. this announcement follows ipa’s recent success with ai-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. about immunoprecise antibodies ltd. immunoprecise (nasdaq: ipa) is a global leader in ai-powered biotherapeutic discovery and development. its proprietary hyft™ technology and lensai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. ipa partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the lensai™ and hyft® platforms; the advancement and regulatory acceptance of ai-native drug discovery methods; the continued development and potential preclinical or clinical progression of ipa’s ai-designed glp-1 peptide program; the feasibility of next-generation delivery strategies; and the company’s ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of ai-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

lensai™ powered by hyft® technology identifies a single multi-factorial target conserved across all dengue serotypes. austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary lensai™ platform powered by their patented hyft® technology. this discovery, made using several proprietary hyft-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. this discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the company’s newly launched, hyft pattern-patented ai-native vaccine discovery engine. dr. jennifer bath, immunoprecise antibodies ceo commented, “this breakthrough highlights a new frontier in ai-driven biology—where discovery is rooted in the biology of a virus itself. by confirming that our sequence-derived patented hyft patterns match structural signatures across all dengue serotypes, we’re setting the stage for a universal vaccine design framework. ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. more importantly, the implications appear to stretch far beyond the dengue virus. this is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.” building on this success in dengue, ipa now intends to extend its ai-driven vaccine design platform to other high-impact infectious diseases, for example, hiv, norovirus, and an improved rsv vaccine. early-stage assessments are also underway to explore the platform’s application in oncology for neoantigen vaccine development and tumor-specific epitope mapping. this discovery underscores ipa’s commitment to advancing drug discovery through innovative, human-relevant ai technologies that align with evolving industry standards. using hyft’s patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the company’s proprietary lensai platform identified a unique epitope shared across all four serotypes of the dengue virus—denv-1, denv-2, denv-3, and denv-4. these serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. unlike traditional trial-and-error methods, ipa’s discovery was achieved entirely in silico, demonstrating the platform’s power to translate complex biological data into actionable vaccine design. breaking the dengue barrier: patented hyft-powered ai achieves what decades of science could not why has a universal dengue vaccine been so elusive? dengue is not just one virus—it’s four distinct, rapidly-evolving serotypes. immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. for decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus’s rapid mutation and complex immune interactions. traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale. confirmed breakthrough: sequence and structural hyft match across all four serotypes ipa’s discovery is a landmark moment in computational vaccinology. using its proprietary lensai™ platform powered by their patented hyft® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes—a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. this achievement marks a critical milestone in the quest for a universal dengue vaccine. what sets this apart is the depth of validation: · patented hyft patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural hyfts across all four dengue serotypes. · this was made possible through lensai’s integration of over 20 million proprietary structural hyfts (s-hyfts), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints. · the validation demonstrates that lensai doesn’t simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-em. this milestone affirms the patented hyft technology’s unique ability to traverse the full biological hierarchy—from dna/rna sequence to molecular structure to therapeutic relevance. it signals that ai-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research. the end-to-end lensai platform integrates patented hyft® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. the result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. these statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the lensai™ and hyft® platforms; the advancement and regulatory acceptance of ai-native drug discovery and vaccine development methods; the expansion of ipa’s discovery engine to additional infectious disease and oncology targets; and the company’s ongoing ability to maintain scientific, regulatory, and commercial momentum. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events. actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the company’s control. such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information regarding risks and uncertainties is included in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly from those currently anticipated. readers are cautioned not to place undue reliance on these forward-looking statements. except as required by law, the company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the lensai™ platform, with a direct comparison to gold-standard wet-lab methods. the results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. lensai’s ai-powered platform was able to match the performance of x-ray crystallography—the industry’s most precise but slowest and most expensive method—using sequence data alone. "in an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn’t a luxury—it’s a necessity," said dr. jennifer bath, ceo of ipa. "with lensai, we’re demonstrating that ai is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work." in the benchmarking study, lensai’s in silico epitope mapping application was tested across five known antibody-antigen pairs and against multiple experimental techniques, including hdx-ms, alanine scanning, and x-ray crystallography. the ai system produced predictive scores (auc 0.79–0.89) comparable to or exceeding those achieved by leading wet-lab methods, while reducing turnaround time from weeks to hours. epitope mapping is a cornerstone of antibody development, informing everything from ip strategy to candidate selection. traditionally, this requires expensive, time-consuming lab work using scarce protein samples. lensai transforms this by delivering early-stage epitope insights from sequence alone, reducing both cost and risk. this breakthrough aligns with growing regulatory and industry momentum around new approach methodologies (nams), including the fda’s recent decision to phase out animal testing requirements for biologics. by eliminating the need for physical materials and enabling near–x-ray-level precision, lensai advances ethical, scalable, and high-resolution approaches to biotherapeutic discovery we view this achievement as a meaningful advancement that enhances the capabilities of drug discovery platforms" added dr. bath. "lensai is now capable of providing pharma and biotech partners with validated, in silico answers to questions that once required months of wet-lab commitment." this latest achievement marks a major step in the broader development of lensai, ipa’s ai-driven discovery platform. building on previous releases, including in silico antibody engineering, epitope prediction, and multi-omics integration, lensai continues to demonstrate its ability to deliver high-resolution, scalable insights across key stages of biotherapeutic discovery. today’s advancement in epitope mapping reflects the growing power of the platform we have been strategically building — connecting sequence-based precision, accelerated timelines, and deep scientific insight to transform the future of therapeutic development. to read the full case study: lensai epitope mapping matches x-ray crystallography about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as "expects," "intends," "anticipates," "believes," or variations thereof, or state that certain actions, events, or results "may," "will," "could," or "might" occur. these statements relate to, among other things, the anticipated benefits, scalability, and adoption of the lensai platform, the broader application of hyft®-based tools, the advancement of ai-native drug discovery methods, and the company’s ability to maintain regulatory alignment and commercial traction. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory changes and acceptance, competitive dynamics, ip protection, platform integration challenges, and financial and operational risks. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law. investor relations contact louie toma managing director, core ir investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) a leader in ai-driven biotherapeutics, today announced its strong support for the u.s. food and drug administration’s (fda) recent decision to phase out animal testing requirements for monoclonal antibodies and other pharmaceutical products. the fda’s announcement marks a significant advancement in regulatory modernization and aligns fully with immunoprecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary ai platform, lensai™. “this policy shift reflects a growing global recognition that traditional animal models are often inadequate in predicting human biology,” said dr. jennifer bath, ceo of immunoprecise antibodies. “ipa has long championed the transition toward more ethical, efficient, and accurate methodologies. our ai-powered lensai™ platform and suite of integrated discovery tools were designed precisely to support this new era of translational science.” ipa provides validated ai-driven methodologies that directly align with the fda's shift towards new approach methodologies (nams). these advanced tools effectively address critical drug development challenges, including safety, toxicity, immunogenicity, and efficacy, by leveraging sophisticated predictive capabilities: 1. safety and toxicity prediction: ipa’s lensai platform utilizes ai analytics to accurately predict potential toxicities by mapping drug interactions across the human proteome, significantly reducing the reliance on animal models. 2. immunogenicity screening: the platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient-specific strategies. 3. knowledge graphs for drug efficacy: ipa’s semantic knowledge graphs integrate biological data and scientific literature, enabling precise predictions of drug efficacy and interactions in human systems. through transitioning from animal testing to ai-driven methodologies, ipa aims to streamline preclinical workflows, reduce development costs, uphold higher ethical standards, and support regulatory compliance in line with the fda’s nams framework. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of ipa’s ai-driven methodologies, the integration of lensai and biostrand’s platforms into drug discovery, and the potential impact of regulatory shifts on ipa’s business and product development. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

programs to be driven through patented ai technology and advanced proprietary b cell platforms partnership advances next-generation adcs and bispecific antibodies to address unmet medical needs austin, texas - immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of antibody-drug conjugates (adcs) and bispecific antibodies for the treatment of cancer. this collaboration focuses on leveraging contract research expertise while integrating ipa’s proprietary b-cell select™ platform and artificial intelligence-driven discovery capabilities to enhance the efficiency and precision of therapeutic development. under the terms of the agreement, the partnership will encompass the discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, with a focus on developing highly selective and effective cancer treatments. ipa’s proprietary multi-omics ai-driven modeling and discovery platform, combined with its b-cell select™ technology, will be integrated at key stages to optimize therapeutic selection and accelerate lead development. the agreement, valued at an initial $8 million with the potential to expand to $10 million based on program progression, will span 18 to 24 months, integrating artificial intelligence across the workflow to enhance discovery and optimization. this collaboration aims to streamline the path from target discovery to preclinical candidate selection, marking a significant step toward advancing next-generation biologics for cancer treatment. “this partnership underscores the power of combining ai-driven discovery with advanced antibody engineering,” said dr. jennifer bath, ceo of immunoprecise antibodies. “with the purchase order secured and work already underway, we are actively leveraging our proprietary b-cell select™ platform and lensai™ technology to accelerate the development of highly targeted cancer therapeutics. this collaboration highlights ipa’s role in shaping the future of next-generation biologics with data-driven precision and efficiency.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of the collaboration, the integration of ai-driven workflows into drug discovery, and the potential impact of the partnership on advancing adc and bispecific antibody development. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to scientific and technological developments, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a global leader in ai-powered antibody discovery and development, today announced a strategic collaboration with ribopro, a pioneering technology provider specializing in mrna and lipid nanoparticle (lnp) technologies. this collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating ribopro’s advanced mrna-based antigen expression expertise with ipa’s in silico and wet-lab antibody discovery capabilities. the collaboration leverages ribopro’s expertise in mrna sequence optimization and lnp-based delivery with ipa’s advanced b-cell screening, single-cell analysis, and deep-learning ai-driven discovery workflows. together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery. transforming antibody discovery with mrna technology the success of generating therapeutic lead antibodies towards complex antigens using traditional immunization-based discovery platforms may be hampered by challenges associated with the proper expression of these antigens. by leveraging ribopro’s proprietary mrna and lnp technologies, this partnership enables precise, efficient antigen expression, thereby facilitating potentially more effective immune responses and possibly accelerating the path to discovering novel antibody therapeutics. “partnering with immunoprecise antibodies enables us to push the boundaries of mrna-based immunization for therapeutic antibody discovery,” said sander van asbeck, ceo of ribopro. “by integrating our expertise in mrna design and nanoparticle delivery with ipa’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen expression, bringing forth new possibilities for precision therapeutics.” driving innovation in ai-powered antibody discovery ipa’s approach combines advanced ai-driven analytics with highly specialized wet-lab methodologies to design and optimize antibodies with the highest clinical relevance. the integration of mrna immunization into ipa’s workflow is expected to further enhance the precision and efficiency of their antibody discovery pipeline. “we are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mrna immunization platform in this alliance,” said dr. ilse roodink, cso of immunoprecise antibodies. “combining ribopro’s and ipa’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.” about ribopro ribopro is a netherlands-based technology and service provider specializing in mrna and lipid nanoparticle (lnp) technologies. founded in 2020, ribopro develops and manufactures high-quality mrna and lnps while offering innovative solutions, including sequence optimization algorithms and a proprietary lnp platform. these technologies are designed to enhance immune responses, improve safety profiles, and enable targeted mrna delivery beyond the liver. ribopro provides cmo, cdmo, and cro services to biotech and pharmaceutical companies seeking next-generation solutions for mrna therapeutics. for more information, visit www.ribopro.eu media contact: silvy van tuijl, chief of staff, ribopro | info@ribopro.eu |+31 85 060 67 62 about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutic research and technology company specializing in ai-driven antibody discovery and development. through its subsidiaries—including talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v.—ipa delivers an end-to-end solution for the development of next-generation antibody therapeutics. the company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets. for more information, visit www.ipatherapeutics.com investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the collaboration between immunoprecise antibodies ltd. (“ipa”) and ribopro, the potential for mrna-based antigen expression to enhance antibody discovery and development, and the ability of the partnership to accelerate the creation of novel immunotherapies. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024, (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas--(business wire)-- immunoprecise antibodies (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of kamil isaev to its board of directors and joseph scheffler as interim chief financial officer (cfo). additionally, ipa announces the planned departure of chris buyse from the board of directors. kamil isaev joins ipa’s board of directors ipa is pleased to welcome dr. isaev, a seasoned technology leader and venture strategist, to its board of directors. with over 30 years of expertise in ai, semiconductor technologies, and global r&d operations, isaev has held leadership roles at intel, dell emc, align technology, and abrt vc. his career has been defined by scaling r&d centers, driving ai-driven innovation, and leading high-impact cross-functional teams to bring emerging technologies to market. isaev currently serves as a venture partner at abrt vc, where he leads the abrt ai lab and the vc score project, developing ai-powered evaluation models to assess and rank ai startups, providing investors with data-driven insights to identify high-potential opportunities. his role at abrt vc is focused on bridging cutting-edge ai research with commercialization strategies, helping ai-driven companies refine their go-to-market approach and maximize scalability. previously, he held key leadership positions at intel corporation, where he served as director of developer relations engineering, overseeing global ai and software development teams and spearheading ai computing optimization, gpu workload migration, and machine learning integration. in this role, he worked closely with intel’s partners and customers to drive adoption and deployment of ai technologies in commercial and enterprise applications. before that, as country r&d general manager, he managed various software initiatives, ensuring efficient deployment of machine learning and deep learning solutions across intel's ecosystem, with a focus on operational efficiency and real-world implementation. beyond intel, isaev has led r&d and technology commercialization efforts at various organizations. at align technology, he managed a 600+ engineer r&d division, driving enterprise-wide digital transformation and agile adoption, while ensuring the successful transition of research initiatives into commercially viable products. as vice president of operations at caresyntax, he played a key role in the company’s u.s. expansion and the development of ai-driven surgical intelligence solutions, ensuring the integration of ai-driven insights into clinical workflows. at dell emc, he led solutions architecture for ai, healthcare, and video surveillance, focusing on bridging advanced technology development with industry adoption. isaev is also a member of ieee, a guest lecturer at leading universities, and a frequent speaker at ai and semiconductor industry conferences. he holds an msc and phd in physics (plasma physics and plasma chemistry) from moscow state university and has authored over 30 scientific publications in plasma physics and semiconductor technology. “we are delighted to welcome dr. isaev to our board,” said dr. jennifer bath, president and ceo. “his deep expertise in ai, r&d leadership, and commercialization of cutting-edge technology will be invaluable as we continue to expand our ai-driven biologics platform. kamil's proven track record in developing go-to-market strategies and his experience in bringing emerging technologies to commercial success aligns perfectly with our mission. his insights will be crucial as we navigate the complex landscape of ai in biologics and accelerate our path from innovation to market impact.” joseph scheffler appointed interim cfo ipa also announces the appointment of joseph scheffler as interim chief financial officer. scheffler is a highly experienced finance professional with over 20 years in public and multinational companies, specializing in financial reporting, forecasting, and business strategy. most recently, as interim corporate controller at nidec - kinetek, scheffler managed consolidated financial reporting for a $400 million global manufacturing firm with 40 subsidiaries worldwide. his background also includes extensive financial consulting for acquisitions and corporate strategy development, making him well-equipped to oversee ipa’s financial operations. “joseph brings a wealth of financial expertise and strategic insight,” said dr. jennifer bath. “his leadership will be instrumental in strengthening our financial strategy and supporting ipa’s continued growth.” scheffler holds an mba in finance and a bachelor’s in accounting from loyola university chicago, combining analytical expertise with strong stakeholder engagement. chris buyse departs board of directors ipa also announces that chris buyse has stepped down from the board of directors following his valuable tenure supporting the company during a transitional phase. “we are grateful to chris for his contributions and financial stewardship during this period of strategic evolution,” said dr. bath. “his expertise has been instrumental in ensuring continuity as we positioned the company for its next phase of growth. we wish him all the best in his future endeavors.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. (nasdaq: ipa) is a biotherapeutic research and technology company specializing in ai-driven antibody discovery and development. through its subsidiaries—including talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v.—ipa delivers an end-to-end solution for the development of next-generation antibody therapeutics. the company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets. for more information, visit www.ipatherapeutics.com investor relations contact investors@ipatherapeutics.com   forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated contributions of kamil isaev as a member of the board of directors, the expected impact of joseph scheffler’s appointment as interim cfo, and the company’s continued strategic growth and execution of its ai-driven biologics initiatives. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to leadership transitions, technological advancements, regulatory developments, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should any of these risks materialize actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

ipa successfully executes strategic capital initiatives, strengthening financial position for growth austin, texas – immunoprecise antibodies ltd. (“ipa” or the “company”) (nasdaq: ipa), a leader in ai-driven antibody discovery and development, today announced the successful completion of its previously disclosed usd $8.8 million “at-the-market” equity offering program (the “atm program”) alongside the full conversion of its outstanding debenture with yorkville advisors, significantly enhancing the company’s capital structure. strategic atm offering raises usd $7.0 million utilizing their atm program, the company generated approximately usd $7.0 million in gross proceeds. the company utilized the atm strategically, enabling them to dramatically reduce the cost of capital while reinforcing their financial position. "the successful execution of our atm program underscores investor confidence in ipa's vision and technology," said dr. jennifer bath, ceo of immunoprecise antibodies. "by deploying this program strategically, we optimized our financing approach, reducing our cost of capital while maintaining the flexibility needed to accelerate innovation in ai-driven antibody discovery." yorkville debenture fully converted in addition to the atm program completion, ipa has now fully satisfied its outstanding obligations with yorkville advisors, as yorkville has converted all principal amounts under the debenture agreement into common shares. this marks a significant milestone in eliminating near-term debt obligations, further strengthening ipa’s balance sheet. "we greatly appreciate the partnership and flexibility provided by yorkville advisors throughout this process," added dr. bath. "their structured investment approach has been instrumental in allowing us to execute on key strategic initiatives while maintaining operational momentum." with the completion of the atm program and yorkville’s full conversion, ipa is in a stronger financial position, allowing the company to continue executing its growth strategy and advancing its ai-powered therapeutic discovery platform, lensai. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits of the company’s capital structure optimization, the potential impact of the atm proceeds and yorkville conversion on financial flexibility, and the company’s ability to execute its growth strategy and advance its ai-driven antibody discovery platform. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including but not limited to market conditions, investor sentiment, regulatory requirements, financial and operational risks, and competitive dynamics. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas – immunoprecise antibodies ltd. (ipa) (nasdaq: ipa) has developed a new class of glp-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. these ai-designed therapeutics aim to improve upon current glp-1 therapies, which are widely used for managing type 2 diabetes and obesity. created using the company's proprietary lensai™ platform, an ai-driven system that analyzes evolutionary patterns in biological data, these novel ai-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience. enhancements are aimed at increased patentability, extended stability and resistance to degradation, improved administration routes for greater compliance, reduced dosing requirements, and more efficient manufacturing methods. the company’s glp-1-like alternatives are currently being evaluated for potential transdermal delivery as non-invasive alternatives to injections. these novel constructs represent the company's first fully ai-generated assets, complementing their growing portfolio of ai-assisted and laboratory-developed therapies. advancing glp-1 therapies current glp-1 drugs for diabetes and obesity management often require frequent injections due to their short half-life. in just two weeks, ipa's lensai generated, developed and optimized novel genetic sequences for glp-1-like constructs that may offer potential advantages over existing treatments. ipa is now investigating whether genetic constructs based on these optimized sequences could support more efficient dosing regimens and enhance patient experience. this rapid sequence generation process showcases lensai's transformative potential in drug discovery, leveraging its unique ability to identify specific patterns embedded in biological material. this approach could revolutionize therapeutic innovation across multiple disease areas, enabling faster and more precise in silico drug development. from ai discovery to preclinical optimization ipa’s lensai™ platformidentified key molecular features by analyzing evolutionary patterns across species. using hyft® technology, the potential therapeutics were refined to improve binding strength, increase resistance to enzymatic breakdown, and optimize their function. instead of chemical modifications to increase therapeutic stability, a standard industry method, ipa applied rational genetic engineering to enhance peptide longevity and performance in early-stage studies. additionally, ipa has optimized its glp-1 alternatives for compatibility with nucleic acid-based expression systems in collaboration with aldevron, llc (a danaher company). while ipa has strategically aligned its therapies with an established nucleic acid delivery technology, its ai-driven approach has tailored the genetic sequences to leverage specific delivery enhancements, including increased gene expression and reduced immune response risks. by incorporating optimized genetic elements, ipa aims to explore long-term, stable therapeutic production within the body as part of its ongoing pre-clinical investigations. exploring a novel drug delivery approach given the unique and miniature nature of the therapeutic molecules as well as their selected gene therapy delivery vehicle, ipa is further evaluating the feasibility of delivering these glp-1-like therapies via a transdermal patch rather than injection. this concept could allow for a steady, controlled release of the peptide, potentially improving absorption and patient convenience. the ai-driven drug optimizations are designed to ensure compatibility with this delivery method, providing a foundation for further investigation into non-invasive metabolic treatments. a paradigm shift in biologic innovation ipa's proprietary hyft patterns, the core of our lensai software, are driving a revolution in therapeutic drug discovery. these unique patterns, exclusive to ipa, enable: entirely in silico drug discovery, development, and optimization rapid and precise code execution reduced energy consumption "lensai's continued breakthroughs underscore the unparalleled power of our hyft patterns," said dr. jennifer bath, ceo of immunoprecise antibodies. "these patterns, which only ipa possesses, are the key to unlocking unprecedented speed and precision in biologics research. lensai is not just accelerating development—it's redefining the very process of therapeutic innovation." this approach positions lensai at the forefront of next-generation biologics, providing end-to-end in silico drug development capabilities with optimized safety and efficacy screening from the earliest stages of development, whether used by ipa or licensed to partners in the industry. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the ai-driven peptide discovery pipeline, the potential for computationally designed glp-1 analogs to improve therapeutic efficacy, and the company’s ability to develop and commercialize transdermal glp-1 candidates. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

austin, texas – immunoprecise antibodies ltd. (nasdaq: ipa) today announced the launch of its ai-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. by combining advanced artificial intelligence with first-principles thinking, the biostrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency. traditional drug discovery often builds on outdated frameworks, layering new tools onto existing systems and perpetuating inefficiencies. ipa’s first-principles approach breaks from this mold by deconstructing challenges to their fundamentals and rebuilding processes from the ground up. this mindset led to the creation of lensai, ipa’s proprietary ai platform, which organizes vast biological datasets into a unified framework, eliminating silos and accelerating discoveries. the ipa pipeline introduces a new era of ai-enhanced therapies designed to meet modern medical demands while addressing critical unmet needs. by pairing cutting-edge computational insights with rigorous lab validation, ipa ensures the delivery of treatments that are not only groundbreaking but also highly effective and reliable. powered by lensai's in silico workflows, the pipeline integrates data with precision at every stage of development, enabling therapies that are faster, more targeted, and impactful for the future of medicine. "our ai-powered pipeline represents a major leap forward for ipa," said dr. jennifer bath, ceo of immunoprecise antibodies. "by harnessing ai and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. this pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose." this launch marks a pivotal moment for ipa as it continues to set new standards in biotherapeutics. by tackling complex therapeutic challenges and addressing some of the world’s most pressing medical needs, ipa is poised to lead the next wave of ai-powered drug discovery. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact investors@ipatherapeutics.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements often include words such as “expects,” “intends,” “anticipates,” “believes,” or variations thereof, or state that certain actions, events, or results “may,” “will,” “could,” or “might” occur. these statements relate to, among other things, the anticipated benefits and impact of the ai-driven pipeline, the potential for ai-enhanced therapeutic assets to accelerate drug discovery, and the company’s ability to develop and commercialize new therapeutic candidates. although the company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. actual results may differ materially from those expressed or implied due to factors largely beyond the company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information on risks and uncertainties can be found in the company’s annual report on form 20-f, as amended, for the year ended april 30, 2024 (available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should any of these risks materialize, actual results could vary significantly. readers are cautioned not to place undue reliance on forward-looking statements, which reflect the company’s expectations only as of the date of this release. the company assumes no obligation to update or revise these statements, except as required by law.

innovative antibodies show promise for antibody-drug conjugate (adc) development, paving the way for transformative cancer treatments victoria, british columbia (canada), november 13, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), a leader in ai-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. this accomplishment not only highlights ipa’s cutting-edge discovery and ai capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by 2028. the tatx-112 program, dedicated to the development of specialized antibodies for cancer treatment, has shown encouraging results, successfully targeting cells that express a protein known as trkb. this achievement has paved the way for several promising candidates for further development. trkb is a protein commonly found in aggressive cancers. ipa is spearheading two programs that target this protein. the tatx-200 program is centered on developing t cell engagers, which boost the body's immune response against tumors. the tatx-112 program is focused on creating antibodies that can deliver cancer-killing drugs directly to tumor cells. the recent advancements in the tatx-112 program have led to the discovery of multiple antibodies that can infiltrate and eliminate trkb-expressing cells in an in vitro surrogate antibody drug conjugate (adc) assay. this suggests that these antibodies could be used to deliver drugs directly to cancer cells, potentially enhancing the effectiveness and safety of cancer treatments targeting trkb. dr. jennifer bath, ceo of immunoprecise antibodies, expressed her excitement: "our tatx-112 program has reached a significant milestone, demonstrating our ability to target and eliminate trkb-expressing cells. this breakthrough accelerates our cancer-fighting antibody development efforts. our innovative discovery process, combined with validation and ai-driven characterization, has enabled us to identify antibodies with high trkb specificity. we are confident in our leadership position in ai-guided development and within our cancer program. we look forward to reaching many more significant milestones in our journey to revolutionize cancer treatment." talem therapeutics' recent development of antibodies potentially suitable for cancer treatment marks a significant step in their mission to transform cancer treatment. talem’s focus on trkb-expressing tumors addresses a critical need in cancer treatment. ipa remains committed to driving innovation and creating long-term value, as it continues to advance the talem pipeline and explore commercialization opportunities in the biopharmaceutical sector. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. about talem therapeutics llc talem therapeutics llc, a subsidiary of immunoprecise antibodies ltd., specializes in the discovery and development of ai-driven, next-generation antibodies with the primary goal of out-licensing them to pharmaceutical partners. talem focuses on creating innovative therapeutic biologics up to the preclinical stage, leveraging advanced platforms to accelerate antibody development for oncology and other therapeutic areas. the company aims to streamline the path to the clinic for its partners by providing high-quality antibody assets ready for further development and clinical testing. for more information, visit www.talemtherapeutics.com. investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects”, “estimates”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or state that certain actions, events, or results “may”, “would”, “might”, or “will” be taken, occur, or be achieved. forward-looking statements include, but are not limited to, statements relating to the effectiveness, safety or readiness of therapeutics in our cancer research initiatives, our internal therapeutic asset programs, our discovery and ai capabilities, and expected outcome on the market, the life sciences, and drug discovery and development. although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to several factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this release. accordingly, readers should not place undue reliance on forward-looking statements contained in this release. the forward-looking statements contained in this release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

victoria, british columbia (canada), november 4, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, announces the details of its upcoming techday event on friday, november 15, 2024, from 9:00 a.m. to 12:30 p.m. est in cambridge, massachusetts. this exclusive gathering will highlight ipa’s latest advancements in ai-driven design, biologics innovation, and strategic technological developments. highlights of techday: presentation by dr. dirk van hyfte: van hyfte will present “accelerating drug discovery with lensai: a comprehensive solution.” he will showcase lensai, biostrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence. key topics include using hyft® universal fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with ai-driven insights. lensai demo: a live demonstration of the lensai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through ai-driven insights. presentation by dr. shuji sato: sato will present ipa’s b cell discovery platform and discuss its integration with the company’s advanced ai and ngs workflows for highly efficient hit expansion. this process includes: fast analysis of complete ngs repertoires multimodal feature extraction that combines sequence, structure, and large language model (llm) embeddings to deliver enhanced insights into sample diversity. add-ons that complement outputs from phage display, b-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders. fireside chat: disruptive dialogue: empowering drug discovery through seamless data integration and ai-powered insights participants: dirk van hyfte, head of innovation and co-founder, biostrand (ipa) jeff fried, director of platform strategy and innovation, intersystems this discussion will explore how vector search intelligence is at the core of the lensai platform, seamlessly integrated with the intersystems iris data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity. ai-driven drug discovery summit usa 2024 additionally, earlier that same week at the ai-driven drug discovery summit usa 2024, ipa will participate in another fireside chat titled beyond conventional biologics: the intersection of machine learning and biological engineering to invent. participants at the ai-driven drug discovery summit usa 2024: adam root, vice president and head of protein sciences, generate biomedicines dirk van hyfte, head of innovation and co-founder, biostrand (ipa) the chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development. a recorded webcast of the techday presentations will be available in the investors section of the ipa website under "events and presentations" at ir.ipatherapeutics.com. interested in joining us for this exclusive techday experience? space is limited - secure your spot by contacting jennifer k. zimmons, phd, mba, at quantum media: jen@quantum-corp.com about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking statements include, but are not limited to, statements regarding the capabilities, impact and results expected from biostrand’s lensai platform. although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

rabbit b cell select® platform yields novel antibodies for studying age-related mitochondrial dysfunction victoria, british columbia (canada), october 28, 2024 – immunoprecise antibodies ltd. ("ipa" or the "company") (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. the research, led by top scientists at the mayo clinic, was initially published in biorxiv and subsequently peer-reviewed and published in the prestigious journal autophagy. titled "development and characterization of phospho-ubiquitin antibodies to monitor pink1-prkn signaling in cells and tissue," this study advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like parkinson's and alzheimer's. the study focuses on the development of antibodies that detect damaged mitochondria, which are more common as we age. immunoprecise played a crucial role in this project by applying its proprietary rabbit b cell select™ platform to isolate and generate highly specific antibodies that target phosphorylated ubiquitin (p-s65-ub), a marker of mitochondrial damage. these antibodies allow researchers to measure mitochondrial health, and the progression of damage related to aging. dr. jennifer bath, ceo of immunoprecise antibodies, commented: "the development of these novel recombinant p-s65-ub antibodies represents a significant advancement in mitochondrial research. ipa’s proprietary high-precision tools not only enhance our understanding of pink1-prkn mediated signaling, but also show promising biomarker potential for various clinical applications. we are proud to have contributed to this groundbreaking research, which opens new avenues for studying mitochondrial dysfunction in aging and neurodegenerative diseases, and may lead to improved diagnostic, prognostic, and therapeutic approaches." ipa is strategically positioned to capitalize on the booming anti-aging market, projected to reach $81.01 billion by 2028 with an 8.2% cagr. the company's proprietary b cell select platform demonstrates its innovative capacity in this high-growth sector. ipa's collaboration with mayo clinic showcases its ability to contribute to groundbreaking research in age-related diseases. simultaneously, ipa maintains a robust internal pipeline through its subsidiary, talem therapeutics, focusing on next-generation therapeutic antibodies. this dual approach of supporting external research while developing proprietary assets establishes ipa as a versatile and valuable player in the longevity and aging fields, potentially unlocking significant market opportunities and shareholder value. immunoprecise's contributions immunoprecise antibodies (ipa) has made a significant contribution to this breakthrough study, showcasing yet another success from their proprietary rabbit b cell select™ platform. the company's advanced antibody discovery process played a crucial role in the research. utilizing the b cell select™ platform, ipa isolated specific immune cells from immunized rabbits. these cells were then meticulously screened to identify those producing antibodies highly specific to phosphorylated ubiquitin, a key indicator of mitochondrial damage. from the top-performing cells, ipa generated and validated recombinant antibodies, ensuring optimal sensitivity and accuracy in detecting damaged mitochondria. this achievement further demonstrates the power and versatility of ipa's rabbit b cell platform in producing high-quality, specific antibodies for cutting-edge research applications. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking statements include, but are not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, and clinical readiness or effectiveness of ipa-discovered therapeutics. although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

victoria, british columbia (canada), october 21, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced that dr. dirk van hyfte, head of innovation at biostrand, ipa’s ai subsidiary, will participate on a fireside chat during the ai driven drug discovery summit usa 2024 taking place at the aloft boston seaport district hotel, boston, massachusetts, november 12-14, 2024. ai driven drug discovery summit date: thursday, november 14 time: 11:30 am est format: fireside chat to register for the event, please click here meet with us for appointment scheduling, please contact jennifer k. zimmons, phd, mba, at quantum media: jen@quantum-corp.com , +1.917.214.3514. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com source: immunoprecise antibodies ltd.

university of washington’s baker lab and google deepmind redefine protein science, paving the way for ai-driven biotherapeutics victoria, british columbia (canada), october 10, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today celebrates the recent nobel prize in chemistry awarded to david baker of the university of washington, seattle, wa, usa, "for computational protein design," and jointly to demis hassabis and john m. jumper of google deepmind, london, uk, "for protein structure prediction." this accolade highlights the vital role of computational tools and ai in advancing our understanding of protein structures—principles that are central to ipa’s research initiatives. these achievements validate the methodologies that underpin ipa’s proprietary foundation ai model, lensai, which leverages similar computational and ai approaches to innovate drug discovery. "as ipa continues to enhance lensai, our proprietary ai platform, we remain committed to leveraging cutting-edge technologies to unravel complex protein interactions. the nobel prize recognition of alphafold underscores the growing importance of ai in scientific breakthroughs. at immunoprecise antibodies, we're dedicated to integrating advanced ai technologies into our workflows, which not only amplifies our capabilities in drug development but also aligns with our mission to pioneer innovative biotherapeutic solutions," said dr. jennifer bath, ceo of immunoprecise antibodies. at ipa, the integration of alphafold, an open-access ai tool developed by google deepmind, into our drug discovery processes has revolutionized how we approach complex biological challenges. by leveraging alphafold's freely available protein structure predictions, ipa enhances the design and optimization of antibodies, making significant strides in developing treatments for diseases that were previously deemed intractable. “our hyft technology amplifies the power of alphafold and other foundational ai models by providing deeper biological context. hyft identifies key functional and structural motifs within protein sequences, enhancing the precision of alphafold's predictions and extending its application in drug discovery, said dr. van hyfte, head of innovation at biostrand. “this combination enables us to push the boundaries of what’s possible in biotherapeutic development, accelerating the path from prediction to solution.” for a deeper dive into alphafold's impact on drug discovery and its integration into ipa's technology stack, explore their subsidiary, biostrand's, blog post: explained: a brief look into alphafold 2. looking ahead, ipa is keen to expand partnerships within academia and industry to further explore ai's potential in developing novel therapies. ipa invites interested parties to join in advancing the application of lensai, aiming for a future where diseases are not merely treated but understood and prevented. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statement this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward–looking statements include, but are not limited to, statements regarding computational and ai approaches to innovate drug discovery. . although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward–looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedar.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

talem therapeutics' antibody asset to be evaluated for bispecific development against solid tumors victoria, british columbia (canada), zhuai, (china), october 2, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, and biotheus inc. (biotheus), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, jointly announce that the two parties have entered into a material transfer and evaluation agreement (mtea) pertaining to a talem therapeutic antibody asset for the development of a bispecific therapy against solid tumors. under this mtea, biotheus will obtain the rights to further evaluate the suitability of talem’s artificial intelligence (ai)-enhanced tatx-20 lead candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors. under this agreement, biotheus will receive a specialized antibody asset from talem therapeutics, a subsidiary of immunoprecise antibodies. biotheus plans to use this asset in conjunction with its own proprietary technology and binders to develop a new class of cancer-fighting drugs. these innovative therapeutics, known as bispecific antibodies, are designed to simultaneously target two different targets on tumors, specifically those found in oxygen-deprived environments. this approach could potentially lead to breakthrough therapies that address the complex challenges of treating cancer, particularly in difficult-to-target tumor environments. the ultimate goal is to identify the most promising molecule for advancement into clinical trials, potentially accelerating the development of novel cancer treatments. "we are happy to enter into a collaboration with immunoprecise antibodies, a leading ai-driven biotech with powerful multi-omics modelling expertise." stated xiaolin liu, co-founder, chairman, and ceo of biotheus. “biotheus' broad expertise in antibody discovery and development is powered by our fully integrated capabilities. by virtue of the ai-informed molecules spawned by immunoprecise's platform, we aim to develop novel bispecific antibodies with first-in-class potential and bring forth breakthrough therapies to cancer patients in the world." dr. jennifer bath, ceo of immunoprecise antibodies, stated: "we're excited to transfer our ai-enhanced therapeutic antibody asset to biotheus for bispecific molecule development. this strategic move leverages our cutting-edge technology in antibody discovery and biotheus' expertise in bispecific engineering. our collaboration aims to accelerate the creation of innovative cancer treatments, potentially leading to groundbreaking clinical outcomes. this agreement not only demonstrates the value of our ai-enhanced assets but also sets the stage for a long-term, mutually beneficial partnership that could transform the landscape of cancer therapeutics. we anticipate this collaboration will drive significant value for both companies and, most importantly, for patients in need of advanced treatment options." the transfer of this therapeutic asset to biotheus aims to accelerate the development of targeted therapies that could potentially improve outcomes for patients with solid tumors. following the transfer, biotheus will evaluate the tatx-20 lead candidate. if the evaluation proves successful, biotheus intends to further develop the bispecific molecules, with the objective of creating a clinically successful product that addresses the challenges associated with treating hypoxic solid tumors resistant to current therapies. about biotheus biotheus inc. is a leading biopharmaceutical company headquartered in zhuhai, china, dedicated to discovering and developing innovative therapies for oncology and immunology diseases. biotheus is focused on creating cutting-edge bispecific antibodies and other biologics to target challenging tumor types and improve patient outcomes. since its inception, biotheus has established several innovative platforms for antibody discovery. with an experienced development team, biotheus has built a robust pipeline of ten programs at various stages of clinical development. for more information, visit www.biotheus.com. about talem therapeutics llc talem therapeutics llc, a subsidiary of immunoprecise antibodies ltd., specializes in the discovery and development of ai-driven, next-generation antibodies with the primary goal of out-licensing them to pharmaceutical partners. talem focuses on creating innovative therapeutic biologics up to the preclinical stage, leveraging advanced platforms to accelerate antibody development for oncology and other therapeutic areas. the company aims to streamline the path to the clinic for its partners by providing high-quality antibody assets ready for further development and clinical testing. for more information, visit [www.talemtherapeutics.com]. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statement this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward–looking statements include, but are not limited to, statements regarding bispecific molecule development and the development of a bispecific therapy against solid tumors. although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward–looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedar.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

rabbit b cell select ® drives clinical breakthroughs in cancer treatment victoria, british columbia--(business wire)-- immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using ipa’s proprietary b cell select ® platform for the clinical-stage company, oncoresponse inc. this achievement underscores ipa’s leadership as a contract research organization creating high-quality therapeutic antibodies, while pioneering work in the field of rabbit monoclonal antibody development. these antibodies are rapidly gaining recognition as a unique tool in therapies due to their distinctive properties, advancing into clinical trials aimed at improving patient outcomes. oncoresponse’s breakthrough in cancer treatment in a live presentation at the recent pegs 2024 conference, oncoresponse shared exciting updates on two novel antibodies, or502 and or641, both of which were discovered and refined using ipa’s innovative b cell select ® platform: or502, a novel, humanized anti-leukocyte immunoglobulin like receptor b2 (lilrb2) antibody, has successfully entered phase i/ii clinical trials, showing excellent safety profile, and is being evaluated for efficacy in treating advanced solid tumors. preclinical models have demonstrated that or502 is a best-in-class anti-lilrb2 antibody that reverses immunosuppression caused by myeloid cells in the tme. or641, a novel, humanized dual antagonist antibody targeting both lilrb1 and lilrb2, has completed cell line development and is undergoing ind-enabling studies. preclinical models have demonstrated its superior ability to reverse immunosuppression caused by myeloid and lymphoid cells compared to other anti-lilrb1/2 antibodies. driving antibody discovery and design for clinical success ipa’s proprietary b cell select ® platform has been instrumental in the rapid design and discovery of antibodies that have advanced to clinical stages for numerous clients. by preserving the natural structure of antibodies, ipa’s technology supports optimal functioning of the therapies in a clinical setting. through comprehensive testing and validation, the process ensures that these antibodies maintain their efficacy and reliability from the lab to the clinic. "at immunoprecise antibodies, our mission is not just to develop antibodies, but to redefine what’s possible in therapeutic interventions," said dr. jennifer bath, president and ceo of ipa. "our innovative platform, built on years of expertise, has consistently delivered antibodies with superior qualities, many of which are now advancing in clinical trials. this reflects our unwavering commitment to innovation and our strategic advantage in the market. we are proud to support our clients in bringing groundbreaking, life-changing treatments to patients around the world, reinforcing the long-term value of our technologies." harnessing rabbit b cell technology for breakthrough antibody discovery the rabbit b cell platform, a rapidly advancing technology in therapeutic antibody development, played a pivotal role in the discovery process. this platform excels at generating high-affinity and highly specific rabbit monoclonal antibodies, a demand met with very limited providers in the market. ipa has successfully utilized their b cell select platform in over 200 antibody programs, achieving remarkable success against a variety of targets, including small molecules, peptides, and proteins. the distinctive properties of rabbit antibodies, combined with ipa’s expertise, have consistently led to the development of promising therapeutic candidates. building on this success, ipa is now offering more complex therapeutic rabbit antibody campaigns as a partnering model, providing companies with greater flexibility in structuring their more complicated programs. outlook the field of rabbit monoclonal antibody (mab) therapeutics is advancing rapidly, driven by innovations in antibody engineering and humanization techniques. these advancements are making rabbit mabs increasingly popular for human therapeutic use. the unique properties of rabbit antibodies, combined with ipa’s full-service technologies, such as in silicohumanization, indicate a strong potential for more rabbit-derived mabs to enter clinical trials and achieve approval in the coming years. the distinctive advantages of rabbit antibodies make them a promising foundation for future therapeutic development. as this technology progresses, ipa remains at the forefront, harnessing these innovations to bring new, effective treatments to the clinic, reinforcing our growing leadership in the industry. dr. kamal d. puri, chief scientific officer of oncoresponse, recognized ipa’s pivotal role in their success, praising the quality and reliability of ipa’s antibody discovery services. “we are thrilled to have worked with ipa to discover our lead therapeutic antibodies. the ipa team’s deep experience and know-how with a battery of customized, high-throughput discovery strategies has played a critical role in the successful discovery of our molecules with unsurpassed speed and efficiency,” said kamal d. puri, chief scientific officer of oncoresponse. about or502 lilrb2 is an immunoinhibitory receptor expressed on tumor-associated macrophages (tams) found in the tumor microenvironment (tme). tams inhibit the activity of checkpoint inhibitor (cpi) therapy and prevent t cells from killing tumors. blocking the inhibitory activity of tams and promoting the activity of tumor-killing t cells reverses inhibition of cpi therapy, potentially leading to more and deeper responses to cpis in patients. this is the mechanism of or502, which modulates lilrb2 by blocking its engagement of hla-g on tumor cells and prevents the suppression of the myeloid cells. elevated expression of lilrb2 correlates with reduced patient survival in various tumor types. this humanized monoclonal antibody, or502, targets lilrb2 and blocks the inhibitory activity of tams and promotes the activity of tumor-killing t cells, reversing inhibition of cpi therapy. about oncoresponse oncoresponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. in a broad strategic alliance with md anderson cancer center, oncoresponse deploys a proprietary b-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment. the company’s lead clinical candidate, or502 is a best-in-class anti-lilrb2 antibody that rescues innate and adaptive immune responses from lilrb2-mediated immune suppression and has entered clinical study in 2023. or502 clinical studies are being conducted with support from the cancer prevention research institute of texas (cprit) dp230076. additional pipeline candidates that modulate suppressive macrophage activity are under development, including or641, a unique dual anti-lilrb2/1 antagonist antibody that promotes a th1-like immune response. for more information, please visit www.oncoresponse.com and follow us on linkedin and x. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). forward-looking statement this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, and clinical readiness or effectiveness of ipa-discovered therapeutics. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time, those assumptions include: the continued successful of ipa’s technology in discovering and developing antibodies, timely regulatory approval and acceptance of therapies developed using the company’s technologies, the potential for partnerships in antibody discovery and development; and the expectation that these technological advancements will drive increased revenue streams and sustained financial growth for the company. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar ). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com source: immunoprecise antibodies ltd.

engineering antibodies in silico using lensai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with ipa's vision to make groundbreaking and safer therapeutics instantly accessible and affordable. key takeaways: highly specific binding of novel antibodies to a tumor microenvironment protein of previously unknown structure - verified in laboratory setting. the targeted protein, residing within the harsh tumor microenvironment, represents a key challenge in healthcare and the treatment of cancers victoria, british columbia (canada), august 19, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutics company, today announced a groundbreaking achievement: the ability to engineer antibodies entirely through computer simulations using lensai. this marks a significant milestone for the biotechnology industry. additionally, the antibodies produced by ipa are highly specific to a challenging oncology target located within the tumor microenvironment (tme). this achievement was made possible by the patented lensai technologies, which began from an exceptionally challenging starting point: the target protein had no previously known structural information. despite this, the lensai platform was able to model the protein's structure and accurately engineer antibodies specifically tailored to bind to it. this is particularly significant because designing effective therapeutics without prior structural knowledge of the target is a major hurdle in drug discovery, often requiring extensive experimentation and resources. lensai's ability to overcome this challenge entirely in silico highlights its advanced capabilities in computational biology and its potential to revolutionize the field of antibody engineering. the potential therapies were engineered to bind exclusively to the oncology target under specific conditions. importantly, it was demonstrated that these therapies do not bind to similar proteins known to be present on healthy cells and tissues, which is crucial because such binding typically leads to the negative side effects seen in chemotherapy. these findings highlight lensai's ability to address one of the toughest challenges in optimizing antibodies for oncology. “this marks a significant milestone for the biotechnology industry, demonstrating lensai's ability to engineer highly specific and validated antibodies for the exceedingly difficult environment around tumors, and doing so entirely on a computer,” said dr. jennifer bath, president and ceo of ipa. “this success, elevated by the fact that important details of the protein being targeted were unknown, represents a major feat in the application of lensai in generating targeted and specific therapies for the potential treatment of cancer. moreover, our continuous advancements and integrations have significantly enhanced our ability to develop these therapies faster, more efficiently, and at a reduced cost compared to traditional methods.” historically, biologic drug discovery has been a risky, time-consuming, and expensive endeavor, with failure rates exceeding 90%. recent data indicates that it now costs approximately $1.3 billion and takes an average of 10 to 15 years to bring a single new drug to market, with costs potentially rising even higher depending on the complexity of the drug and therapeutic area. the market has seen major successes like humira, which has shown potential in the tumor microenvironment and has generated over $20 billion in annual sales. similarly, keytruda has demonstrated effectiveness in modulating the tumor microenvironment and has generated over $14 billion annually. however, the time, cost, and risk associated with developing such biologics have historically limited the number of these therapies that can be pursued, creating a bottleneck in the availability of life-saving treatments. “the successful application of lensai, along with laboratory validation of these novel antibodies, underscores lensai’s potential to accelerate the development of precision-targeted treatments, aimed at more effective cancer therapies with fewer side effects,” stated dr. dirk van hyfte, md, phd, co-founder and head of innovation at biostrand, an ipa subsidiary. “what lensai has accomplished today is just one of the reasons we firmly believe in its ability to bring potentially life-changing biologics to patients with the power of our ai.” about immunoprecise antibodies ltd. the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. source: immunoprecise antibodies ltd. investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, which include accelerating the development of precision-targeted treatments, aimed at more effective cancer therapies with fewer side effects and our belief that we are bringing potentially life-changing biologics to patients with the power of our ai and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time, those assumptions include: the continued successful application of lensai technology in engineering highly specific antibodies, including within challenging tumor microenvironments where traditional methods have been less effective; sustained market demand for ai-driven therapeutics that offer more efficient and cost-effective biologic therapies; timely regulatory approval and acceptance of therapies developed using lensai, ensuring market access without significant delays; ongoing advancements and integration in ai and computational methods to enhance the efficiency and accuracy of the lensai platform; the ability of lensai to consistently reduce development time and costs compared to traditional drug discovery methods; and the expectation that these technological advancements will drive increased revenue streams and sustained financial growth for the company. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedar.com and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

engineering antibodies in silico using lensai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with ipa's vision to make groundbreaking and safer therapeutics instantly accessible and affordable. key takeaways: highly specific binding of novel antibodies to a tumor microenvironment protein of previously unknown structure - verified in laboratory setting. the targeted protein, residing within the harsh tumor microenvironment, represents a key challenge in healthcare and the treatment of cancers victoria, british columbia (canada), august 19, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutics company, today announced a groundbreaking achievement: the ability to engineer antibodies entirely through computer simulations using lensai. this marks a significant milestone for the biotechnology industry. additionally, the antibodies produced by ipa are highly specific to a challenging oncology target located within the tumor microenvironment (tme). this achievement was made possible by the patented lensai technologies, which began from an exceptionally challenging starting point: the target protein had no previously known structural information. despite this, the lensai platform was able to model the protein's structure and accurately engineer antibodies specifically tailored to bind to it. this is particularly significant because designing effective therapeutics without prior structural knowledge of the target is a major hurdle in drug discovery, often requiring extensive experimentation and resources. lensai's ability to overcome this challenge entirely in silico highlights its advanced capabilities in computational biology and its potential to revolutionize the field of antibody engineering. the potential therapies were engineered to bind exclusively to the oncology target under specific conditions. importantly, it was demonstrated that these therapies do not bind to similar proteins known to be present on healthy cells and tissues, which is crucial because such binding typically leads to the negative side effects seen in chemotherapy. these findings highlight lensai's ability to address one of the toughest challenges in optimizing antibodies for oncology. “this marks a significant milestone for the biotechnology industry, demonstrating lensai's ability to engineer highly specific and validated antibodies for the exceedingly difficult environment around tumors, and doing so entirely on a computer,” said dr. jennifer bath, president and ceo of ipa. “this success, elevated by the fact that important details of the protein being targeted were unknown, represents a major feat in the application of lensai in generating targeted and specific therapies for the potential treatment of cancer. moreover, our continuous advancements and integrations have significantly enhanced our ability to develop these therapies faster, more efficiently, and at a reduced cost compared to traditional methods.” historically, biologic drug discovery has been a risky, time-consuming, and expensive endeavor, with failure rates exceeding 90%. recent data indicates that it now costs approximately $1.3 billion and takes an average of 10 to 15 years to bring a single new drug to market, with costs potentially rising even higher depending on the complexity of the drug and therapeutic area. the market has seen major successes like humira, which has shown potential in the tumor microenvironment and has generated over $20 billion in annual sales. similarly, keytruda has demonstrated effectiveness in modulating the tumor microenvironment and has generated over $14 billion annually. however, the time, cost, and risk associated with developing such biologics have historically limited the number of these therapies that can be pursued, creating a bottleneck in the availability of life-saving treatments. “the successful application of lensai, along with laboratory validation of these novel antibodies, underscores lensai’s potential to accelerate the development of precision-targeted treatments, aimed at more effective cancer therapies with fewer side effects,” stated dr. dirk van hyfte, md, phd, co-founder and head of innovation at biostrand, an ipa subsidiary. “what lensai has accomplished today is just one of the reasons we firmly believe in its ability to bring potentially life-changing biologics to patients with the power of our ai.” about immunoprecise antibodies ltd. the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. source: immunoprecise antibodies ltd. investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, which include accelerating the development of precision-targeted treatments, aimed at more effective cancer therapies with fewer side effects and our belief that we are bringing potentially life-changing biologics to patients with the power of our ai and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time, those assumptions include: the continued successful application of lensai technology in engineering highly specific antibodies, including within challenging tumor microenvironments where traditional methods have been less effective; sustained market demand for ai-driven therapeutics that offer more efficient and cost-effective biologic therapies; timely regulatory approval and acceptance of therapies developed using lensai, ensuring market access without significant delays; ongoing advancements and integration in ai and computational methods to enhance the efficiency and accuracy of the lensai platform; the ability of lensai to consistently reduce development time and costs compared to traditional drug discovery methods; and the expectation that these technological advancements will drive increased revenue streams and sustained financial growth for the company.

victoria, british columbia (canada), june 27, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, is pleased to announce the appointment of kristin taylor as chief financial officer, effective immediately. ms. taylor has been serving as interim cfo since september 19th, 2023, and now transitions into the role on a permanent basis. ms. taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. she has a strong background in driving growth, establishing infrastructure, and implementing effective strategies for value creation in dynamic, scaling environments. prior to joining ipa, ms. taylor served as the chief financial officer of bay west llc and b-mogen biotechnologies inc., along with capital markets and liquidity management roles at prime therapeutics and medtronic. previous to her corporate experience, she held technical and consulting roles in public accounting. her expertise spans growth strategies and execution, fundraising and recapitalizations, due diligence and acquisition integration, financial analysis, accounting, audit and tax compliance, staff leadership and development, process development and it initiatives, and board and investor relations. ms. taylor holds an mba in finance and strategic management from the carlson school of management at the university of minnesota, where she was a carlson scholar, and a bachelor of science in business administration with a major in accounting and a minor in communications. she is also a certified public accountant (inactive). “we are thrilled to welcome kristin to immunoprecise as our new cfo,” said jennifer bath, ceo of ipa. “her extensive experience and proven track record in financial leadership will be invaluable as we continue to drive our growth and strategic initiatives forward. her performance during her interim tenure has been exemplary, and we are confident in her ability to lead our financial operations.” about immunoprecise antibodies ltd. the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com source: immunoprecise antibodies ltd. forward-looking statement forward-looking statement: this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia (canada), june 25, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced that its subsidiary, biostrand, is collaborating with pgxai to leverage biostrand's patented foundation ai model, lensai. this collaboration advances the precision medicine field of pharmacogenomics and supports lensai application programming interface (“api”) commercial rollout through expanding lensai features and market reach. pharmacogenomics, the study of how genetic variations affect drug response, is integral to ipa’s goal to efficiently create tailored therapies and improve patient outcomes. the vast amount of genetic data has historically been difficult for researchers to access, manage, and interpret. lensai was built to address that challenge through its unique ability to analyze large language models simultaneously with many disparate forms of research and patient data. lensai was recently made available by biostrand to certain current and prospective partners through an api. biostrand’s collaboration with pgxai is an important next step aimed at providing lensai users the ability to apply pharmacogenetic analysis, reflecting our shared mission of better healthcare solutions through advanced technology. “the work we’ve begun with pgxai marks a significant application of lensai to a critical real-world challenge, enabling the development of a unique pharmacogenomics ai model,” said dr. jennifer bath, president, and ceo of ipa. “with more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict treatment responses and adverse drug reactions. we believe that lensai offers a potentially groundbreaking approach to creating an adaptive ai model that is designed to predict individual patient responses to both existing and new drugs.” mike zack, md, phd, ceo of pgxai, commented, “we are excited to partner with biostrand, a leader in ai-powered biotherapeutic solutions. our collaboration aims to create a transformative ai model for the pharmacogenomics sector, enhancing our ability to predict effective and safe therapies. this partnership represents a significant step toward revolutionizing personalized medicine.” allan gobbs, executive chairman of pgxai, added, “the clinical value of pharmacogenomics is increasingly recognized by healthcare providers and payers. we believe that our model will enable unprecedented personalization and precision in pharmacogenetic recommendations, potentially transforming medication prescription practices on a global scale.” despite advancements in generative ai, vector search, and multi-omics, practical applications of precision medicine remain limited, contributing to over 30% of adverse drug reactions, as noted in the lancet1. by sequencing the human genome and cataloging genetic variants, we can better understand and predict how patients will respond to specific drugs. integrating pharmacogenomics with electronic health records (ehrs) and artificial intelligence (ai) offers significant potential to personalize treatments and enhance patient outcomes. a robust ai model in this field has the potential to revolutionize the $400 billion2 prescription drug market, significantly improving patient outcomes and driving innovation in precision medicine. this presents a compelling investment opportunity to transform healthcare by delivering cutting-edge solutions in the rapidly evolving precision medicine landscape. dirk van hyfte, md, phd, head of technology at ipa and co-founder of biostrand, stated, "we are thrilled to deploy our lensai software, available through api, to support pgxai’s cutting-edge initiatives. our collaboration is set to enhance rational drug design by integrating advanced ai analysis of vast genomic data, enabling the precise tailoring of therapies to individual genetic profiles. this approach not only boosts the efficacy and safety of treatments but also streamlines the drug development process, reducing both timelines and costs. our technology is developed to help optimize drug therapies for specific patient needs, marking a significant advancement in personalized medicine." 1 https://www.thelancet.com/journals/lancet/article/piis0140-6736(22)01841-4/abstract 2 https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2023 about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com about pgxai pgxai is a leading ai-powered pharmacogenetics platform that is transforming precision medicine through proprietary algorithms and real-world data analysis. in partnership with intersystems, pgxai utilizes advanced tools like vector search and generative ai to analyze extensive real-world data, addressing challenges in drug selection, dosage personalization, and identifying significant drug-drug interactions. contact email - admin@pgx.ai corporate presentation use this link forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the potential of lensai and the collaboration with pgxai, the impact technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia, june 12, 2024 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, today announces that its subsidiary, biostrand, has been honored with the prestigious 2024 impact award, sponsored by intersystems. this recognition highlights biostrand’s groundbreaking work in biotherapeutic research, which has made a significant impact and set a new standard for innovation in the industry. the 2024 impact award acknowledges biostrand’s innovative lensai technology, selected from over 1,000 client projects for its remarkable contributions. the selection committee, chaired by professor roberto zicari, identified biostrand’s work based on three key criteria: makes a significant difference: lensai’s innovative approach has substantially advanced the field of biotherapeutics. breaks new ground: the technology introduces novel methods and solutions, pushing the boundaries of current research and development. sets an example: biostrand’s achievements serve as a benchmark for other organizations, demonstrating excellence in innovation. the award will be presented today at the intersystems annual global summit, at the gaylord national resort and convention center in maryland, usa. this premier event attracts industry leaders and top professionals from around the globe, including c-level executives, subject matter experts, visionary leaders, managers, directors, and developers. this year’s summit expects over 1,200 attendees from more than 28 countries. the award celebration will take place today, from 10:30-11:00 am et, during a personalized award presentation session. the event offers an additional excellent opportunity for biostrand and ipa to showcase their innovative contributions to a global audience. “we are incredibly proud of biostrand’s achievements and this recognition from intersystems,” said dr. jennifer bath, ceo of immunoprecise antibodies ltd. “the impact award underscores the significance of biostrand’s pioneering work and reinforces our commitment to driving innovation in biotherapeutic research.” for more information about the intersystems global summit, the impact award, and to view dr. van hyfte’s formal acceptance of the award please visit today’s live stream starting at 9am et, at the intersystems global summit 2024: https://www.linkedin.com/events/7203844810565111808/about/ about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a leader in ai-driven biotherapeutic research and technology, providing comprehensive solutions for the discovery, development, and optimization of therapeutic antibodies. through its subsidiaries, including biostrand, immunoprecise leverages advanced technologies to accelerate the development of novel biotherapeutics. about biostrand biostrand, a subsidiary of immunoprecise antibodies ltd., specializes in innovative biotherapeutic research and development. biostrand’s lensai technology represents a groundbreaking approach in the field, driving significant advancements and setting new standards for innovation. investor contact: investors@ipatherapeutics.com   forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

-biostrand now offers a customizable application programming interface (api) with its new software offering, lensai api, featuring the ability to integrate sizable databases and electronic health records with large language models. -biostrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. -this proprietary software provides the integration of electronic health records, enhancing ai-driven drug discovery and development for industry professionals. victoria, british columbia, june 10, 2024 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, today announces the commercial release of lensai api, hereafter referred to as the ‘software’, by its subsidiary, biostrand. this advanced ai-driven software solution is available immediately. more details on this new offering will be unveiled today at 2:00 pm et, with an additional presentation, live demonstration, and interview at 6:30 pm et, all taking place at the intersystems global summit 2024. this premier event, which attracts over 1,200 industry leaders from more than 28 countries, showcases the latest innovations in the field. ipa, the #1 ranked contract research organization by roots analysis2, serves 19 of the top 20 global pharmaceutical companies and over 600 clients in the pharmaceutical and biotech industries. leveraging feedback from these long-term relationships, the development of this ai-driven software is in direct response to meeting ongoing industry pain points and needs. these new software capabilities demonstrate innovation by combining biostrand’s patented lensai technology with electronic health records through a customizable interface to enable unprecedented research and drug discovery capabilities. dr. dirk van hyfte is leading the launch of this exciting integration, enabling industry professionals to quickly and easily access and merge patient data, company research data, and extensive life science databases. through this new release, corporations will be able to analyze major datasets related to generating novel and potentially safer and more effective drugs, as the biostrand team continues to develop a full lensai data management platform, expected to be released in q1/q2 2025. dr. dirk van hyfte stated, "we have received significant interest in our new technology from large healthcare, pharmaceutical, and technology companies. they are keen on accessing our unique capabilities through an integration that enables them to benefit directly from biostrand's novel applications for data analysis and cutting-edge drug discovery. the company regards the commercial launch of this pioneering software as its most significant ai breakthrough to date, poised to significantly enhance global drug discovery and development processes. by integrating biostrand’s software with electronic health records, and adding biostrand’s application programming interface, we have surpassed internal timelines and milestones, supporting the rapid commercialization of these high-demand capabilities." these new commercial capabilities will significantly enhance biostrand’s ability to commercialize: partnerships with large companies: major pharmaceutical, technology, and healthcare companies will be able to rapidly leverage biostrand’s new software capabilities through partnerships that may include upfront payments, clinical milestones and commercial royalties. subscription model: biostrand is offering a subscription service that enables a wide range of technology, healthcare, and pharmaceutical companies to access biostrand’s unique capabilities using integration of the software into their existing platforms, with a strong probability of enhancing their drug discovery and development programs. in light of the upcoming presentation at the intersystem’s global summit 2024, dr. dirk van hyfte has requested that the live podcast, media events, and interviews be recorded and made available to the public whenever possible. we also encourage everyone who can attend the live demonstration at the summit to join and support this exciting public commercial launch. you can register: intersystems global summit 2024 registration. investor contact: investors@ipatherapeutics.com 1www.strategyand.pwc.com/de/en/industries/pharma-life-science/re-inventing-pharma-with-artificial-intelligence.html 2roots 2022, antibody discovery services and platforms market (4th edition), 2021-2035; pp.118 about immunoprecise antibodies ltd. the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

dirk van hyfte md, phd, head of technology, ipa, to present live demonstration at the intersystems global summit 2024 june 9-12, 2024 - national harbor, maryland victoria, british columbia (canada), june 04, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its belgian subsidiary, biostrand, is leveraging their patented foundation ai model, lensai, by applying advanced large language models (llm) to capture real world data from electronic health records (ehr). lensai significantly enhances the analysis and integration of ehr data, enabling the integrated use of real-world data and evidence in drug discovery and the development of precision medicines. “ipa’s partners and customers are experiencing impactful results from the lensai next generation, hyft® enabled in silico tools, as they strive to analyze and utilize increasing volumes of rich biological data. these valued partners and customers, as well as potential new users, often encounter challenges with existing omics processing platforms, which struggle to connect diverse datasets. using lensai, ipa has recently demonstrated the ability to generate novel in silico antibodies to challenging diseases where traditional technologies have failed. the ability to efficiently and effectively utilize ehr further strengthens our value proposition”, stated dr. jennifer bath, president and ceo of ipa. "ipa's biostrand group continues to innovate. this model has the potential of dramatically simplifying the connection between real-world evidence and therapeutic discovery and development." said jeff fried, director of platform strategy & innovation at intersystems. "we're proud that they are using intersystems iris; with over 40 years’ experience in ehr integration, the intersystems iris platform is uniquely suited to support biostrand's breakthroughs." positioning ehr as a high-value commodity as tech giants like amazon, microsoft, apple, and alphabet invest heavily in health and wellness, ehrs have become a critical commodity. by integrating ehrs, biostrand enhances its ability to analyze and utilize vast amounts of health data. this capability enables biostrand to deliver superior insights and drive innovation in the rapidly evolving healthcare market. biostrand's business opportunity is centered around leveraging its foundation ai model to drive innovation in drug discovery and precision medicine. the integration of this functionality further strengthens biostrand's ability to scale its operations and expand its market reach, positioning the company as a frontrunner in the biopharmaceutical industry. "the integration of clinical patient data encapsulated in ehr systems within our foundation ai model represents a major step forward," stated dirk van hyfte md, phd, head of technology, ipa (co-founder and head of innovation, biostrand). "this pre-commercial model allows us to leverage extensive patient data, making more informed decisions and accelerating the development of personalized therapies." by invitation, dr. dirk van hyfte will provide a live demonstration to industry leaders and developers at the upcoming intersystems global summit 2024, june 9-12, 2024, in national harbor, maryland. for more details on the event schedule, please visit the summit's website (https://www.intersystems.com/global-summit/). about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: info@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia (canada), march 28, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), intersystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with immunoprecise antibodies ltd. (ipa) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. this collaboration integrates the new vector search capability of the intersystems iris® data platform with ipa’s subsidiary biostrand's lensai platform, setting a new standard for ai-driven applications in healthcare and life sciences. this collaboration signifies a leap in technological advancement for addressing challenges with increasing volumes of data that the healthcare and life sciences industries are contending with today. with the global ai market projected to grow to over $1.3 trillion by 2032, the collaboration between intersystems and ipa highlights both companies' commitment to innovation, excellence, and the development of solutions that not only meet the current needs of the healthcare and life sciences sectors but also anticipate future challenges, with additional client solutions and developments expected as vector search and lensai redefine the interaction between data and ai applications in healthcare and life sciences. “as the latest addition to the intersystems iris data platform, vector search has helped to supercharge the identification and creation of novel drug compounds, significantly reducing r&d timelines from development to commercialization” said scott gnau, head of global data platforms at intersystems. “we look forward to seeing how vector search within intersystems iris empowers other developers to build additional ai applications on our platform.” "by combining intersystem’s vector search with ipa's lensai, we're empowering developers and researchers in the life sciences with unparalleled tools for extracting value and insights from complex datasets, driving forward the potential for ai in every application within the healthcare and life sciences sectors," said dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "we are at the cusp of a new era in ai-driven applications, where the integration of sophisticated data analysis tools like vector search with the deep biological insights provided by lensai can lead to breakthroughs in patient care and treatment methodologies.” vector search and lensai: a synergistic integration this innovative integration marries the precision of vector search, which enables efficient and accurate retrieval of relevant information from massive datasets using vector embeddings, with the depth of analysis provided by lensai universal foundation ai model and biostrand's patented hyft technology. the result is a platform that offers unmatched capabilities in accessing, analyzing, and leveraging complex biological data for drug discovery, understanding disease mechanisms, and beyond. advancing healthcare and life sciences the collaboration between intersystems and ipa leverages the strengths of both platforms to offer several transformative benefits: precision and depth in data analysis: the integration enables more precise, semantically rich searches across vast repositories of unstructured biological data, uncovering insights that were previously difficult to obtain. accelerated drug discovery and development: researchers can now leverage the combined power of vector search and lensai to identify novel therapeutic targets more quickly, streamlining the drug discovery process and reducing the time from discovery to clinical trials. enhanced integration and scalability: by providing lensai capabilities within the intersystems iris data platform, companies in healthcare and life sciences gain a tool that seamlessly integrates with their existing infrastructure, offering scalability and enhanced performance without compromising security. about intersystems intersystems is a leading provider of next-generation solutions for enterprise digital transformations in the healthcare, finance, manufacturing, and supply chain sectors. its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. intersystems offers a range of software, including its flagship data platform software, intersystems iris, and a set of industry specific applications that speed and simplify the process of making data “ai ready.” intersystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. privately held and headquartered in cambridge, massachusetts, intersystems was established in 1978 and now has 39 offices in 28 countries worldwide. for more information, please visit intersystems.com. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, healthcare, integration and / or success of lensai with vector search, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology and vector search may not have the expected results, risks that the expected healthcare benefits won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

significant throughput of lsa to advance ipa’s diversity- and data-driven drug development and to enrich lensai™. victoria, british columbia (canada), march 20, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the lsa® instrument platform from carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. this instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the company’s capacity in performing various label-free protein interaction analyses including best-in-class kinetics, epitope binning, quantitation, epitope mapping, and blocking/neutralization assays. ipa remains committed to expanding its contract research organization (cro) capabilities and leveraging technology to drive innovation and efficiency, particularly in ai-driven drug design. carterra’s lsa instrument delivers significant throughput in short time frames requiring only small sample volumes. this fits well with the company’s established high throughput capabilities and diversity- and data-driven drug discovery, delivering huge amounts of valuable data points at an early-stage to advance the lead triaging process. the efficiency gain resulting from the acquisition will not only expedite the company’s in vitro characterizations for clients and partners, but also rapidly fuels lensai with valuable data sets to optimize models for next gen in silico drug discovery and development utilizing their proprietary hyfts to aggregate and integrate biological data. “the significance of our lensai technology extends beyond just the creation of an advanced tool,” says ipa’s chief executive officer and president, jennifer bath, phd. “it represents a strategic move to capture the growing interest in and huge potential of ai-driven drug discovery and digital biology. complementing our well-established high throughput antibody discovery, production, and screening capabilities, carterra’s lsa gets us closer to making ours the fastest and most cost-effective drug discovery workflow.” “we couldn’t be more excited to join with ipa in changing the way drugs are discovered,” said tim germann, chief commercial officer at carterra. “the lsa has made the use of ai in antibody discovery a reality; nothing generates more data in as little time to train ai/ml engines.” about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. ipa contact: info@ipatherapeutics.com about carterra, inc.: carterra, inc. is a privately held company. its ht-spr technology provides large-molecule and small-molecule drug discovery customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days. our solutions have enabled multiple therapeutics and breakthrough research and helped academic and translational researchers and biopharmaceutical companies in oncology, immunology, neuroscience, and more. carterra is based in salt lake city, utah, and has customer experience centers in san francisco, salt lake city, boston, manchester, england, and munich, germany. carterra products are available in asia-pacific and oceania through our exclusive distributor, revvity. to learn more, visit www.carterra-bio.com or connect with us on linkedin or x (twitter). carterra contact: cheri salazar sr. marketing manager +1 (408) 594-9400 forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments will not be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

dirk van hyfte md, phd, co-founder and head of innovation of biostrand, to present findings live next week at the himss24 conference in orlando, florida victoria, british columbia (canada), march 7, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today announced the development of a foundation ai model that represents a significant advancement in life sciences research and development. the company’s model uniquely combines the strengths of large language models (llms) through an advanced stacking technique with biostrand's patented hyft® technology. the hyft's ability to pinpoint unique 'fingerprints' in biological sequences enables the stacked llms to apply their vast knowledge base with greater specificity, leading to more accurate predictions and insights. this integration marks a pivotal moment in the utilization of artificial intelligence for complex biological data analysis and drug discovery. unveiling the intricacies of hyft technology central to the success of biostrand's foundation ai model is its utilization of its patented hyft technology, a sophisticated framework designed to identify and leverage universal fingerprint™ patterns across the biosphere. these fingerprints act as critical anchor points, encompassing detailed information layers that bridge sequence data to structural data, functional information, bibliographic insights, and beyond, serving as the great connector between disparate realms of knowledge. biostrand’s platform core is built upon a comprehensive and continuously expanding knowledge graph, mapping 25 billion relationships across 660 million data objects, and linking sequence, structural, and functional data from the entire biosphere to written text such as scientific literature, providing a holistic understanding of the relationships between genes, proteins, and biological pathways. the seamless integration of hyfts with stacked llms enables the biostrand ai model to decode the complex language of proteins, unlocking insights crucial for antibody drug development and precision medicine. large language models (llm), originally developed for natural language processing (nlp), can also be applied on “the language of proteins” enabling insights into tasks including, but not limited to, protein structure prediction, antibody binding optimization, and protein mutagenesis. to understand ‘the language of proteins’, it is essential to detect meaningful words and word boundaries. this is where the hyfts serve as critical enablers. by harnessing hyft's sophisticated computational capabilities, the previously abstract notion of identifying functional units or "words" in protein sequences is made tangible, allowing for precise mapping and analysis. the advanced foundation ai model employs a distinctive approach known as "llm stacking" to intelligently combine different llms, with the hyfts linked to specific features found in various llms. using a natural language analogy, this would mean one is able to distinguish the meaning of ‘apple’ based specifically on the context of the word, in other words, is the word “apple” referring to a type of fruit versus ‘apple’, silicon valley pioneer. in a life sciences context, these features, for example, could include identification of critical amino acid residues involved in protein binding or detecting sequence variations associated with disease susceptibility. the sequence diversity harnessed by the hyfts was discovered during the clustering of next generation sequencing data sourced from ipa’s pipeline subsidiary, talem therapeutics, utilizing the hyft network combined with llm stacking. through the incorporation of various features provided by llm stacking in this study, it was possible to differentiate between binding and non-binding antibodies, even when they shared similar hyft patterns. pioneering a new frontier in life sciences the concept of "word boundaries" within protein languages offers a groundbreaking approach to unlocking the complexities of protein structure and function, filling a void in the knowledge base of researchers and drug developers alike. by enabling precise identification and manipulation of functional units within proteins, this innovative methodology paves the way for advancements in drug discovery, protein-based therapeutics, and synthetic biology. it promises not only to accelerate the development of targeted treatments with higher efficacy and lower side effects but also to revolutionize protein engineering and design. this approach, leveraging cutting-edge computational models and analysis techniques, stands to significantly reduce research and development timelines and costs . advancing drug discovery and precision medicine - lensai ™ integrated intelligence technology™ this methodology revolutionizes biotechnology and pharmaceutical research by providing a robust framework for drug discovery, protein engineering, and the development of protein-based therapeutics. the hyft technology’s application of "word boundaries" is particularly compelling, as it aims to significantly accelerate research and development processes. through the facilitation of targeted treatments and the innovation of novel therapies, the hyft technology offers a reduction in development timelines and costs . by providing a comprehensive understanding of the complex relationships between genes, proteins, and biological pathways, the model paves the way for the development of targeted therapies and personalized treatment strategies. reaffirming biostrand's leadership in biotech innovation "the development of our foundation ai model, powered by our unique 'llm stacking' approach and patented hyft technology, marks a significant milestone in the field of biotechnological research," stated dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "this innovation not only expands the boundaries of current biotech research, but also establishes a new standard for the application of ai in solving complex biological challenges." “as the global community recognizes the transformative potential of artificial intelligence in the life sciences,” dr. hyfte continued, “i am confident that biostrand's foundation ai model will stand at the forefront of innovation and the future of ai-driven solutions in biology and drug discovery.” a future of collaborative discovery in alignment with our mission to foster collaboration and innovation within the life sciences community, we are excited to announce that ipa's ceo, dr. jennifer bath, will participate in the h.c. wainwright 1st annual artificial intelligence based drug discovery & development virtual conference today march 7th, 2024. this participation underscores our commitment to leading the conversation on the future of ai-driven solutions in biology and medicine. additionally, we are thrilled to announce the participation of dirk van hyfte md, phd, co-founder and head of innovation of biostrand, alongside our esteemed technology partner, intersystems, at this year's himss24 conference in orlando, florida. together, we will be showcasing our latest advancements in the field of healthcare technology through intersystems’s innovator introduction program. our presentation will focus on introducing our groundbreaking universal foundation ai model for multiscale biological data integration. we invite you to join us for our lightning pitch session, where we will delve into the capabilities and potential impact of our universal foundation ai model. also, we welcome you to engage in fruitful conversations at intersystem's booth, #1361 at the himss conference, march 12th-14th, 2024. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments with higher efficacy and lower side effects will not be achieved, risks that the benefits to drug discovery, protein-based therapeutics, and synthetic biology won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia (canada), december 14, 2023 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year (“fy24”), which ended october 31, 2023. "we report our third consecutive quarter of record revenue, reflecting both existing and new customers’ needs for our end-to-end support of antibody discovery through development, designed to reduce risk, cost and time. our laboratory’s b cell select® platform, as well as our manufacturing facility with its expanded capacity, continue to experience strong growth. additionally, we have reduced our cash burn from $1.6 million fy24 q1 to $0.7 million in fy24 q2, reflecting the impact of our revenue growth and strategic cost cutting while we continue to invest in capabilities to support our clients. our subsidiary, biostrand, recognized early revenue from lensai-driven client programs and continues to progress towards the next phase of the launch of their lensai portal and software as a service (saas) platforms. with our talem assets, we remain committed to our strategy of driving revenue through out-licensing opportunities and are pleased to provide an update on the talem asset highlighted in september’s earnings call, as we have recently received and executed a letter of intent to engage in a material transfer agreement (mta) for this asset. we also continue to leverage talem’s strategic partnerships, which are contributing to our contract research revenue and generating new client opportunities for biostrand," said dr. jennifer bath, ceo of immunoprecise antibodies. business highlights and corporate update ipa's strategy to offer a fully integrated suite of antibody discovery and development services is showing clear results. in the recent quarter, the company recorded revenues of $6.2 million and $11.8 million for the three- and six-months ending october 31, 2023, respectively. these figures mark increases of 18.6% and 19.9% compared to the $5.2 million and $9.9 million revenues during the same periods in 2022. this is the second consecutive quarter in which we have experienced a year-over-year increase in revenue of approximately $1 million. specifically, ipa canada's laboratory revenue rose by 17%, while our utrecht, netherlands manufacturing facility experienced a significant 43% growth in revenue, reinforcing our expansion strategy to meet customer needs. biostrand is generating fee-for-service revenue through its lensai platform and is progressing in the development of commercial products to meet the needs of ipa's client base of over 600 companies. during fy24 q2, biostrand introduced two key services: epitope mapping and binning. these are expected to be fully integrated into ipa’s discovery offerings by the end of the current quarter. this advancement is a significant step towards the upcoming rollout of the lensai portal to all ipa clients, followed by the public launch of biostrand's comprehensive saas platform. the company’s decrease in r&d spending reflects the previous investments to develop the internal therapeutic talem assets, which are now in the next phase of revenue generation, and now primarily represent biostrand r&d. efforts are underway to pursue out-licensing opportunities for those internally developed talem assets. we recently received and executed a letter of intent (loi) for talem to engage in a material transfer agreement (mta) on an asset targeting an incurable, progressive disease, an asset previously highlighted in our fy24 q1 earnings call. the mta, targeted for execution prior to the end of a six week deadline, will enable the partner to conduct an independent review of the asset under contemplation of an out-licensing. simultaneously, the company's marketing partnerships are enhancing revenue in contract research and creating new opportunities in biostrand. the company recently completed a 1.265 million common share capital raise, in part for additional wet lab capacity to meet customer demand and to advance r&d for our biostrand initiatives in response to customer needs in the competitive artificial intelligence landscape. we believe our revenue growth, along with positive customer traction on our complementary biostrand products, reinforce our strategy of long-term value creation through cultivating and expanding our strong customer base while providing higher margin revenue growth. second quarter fy24 financial results revenue:total revenue was $6.2 million, compared to revenue of $5.2 million in fiscal year 2023 (“fy23”) q2. project revenue generated $5.5 million, including $0.2 million of work completed by biostrand, and compared to $4.7 million in fy23 q2. product sales and cryostorage revenue were $0.7 million, compared to $0.5 million in fy23 q2. research & development (r&d) expenses:r&d expenses were $1 million, compared to $5 million in fy23 q2, with the decrease reflecting reduced expenditures related to the company's polytope® antibody combination therapy. sales & marketing (s&m) expenses:s&m expenses were $0.9 million, compared to $0.8 million in fy23 q2. general & administrative (g&a) expenses: g&a expenses were $3.3 million, compared to $3.8 million in fy23 q2. this decrease reflects a reduction of $0.5million in g&a professional fees. net loss:net loss of $2.6 million, or $(0.10) per share on a basic and diluted basis, compared to a net loss of $7.4 million or $(0.30) on a basic and diluted basis in fy23 q2. liquidity:$6.1 million of total cash, cash equivalents and marketable securities, with a reduced cash burn of $0.7 million for fy24 q2, compared to cash burn of $1.6 million for fy24 q1. *expressed in canadian dollars, unless otherwise indicated. conference call and webcast details the company will host a live conference call and webcast to discuss these results and provide a corporate update on thursday, december 14, 2023, at 10:30am et. to participate in the call, please dial 1-888-550-5658 (domestic) or 1-646-960-0289 (international) and provide conference id 9236374. the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. attendee url: for inclusion in your invitations to shareholders and guests. https://events.q4inc.com/attendee/905281713 about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. cautionary statement regarding forward looking information this news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable united states securities laws and canadian securities laws (collectively, “forward-looking statements”). forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking statements contained in this news release include, but are not limited to, statements regarding our revenue growth, out-licensing and new client opportunities, strategic partnerships, expansion strategy, the integration of biostrand services and the loi and mta with talem and our ability to create long-term value for customers. in respect of the forward-looking statements contained herein, ipa has provided such statements in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, including risks discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedarplus.com), and the company’s annual report on form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor contact investors@ipatherapeutics.com

victoria, british columbia, november 27, 2023 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is pleased to announce important board of director changes and upcoming financial reporting activities. new board chairman mitch levine joined the board of directors of ipa at ipa’s recent annual general meeting and has been appointed as chairman of the board, bringing a wealth of experience from the life sciences industry and financial strategy, particularly in nasdaq market operations. as ceo and chairman of smarthealth dx since 2022, levine has focused the company’s strategy, operational efficiency, and boosted corporate value. at oncocyte, he drove significant growth as cfo from 2017 to 2022, overseeing all financial operations of the company, managing capital raises, navigating nasdaq complexities, and leading major acquisitions and a key licensing deal in china. his capital markets expertise was widely recognized as founder and managing member of enable capital management, llc, where for 17 years they provided growth capital to small- and mid-sized public companies, many traded on nasdaq. his background also includes a foundational role at the shemano group, a san francisco-based investment bank focused on technology and life sciences sectors. dr. jennifer bath, ceo of immunoprecise antibodies, lauds levine’s combination of life sciences and financial acumen as invaluable for ipa. his guidance is expected to be crucial for ipa's innovative growth, particularly in antibody discovery and development, and to further establish ipa as a leader in the biotech industry. “we anticipate his guidance in financial strategies and market dynamics to be a significant asset in driving ipa's innovative growth and expansion, especially as we progress our cutting-edge biotechnologies like hyft® and lensai™.” remuneration and nomination committee chairman chris buyse is currently the chairman of the remuneration and nomination committee, effective october 2, 2023. mr. buyse brings both experience with nasdaq traded life science companies as well as pharmaceutical industry experience. he is currently a board member and chairman of the audit committee of inventiva sa, a dual-listed company on euronext paris and nasdaq, and a board member and member of the audit committee of hyloris pharmaceuticals, a company listed on euronext brussels. new audit committee chairman additionally, ipa is pleased to announce the appointment of dirk witters as the new chairman of the audit committee, effective november 15, 2023. mr. witters brings a strong background in finance and auditing, having previously served as executive partner in a corporate finance boutique and was advisor to the founder of new rhein healthcare investors, a private equity investment firm focused on healthcare therapeutics and medical devices, where he assisted with the capital raise of the second investment fund. mr. witters also spent 20+ years with kbc group’s corporate and investment banking division where he gained experience in business development, strategy execution, advisory and corporate finance. the appointment of mr. witters as chairman of ipa’s audit committee underscores ipa's commitment to maintaining the highest standards of financial oversight and corporate governance. "we at ipa are thrilled to embark on this exciting new chapter with the support of our shareholders and stakeholders, guided by our esteemed leadership team. the appointment of mitch levine as our chairman, along with chris buyse as chairman of the remuneration and nomination committee, and dirk witters as the new chairman of the audit committee, marks a significant milestone for our company, stated dr. bath.” their combined expertise in the life sciences sector, financial strategy, and corporate governance, especially in nasdaq-listed environments, not only reflects the strong backing we have from our shareholders but also reinforces our commitment to excellence and innovation in biotechnology. we believe that their leadership and insights will be instrumental in steering ipa towards groundbreaking advancements and sustained growth in the industry." upcoming second quarter 2023 earnings release call ipa will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2024, on thursday, december 14, 2023, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. investors, analysts, and other stakeholders are invited to participate in the conference call, during which ipa's senior leadership will discuss the financial results and provide insights into the company's performance and future outlook. title: ipa reports financial results and recent business highlights for second quarter fiscal year 2024 event date: december 14, 2023 event time: 10:30 et webcast url: https://events.q4inc.com/attendee/905281713 participant details participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 conference id: 9236374 about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com source: immunoprecise antibodies ltd. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the future expectations for ipa, including expectations regarding ipa achieving groundbreaking advancements and sustained growth in the industry. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia--(business wire)-- immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, biostrand®, has published a preprint of its groundbreaking white paper titled, "new paradigm for biological sequence retrieval inspired by natural language processing and database research" on biorχiv. the publication delves into the intricacies of one of biostrand’s applications based on its patented hyft-based methodology, a novel and proprietary approach to biological sequence retrieval, and its clear advantages over the gold standard algorithm, basic local alignment search tool “blast”. by detailing their innovative approach and its potential implications for the scientific community, biostrand aims to foster collaboration and drive innovation in the realm of bioinformatics. key highlights from the white paper: introduction to hyft patterns: the paper introduces hyft patterns as unique signature sequences, akin to biological fingerprints, found in amino acids, dna, and rna. these patterns serve as a tool to tokenize and harmonize all biological data into a unified omics language. parsing and indexing with hyfts: the paper details the two-step process of parsing biological sequences to retrieve hyft patterns and then indexing them. this approach prioritizes non-overlapping hyfts with lower ranks, ensuring comprehensive coverage of the sequence. benchmarking results: a comparative study between blast and the hyft methodology revealed that while blast excels in retrieving distant homologous sequences, hyft is particularly relevant for higher identity matches. dirk van hyfte, md, phd, co-founder and head of innovation of biostrand, remarked, "the publication of our research on biorxiv.org is not just a milestone for biostrand, but a significant contribution to the bioinformatics community. we believe, given the ever-increasing availability of sequence data, our hyft-based sequence similarity search methodology offers the scalability needed in this era of big data without losing precision, and we eagerly anticipate the discourse and collaboration it will inspire." lensai: the next-generation advanced ai platform recently, biostrand successfully rolled out its next-generation unified knowledge graph-large language model (llm) framework for holistic life sciences research. at the core of their lensai platform is a comprehensive and continuously expanding knowledge graph that maps a remarkable 25 billion relationships across 660 million data objects, linking sequence, structure, function, and literature information from the entire biosphere. their first-in-class technology provides a comprehensive understanding of the relationships between genes, proteins, structures, and biological pathways, thereby opening powerful new opportunities for drug discovery and development. the platform leverages the latest advances in ontology-driven nlp and ai-driven llms to connect and correlate syntax (multi-modal sequential and structural data) and semantics (biological functions). biostrand’s unified approach to biomedical knowledge graphs, retrieval augmented generation (rag) models, and llms combines the reasoning capabilities of llms, the semantic proficiency of knowledge graphs, and the versatile information retrieval capabilities of rag, to streamline the integration, exploration, and analysis of biomedical data, potentially unlocking a realm of uncharted possibilities. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, integration and / or success of lensai, llms, rag, or hyft technologies, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

biostrand unveils groundbreaking retrieval augmented generation (rag)-based llm platform integrated with patented hyft technology biostrand's work exemplifies the ipa family's investment in advanced ai, aiding partners in developing new biologics for previously undruggable targets victoria, british columbia, october 25 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, announces that its subsidiary, biostrand®, has commercially launched its state-of-the-art retrieval augmented generation (rag)-based large language model (llm) platform. this pioneering platform seamlessly integrates with the company’s patented hyft technology and lensai platform, signifying a noteworthy leap in the market as the company aims at ensuring unparalleled accuracy, interpretability, and data-centric design in generative ai tools. biostrand's innovative approach to solving the information integration dilemma (iid) has led to the development of a unique technology design that encapsulates and unifies diverse data modalities. this includes syntactical (sequence) data, 3d structural data, unstructured scientific information (e.g., scientific literature), all integrated within a singular framework, the lensai knowledge graph. this breakthrough facilitates efficient data fusion, enabling a comprehensive analysis and interpretation of complex biological data. knowledge graphs and llms have been recognized for their superior performance over conventional approaches in drug discovery. biostrand’s integration of their proprietary and patented technologies with llm synergizes strengths and addresses limitations, leading to a more efficient drug discovery platform. biomedical llms, specifically those pre-trained on domain-specific vocabulary, outperform traditional tools in many biological data-based tasks. for instance, for the important step of identifying drug targets, ai-powered language models have demonstrated superiority over even the most state-of-the-art approaches. furthermore, ai-enabled llms are now being utilized across the drug discovery and development pipeline for predicting drug-target interactions, molecular properties, and even potential drug withdrawals due to safety concerns. key features of biostrand’s lensai platform: holistic integration of data: lensai offers a unified approach, linking sequence, structure, function, and literature information from the entire biosphere, providing a comprehensive view of life sciences data. expansive knowledge graph: at its core, lensai boasts a knowledge graph that maps 25 billion relationships across 660 million data objects, ensuring a deep and interconnected understanding of genes, proteins, and biological pathways. neuro symbolic methodology: a fusion of deep learning and symbolic logic techniques, a branch of mathematics and philosophical logic that uses symbols to represent logical expressions, rather than using words. this approach harnesses the data-driven strengths of llms and the reasoning capabilities of symbolic systems, offering both adaptability from llm methods and transparency from symbolic logic, ensuring comprehensive and interpretable outcomes for inquiries. retrieval-augmented generation (rag) integration: lensai utilizes rag to enhance the accuracy of the generated responses of llms. by integrating with the hyfts technology as its proprietary knowledge graph, rag ensures that the platform provides up-to-date and factual information, reducing the chances of generating inaccurate or "hallucinated" content. this synergy is designed to allow lensai to deliver more informed and precise answers, bridging the gap between the vast generative capabilities of llms and the concrete data from hyfts technology. traceability and credibility: all results generated by lensai can be referenced back to their original sources, ensuring authenticity and reliability in research outcomes. "i am pleased to share that biostrand's advanced ai platform has now integrated a retrieval augmented generation plugin with a large language model, marking a significant technological advancement. this integration, viewed through the prism of our patented hyfts, not only simplifies complex information but opens a new dimension of predictive analysis. it notably enhances the platform's ability to delineate the structure, function, and potential applications of large molecules, representing a meaningful step towards more intuitive and insightful data analysis in the life sciences sector. "as we focus on advancing drug discovery and development processes, we have commenced a limited release of our platform through a well-structured phased rollout strategy extending over the upcoming year. this approach is aimed at ensuring a smooth transition into ipa's existing customer offerings while also allowing us to collect valuable feedback. the feedback garnered will be instrumental for the ongoing refinement and optimization of the platform, ensuring it continues to meet the evolving needs of our clientele," shares dirk van hyfte, md, phd, co-founder and head of innovation of biostrand. lensai: the next-generation advanced ai platform biostrand has successfully rolled out a next-generation unified knowledge graph-llm framework for holistic life sciences research. at the core of their lensai platform is a comprehensive and continuously expanding knowledge graph that maps a remarkable 25 billion relationships across 660 million data objects, linking sequence, structure, function, and literature information from the entire biosphere. their first-in-class technology provides a comprehensive understanding of the relationships between genes, proteins, structures, and biological pathways, thereby opening powerful new opportunities for drug discovery and development. the platform leverages the latest advances in ontology-driven nlp and ai-driven llms to connect and correlate syntax (multi-modal sequential and structural data) and semantics (functions). biostrand’s unified approach to biomedical knowledge graphs, rag models, and llms combines the reasoning capabilities of llms, the semantic proficiency of knowledge graphs, and the versatile information retrieval capabilities of rag to streamline the integration, exploration, and analysis of biomedical data, potentially unlocking a realm of uncharted possibilities. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential,” “plans,” “expects” or “does not expect,” “is expected,” “estimates,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensaiin silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

victoria, british columbia, october 23 - immunoprecise antibodies ltd. (nasdaq: ipa) ("ipa" or the "company"), an ai-driven biotherapeutic research and technology company wishes to provide an update on its overall growth strategy, particularly in light of recent market developments. ipa remains committed to expanding its contract research organization (cro) capabilities and leveraging technology to drive innovation and efficiency. the pioneering work at ipa’s subsidiary, biostrand, reinforces ipa’s commitment to investing in cutting-edge biotechnology solutions to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. ipa provides highly specialized full-service antibody discovery, development and through a biostrand’s integrated platform, designed to enhance customers' drug discovery and development, has begun its limited release through a phased rollout strategy spanning the coming year. the company is currently charging as a fee-for-service with a planned roll-up to a software as a service (saas) offering. this approach is designed to ensure a seamless integration into its existing customer offerings, while allowing the company to gather valuable feedback from customers for further development and optimization to support its goal of profitable growth. along with its commitment and investment in the complementary biostrand platform, ipa continues to grow its core business of being the #1 globally ranked antibody discovery contract research organization (cro) with 95% of top 20 pharma as clients. the ipa strategy of providing highly specialized full-service antibody discovery and development, while gaining a competitive edge for profitable growth through technology and scale, continues to pay off. ipa’s first quarter fiscal year 2024, which ended july 31, 2023, reported a record 21.3% increase in revenue compared to the same period last year, but also witnessed ipa’s protein manufacturing facility leverage its expanded capabilities, marking an impressive 44.0% growth year over year. in addition, as a testament to a focus on shareholder value, ipa achieved a reduced quarterly burn to $1.6 million canadian dollars. ipa’s focus on operational optimization while continuing to invest in sustainable growth continues in fiscal 2024. ipa does not believe the recent drop in stock price matches the value creation it is building with its growth strategy. “based on the current trajectory of customer orders, we are optimistic about the future and anticipate sustained growth. in tandem with this, we have initiated measures to further optimize our expense base, ensuring we continue on a path of financial prudence and growth,” concluded dr. jennifer bath, chief executive officer of ipa. “we understand the importance of transparent and timely communication with our shareholders. as such, we are eager to delve deeper into our performance, future plans including ongoing advancements with our subsidiaries biostrand and talem, and address queries you might have during our upcoming 2q earnings call,” added dr. bath. “your trust and investment in ipa are deeply valued. we remain committed to driving value for all our shareholders and stakeholders and thank you for your continued support." about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

brad mcconn to step down later this month kristin taylor, mba, cpa, named interim cfo victoria, british columbia, september 19 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), today announced that it has accepted the resignation of brad mcconn, cfo, effective september 29, 2023. ipa has named kristin taylor, mba, cpa, as interim chief financial officer. “on behalf of ipa, i thank brad for his leadership and contributions and wish him every success in his future endeavors,” said dr. james kuo, chairman of the board. “i also welcome kristin as interim cfo. ms. taylor brings extensive executive management and life sciences experience, as well as strong background in capital markets and investor relations. combined with ipa’s strong accounting, financial reporting, and treasury teams we have in place, we are confident all cfo-related capabilities and responsibilities will be sustained for a smooth transition.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor contact: investors@immunoprecise.com source: immunoprecise antibodies ltd.

company recorded record quarterly revenue, an increase of 21.3% compared to the same quarter last year. significantly higher net income before taxes when compared to q1 of last year, a difference of approximately $6 million dollars, another positive back-to-back quarter trend. victoria, british columbia, september 14 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2024, which ended july 31, 2023. “we are immensely proud to share that immunoprecise antibodies has commenced fiscal year 2024 with unparalleled vigor and determination. this quarter, we've not only achieved a record 21.3% surge in our revenue compared to the same period last year but also witnessed our protein manufacturing facility leverage its expanded capabilities, marking an impressive 44.0% growth year over year. furthermore, our consolidated financial performance, including a significant change in net income before taxes, a difference of approximately $6 million dollars from q1 of the previous year, and a reduced quarterly burn to $1.6 million canadian dollars, stands as a testament to our unwavering commitment to excellence and shareholder value”, stated dr. jennifer bath, ceo of ipa. “the recent induction of esteemed professionals like chris buyse, dr. barry springer, and dirk witters into our board of directors signifies a renewed era for ipa”, dr. bath continued. “their collective expertise, combined with our management's dedication, will chart a visionary path for the company. chris buyse's financial acumen, dr. springer's therapeutic antibody expertise, and dirk witters' profound knowledge in capital raising and executive leadership, together, promise to amplify our trajectory, ensuring we harness the vast opportunities that lie ahead. the unwavering support and trust of our shareholders has been instrumental in our journey, and as we turn this new chapter, we remain more committed than ever to innovation, collaboration, and excellence. we are confident that with our current trajectory and the strategic initiatives in focus, the future holds unparalleled promise for ipa and all our stakeholders.” ipa announces appointments of chris buyse, dr. barry springer, and dirk witters to board of directors as of september 5th, 2023. company demonstrates record quarterly revenue, an increase of 21.3% compared to the same quarter last year. significantly higher net income before taxes when compared to q1 of last year, a difference of approximately $6 million dollars, another positive back-to-back quarter trend. ipa demonstrates reduction in quarterly burn to $1.6 million canadian dollars. manufacturing facility up 44.0% in quarterly revenue compared to same quarter last year. ipa seamlessly integrates state-of-the-art lab techniques and proprietary computational methodologies to advance therapeutic lead nomination. ipa engages jefferies investment bank. filed an f-3 form with the sec, allows ipa to register securities for a 'shelf offering'. ipa’s subsidiary, biostrand, unveils use case demonstrating the application of their software in solving the information integration dilemma (iid). ipa releases new hyft-powered in silico humanization platform, aims to disrupt the transgenic animal model market. ipa's subsidiary, biostrand, solves the information integration dilemma (iid) for systems biology. ipa’s ceo gives inaugural presentations at jefferies healthcare conference and nasdaq. first quarter fiscal year 2024 financial summary* (all comparisons are to the period ended july 31, 2022) ipa achieved revenue of $5.7 million during the three months ended july 31, 2023, an increase of 21.3% compared to the three months ended july 31, 2022. gross profit increased 12.7% to $2.8 million for the three months ended july 31, 2023, as compared to the same period last year. ipa held cash of $6.8 million as of july 31, 2023. *expressed in canadian dollars, unless otherwise indicated. financial results revenue & gross profit ipa achieved revenue of $5.7 million during the three months ended july 31, 2023, a 21.3% increase from the three months ended july 31, 2022. profit increased 12.7% to $2.8 million from the same period last year. research and development during the three months ended july 31, 2023, research and development expenses decreased to $0.4 million from $6.2 million during the three months ended july 31, 2022, primarily due to significantly reduced expenditures related to the company's polytope® antibody combination therapy. research and development expenses for the three months ended july 31, 2023, include $0.3 million in salary costs, including share-based payments (2022 - $0.3 million), and $0.2 million in research expense (2022 - $5.8 million). sales and marketing sales and marketing expenses totaled $1.1 million during the three months ended july 31, 2023, compared to $1.0 million during the three months ended july 31, 2022. expenditures during the three months ended july 31, 2023, include $0.8 million in salary costs, including share-based payments (2022 - $0.7 million), and $0.2 million in advertising cost (2022 - $0.3 million). general and administrative during the three months ended july 31, 2023, general and administrative expenses totaled $4.6 million, an increase of $0.4 million compared to the three months ended july 31, 2022. notable increases include salary costs of $0.1 million and interest recorded on the company's leases of $0.1 million. liquidity and capital resources as of july 31, 2023, ipa held $6.8 million of cash, as compared to $8.4 million as of april 30, 2023, and had working capital of $9.3 million. during the three months ended july 31, 2023, the cash used in operating activities was $0.7 million. as part of the investing activities, the company made equipment purchases of $0.1 million, paid deferred acquisition payments of $0.1 million, and sold shares of qvq holdings bv for proceeds of $0.1 million. as part of the financing activities, the company incurred lease repayments of $0.4 million. conference call: date: thursday, september 14, 2023 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/997889510 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models and wet-lab experiments may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor contact: investors@immunoprecise.com source: immunoprecise antibodies ltd.

the company to host an earnings conference call via webcast victoria, british columbia, september 8 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on thursday, september 14, 2023, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. immunoprecise management will host the conference call followed by a question-and-answer period. conference call: date: thursday, september 14, 2023 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/997889510 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com source: immunoprecise antibodies ltd.

pa appoints barry a. springer, dirk witters and chris buyse to the board of directors victoria, british columbia, september 5 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated august 9, 2023, it has appointed, in its search for optimal board composition, barry a. springer, dirk witters and chris buyse to the board of directors of the company. appointment of new directors to the board of directors in surveying the new appointees, dr. james kuo, chair of the board of ipa, highlighted the following: “it is a testament to our board’s reputation for transparency and shareholder engagement, that our search has resulted in the appointment of three individuals. the appointees will add complementary skills to the board's skill matrix, and underline ipa’s commitment to the optimal board composition. the appointment of barry a. springer, dirk witters and chris buyse to the board will bring significant experience and expertise to complement the capabilities of the board, and drive shareholder value.” will mchale, director at ingalls & snyder, llc, the largest independent shareholder of the company, commented: "i appreciate the actions announced today by ipa's board. the appointment of messrs. springer, witters and buyse and additional refreshment at the near term annual general meeting provides ipa’s board with experience and expertise required for ipa to take its next steps and maximize value for shareholders." barry a. springer is currently the principal at springer bio-tech consulting, llc and was previously the vice president of janssen strategy, operations and innovation. mr. springer advised biotechnology and pharmaceutical companies providing executive level strategic advice in the areas of biologics and small molecule drug discovery and development, and platform technology development. dirk witters founded conanti consult bv in 2019, an advisory boutique, where he, among other things, advises on the execution of acquisitions and capital raising assignments. prior to that, mr. witters also served as an advisor to the founder of new rhein healthcare investors, a private equity investment firm focused on healthcare therapeutics and medical devices. in addition to this more recent capital raising experience, mr. witters also spent 20+ years with kbc group in corporate and investment banking, including eight years as ceo of kbc france. chris buyse is currently a board member and chairman of the audit committee of inventiva sa, a dual-listed company on euronext paris and nasdaq and a board member and member of the audit committee of hyloris pharmaceuticals a company listed on euronext brussels. mr. buyse has extensive experience in capital raising endeavours having co-founded fund+ nv/sa, a private fund, investing in companies in the life sciences sector with a european focus, where he is currently a board member. he was also previously the cfo at thrombogenics, a biopharmaceutical company listed on the euronext brussels stock market, where he guided the company through its ipo and four capital raises (the raises totaling an aggregate of €500m). other governance matters in addition to the above appointments, the company wishes to announce that: gregory s. smith has resigned as a director of the company, effective immediately. the company thanks mr. smith for his service and wishes him all the best in his future endeavours; and none of ipa’s three incumbent non-executive board directors (dr. james kuo, dr. robert burke and lisa helbling) will stand for re-election at the upcoming annual general meeting, to be held no later than early november 2023. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes but is not limited to the expected results of the appointment of the three new directors to the board, and mr. smith’s resignation from the board. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the appointment of the three new directors to the board and mr. smith’s resignation from the board may not yield desired results, or that the upcoming annual general meeting is not held by early november 2023, as well as those risks discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedarplus.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

ipa responds to 13d filing by ingalls & snyder, llc victoria, british columbia, august 9 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, today issued the following statement in response to the schedule 13d filing made on july 7, 2023 by ingalls & snyder, llc a new york-based investment manager. "ipa’s board of directors and management team value constructive input and welcome open communication with our shareholders including ingalls & snyder, llc. we are committed to acting in the best interest of ipa and strive to have the optimal board of directors’ composition to attain ipa’s strategic priorities and to maximize long-term shareholder value," said dr. james kuo, chair of the board of ipa. "we have opened the dialogue with ingalls & snyder llc and will continue to engage in discussions with them as we carefully consider their views. we will update shareholders in due course." underscoring this commitment, ipa announced that it has recently begun interviewing potential candidates to refresh its board of directors (the “board”) in its search for the optimal board composition. majority voting policy furthermore, in its commitment to address shareholders’ concerns and as part of its continuous review and improvement process, the company announced that the board has also adopted a majority voting policy (the “majority voting policy”) based on its belief that each of its directors should carry the confidence and support of ipa’s shareholders and its commitment to upholding high standards in corporate governance. under the majority voting policy, any director who receives more "withheld" votes than "for" votes will be required to tender his or her resignation to the board. absent extraordinary circumstances, the board is expected to accept such resignation. the majority voting policy is effective immediately. the full text of the majority voting policy is available under the company’s profile at www.sedarplus.com, or www.sec.gov and on the company’s website at www.ipatherapeutics.com. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the expected outcome of adopting the majority voting policy, as well as the expected results of the ongoing board refreshment process. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the ongoing board refreshment process may not yield desired results, as well as those risks discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedarplus.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

victoria, british columbia, july 14 - immunoprecise antibodies ltd. (nasdaq: ipa) ("ipa" or the "company"), an ai-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other interested parties to participate in an upcoming interview hosted by market radius research. martin gagel, founder of market radius research, will join forces with dr. jennifer bath, ceo of ipa, to delve into the intricate details of ipa's revolutionary platform. ipa’s patented technology seamlessly integrates multiple modalities of biological data, multi-omics modeling, and artificial intelligence, a unique capability within the field of biotherapeutic research. additionally, the interview will shed light on ipa's in silico commercialization and market development strategies. the event will be presented as a dynamic and interactive online webinar, offering attendees the opportunity to engage with the company in real-time by posing questions following the interview. for those unable to join the event live on the designated day, an archived webcast will be made accessible for later viewing. don't miss this exclusive occasion to gain valuable insights into immunoprecise antibodies’ groundbreaking advancements. mark your calendars and join us on the webinar to witness the future of biotherapeutic research and development. event: radius research pitch, deep dive and q&a with immunoprecise antibodies presentation date & time: wednesday, july 19th at 4 pm et / 1 pm pt webcast registration link: https://us02web.zoom.us/webinar/register/8216884929254/wn_pypmine_sygvbg4ufxtmkg the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx market radius research gives individual investors access to in-depth ceo interviews with deep-dive institutional level discussion and q&a. market radius is hosted by martin gagel, former top-ranked technology analyst. by registering for this webinar, you agree to receive email communications from market radius capital, inc. and from the presenting company (with unsubscribe). your email will not be further shared. martin gagel and market radius capital, inc. are not registered or licensed to provide investment advice and may own shares in mentioned companies and may be compensated for these services. content is for information purposes only and is not advice or recommendations and may include incomplete or incorrect information. investing entails a high degree of risk. this is a production of market radius capital, inc. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investors: investors@ipatherapeutics.com source: immunoprecise antibodies ltd.

the company achieved revenue of $20.7 million during the year ended april 30, 2023, a 6.7% increase from the year ended april 30, 2022. yoy growth increases to 9.0% when adjusting for the effects of currency translation. the company recorded total revenue of $5.6 million during the three months ended april 30, 2023, the highest quarterly revenue total the company has recorded. victoria, british columbia, july 7, 2023 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended april 30, 2023. "as we usher in fiscal year 2024, we carry with us a strong momentum from the impressive strides we made in the previous year. in the fiscal year ended april 30, 2023, we achieved a revenue of $20.7 million, marking a notable 6.7% (or 9% when adjusting for the effects of currency translation) increase compared to the year ended april 30, 2022. we also recorded our highest quarterly revenue total of $5.6 million in the last quarter ending april 30, 2023. these milestones serve as a testament to the soundness of our strategies and the dedication of our team. as we look ahead to fiscal year 2024, we see immense potential for our in silico suite of services and data management capabilities to further bolster our growth. we expect these innovative offerings to significantly contribute to our financial performance this year and set the stage for long-term success. our unwavering commitment to excellence, coupled with our robust pipeline and agile execution, position us to deliver continued strong performance this year and beyond. this is a thrilling period for our company, and we are eager to embark on the new fiscal year, further driving innovation and growth." stated dr. jennifer bath, ceo of ipa. recent and fiscal 2023 operational highlights talem entered into exclusive research collaboration and license option agreement with astellas targeting an undisclosed protein in the tumor microenvironment (tme) talem presented its latest data on the development of bispecific t-cell engagers targeting trkb at the annual aacr meeting in orlando, florida, in april 2023. talem entered into a multi-target license agreement with omniab, inc to further the development and commercialization of immuno-oncology antibody panels. biostrand entered into a research collaboration and license agreement with briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) ipa’s subsidiary, biostrand, secured second €460,000 vlaio research grant. biostrand has successfully solved the information integration dilemma (iid) biostrand® publicly unveiled use case showing solution of the information integration dilemma (iid) biostrand completed the full integration of 20 million structural hyfts with deepmind’s alphafold and meta’s esm-2 fold platforms. epo granted biokey’s patent application covering the company’s hyft® technology used to organize and analyze biological sequence information. ipa achieved a record global cro revenue of $5.6 million in q4 fy23, representing a 7.3% increase from the previous year, reflecting strong demand and stability. ipa secured $4.65m sales orders for future fee-for-service work in q4, demonstrating market confidence and high demand for services. ipa europe's human phage display and humanization offerings experienced financial growth and improved capabilities with newly generated phage libraries and modernized workflows. ipa expanded its single b cell screening capabilities to include species from the camelid family, leading to increased requests for vhh-based discovery programs and new revenue opportunities. talem, a subsidiary of ipa, elevated three key programs with significant value potential, generating interest from prospective partners and focusing on partnering discussions with larger corporations. ipa's revenue streams consist of non-cannibalistic in silico technologies, in silico de novo antibody discovery and development partnerships, and a data organization and management platform, all demonstrating robust growth. ipa's commitment to innovation is reflected in its unique platform that integrates biological data dimensions using ai and hyft technology to unlock valuable insights and connections. the ongoing advancements in software development, including lensai software, have enabled ipa to solve real-life biological problems and overcome the challenges of omics data integration and analysis. ipa has strategically positioned itself to capture opportunities in multiple revenue streams, including in silico technologies, de novo antibody discovery, and data organization and management. the investor call will dive deeper into ipa's achievements, discuss exciting prospects, and invite participants to join in driving innovation in ai-driven antibody discovery. financial results revenue the company achieved record revenue of $20.7 million during the year ended april 30, 2023, a 6.7% increase from the year ended april 30, 2022. revenue growth from the prior year was 9.0% when adjusting for the effect of currency translations. the increase in revenue was primarily driven by growth in the company’s b cell select® platform and protein manufacturing services. research and development during the year ended april 30, 2023, research and development expenses increased to $12.3 million from $7.7 million during the year ended april 30, 2022. expenditures on research activities totaled $10.8 million during the year ended april 30, 2023 (2022 - $6.7 million), including $8.3 million on talem’s polytope® antibody combination therapy. additional expenditures include compensation expense of $1.2 million (2022 - $0.7 million), and depreciation of $0.2 million (2022 - $0.2 million). sales and marketing sales and marketing expenses totaled $3.6 million during the year ended april 30, 2023, compared to $2.7 million during the year ended april 30, 2022. expenditures during the year ended april 30, 2023, include $2.5 million in compensation expense (2022 - $2.1 million), $0.7 million in advertising costs (2022 - $0.5 million), and $0.2 million in travel costs (2022 - $0.03 million). general and administrative during the year ended april 30, 2023, general and administrative expenses totaled $19.8 million, an increase of $4.4 million compared to the year ended april 30, 2022. salaries and benefits increased $2.1 million due primarily to the addition of staff at biostrand and routine pay increases. the company recorded an impairment charge of $2.5 million related to the biostrand cash-generating unit. professional fees decreased $0.2 million, driven primarily by a decrease in legal costs. management fees increased $1.3 million due to contracted general managers at the biostrand site. share-based payment expenses decreased by $1.0 million. other income / expense the company recorded other income of $0.8 during the year ended april 30, 2023, compared to other income of $0.9 million during the year ended april 30, 2022. the most noteworthy variance is the decrease in unrealized foreign exchange gain of $0.4 million compared to the year ended april 30, 2022, a result of currency revaluations at the current quarter-end exchange rate. grant income increased $0.3 million compared to the year prior, as the company recorded the first round of grant funding from vlaio (flanders innovation & entrepreneurship), the research fund of the flemish regional government in belgium. net loss the company recorded a net loss of $26.6 million during the year ended april 30, 2023, compared to a net loss of $16.7 million during the year ended april 30, 2022. the increased net loss is the result of an increase in gross profit of $0.6 million, offset by an increase in research and development expenses of $4.6 million, an increase in sales and marketing expenses of $0.9 million, an increase in general and administrative expenses of $4.4 million. liquidity and capital resources as of april 30, 2023, the company had cash on hand of $8.4 million compared to $30.0 million as of april 30, 2022, and had working capital of $11.1 million (april 30, 2022 - $28.2 million). during the year ended april 30, 2023, the cash used in operating activities was $19.8 million. as part of investing activities, the company made equipment purchases of $1.5 million, and paid deferred acquisition payments of $0.6 million. as part of financing activities, the company received $0.7 million from issuing common shares, and incurred lease repayments of $1.3 million. conference call: event date: july 07, 2023 event time: 10:30 et participant details: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/109374701 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. investor contact: investors@immunoprecise.com source: immunoprecise antibodies ltd.

the company to host an earnings conference call via webcast victoria, british columbia, june 29, 2023 - ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), a leader in ai-driven biotherapeutic research and technology, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and fiscal year end 2023, on friday, july 7, 2023, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. immunoprecise management will host the conference call followed by a question-and-answer period. conference call: event date: july 07, 2023 event time: 10:30 et participant details: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/109374701 about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com source: immunoprecise antibodies ltd.

victoria, british columbia, june 13, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is excited to announce a new use case for the information integration dilemma (iid) solution developed by its subsidiary, biostrand®. link to use case here the iid has long been a significant challenge in the biotechnology industry, with researchers and investors grappling with the complexities of integrating diverse data types to gain meaningful insights. biostrand's lensaitm platform and patented hyft® technology have successfully addressed this issue, providing a unified framework that encapsulates and integrates diverse data modalities, including syntactical (sequence) data, 3d structural data, unstructured scientific information, and more. this breakthrough approach has paved the way for quicker and more potent biological discoveries, and the unveiling of this use case demonstrates the practical application of this technology in the field of biotechnology. this use case provides a detailed look at how hyft technology and the lensai platform can be utilized to solve complex biological problems, offering a glimpse into the future of biotherapeutic research and development. "our newest use case stands as a potent testament to how we've successfully navigated the iid. it demonstrates the power of integrating and organizing heterogeneous data types and reflects depth of insights gleamed using our comprehensive knowledge graph. this graph, teeming with over 25 billion relations, bridges the gap between sequence, structure, and textual data in a manner that was previously inconceivable. the application of these interconnections has unearthed insights and relationships that were otherwise invisible, enhancing our understanding of biological systems.” the unveiling of this use case is a testament to immunoprecise's commitment to innovation and its dedication to solving complex problems in the field of biotechnology. the company continues to lead the way in ai-driven biotherapeutic research and technology, and this latest development further solidifies its position as a pioneer in the industry. about biostrand’s hyft technology biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensai in silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, british columbia, june 6, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”) today introduced a transformative ai-driven rapid therapeutic screening platform, the result of a collaboration between ipa canada and its subsidiary, biostrand®. this innovative solution aims to significantly expedite the early stages of drug discovery by enabling the early elimination of less promising therapeutic candidates, thereby reducing time, cost, and the risk of failure during later stage discovery. the current transgenic animal model market, reaching usd 17.7 billion in 2021 and expected to grow by 8.1% cagr from 2022 to 2028¹, has been widely adopted in novel therapeutic discovery, primarily to avoid what was previously seen as time-consuming, expensive, risk-laden, and sometimes unsuccessful humanization processes. however, despite its widespread adoption, transgenics pose limitations of their own, such as a lack of diversity in therapeutic outputs, loss of therapeutic efficacy, and high costs. addressing these challenges, biostrand's recently patented technology introduces a reliable, scalable, and cost-effective alternative for early-stage therapeutic discovery. biostrand’s platform, termed the hyft® proprietary proteome presence assessment, optimizes potential therapeutic drug candidates at an early stage using the multi-functional lensai™ in silico humanization platform integrated with its patented hyft technology. this allows a multitude of potential therapies to be analyzed concurrently, reducing analysis time and costs, and ensuring that only the most promising candidates proceed further into the drug discovery process. (left) traditional antibody discovery and development timeline. linear model imposes increased risk of attrition due to the cost of lead candidate advancement with minimal insight into future clinical viability. (right) the new enhanced predictive insights gained by ipa’s new in silico-driven discovery cycle, which increases the probability of clinical success, saving our partners time and money. the concept of in silico humanization refers to the computational process of making an antibody or protein from a non-human source resemble human proteins. this is crucial for reducing the likelihood of immune responses against therapeutics, while preserving their functionality. biostrand's patented hyft technology, incorporated into their proprietary lensai software, screens the entire human proteome (the entire complement of proteins that is or can be expressed by a cell, tissue, or organism), as well as various animal proteomes, against candidate therapeutics. this screening is accomplished in under one minute per candidate molecule. this process advances the most 'human-like' molecules, speeding up humanization, reducing the manipulation required before use in clinical trials, and offering a rapid, scalable, and cost-effective alternative to transgenic animal models. other existing methods can only assess candidates against a subset of the human proteome, which can result in an incomplete evaluation of a protein's humanness and immunogenicity. hyft technology, however, uniquely addresses this limitation with several distinct advantages, including: use of the most comprehensive human proteome reference set, enabling more thorough comparisons. the ability to extract unique universal fingerprint™ patterns from biological sequences. the capacity to compare the humanized therapeutics to the human proteome, evaluating its similarity to endogenous proteins. the ability to capture both sequence and structural information, enabling a better understanding of the protein's function. scalability and high-throughput capabilities, allowing for rapid assessments of numerous candidate proteins against extensive reference datasets. leveraging these unique capabilities, the hyft proprietary proteome presence assessment offers a more accurate and complete assessment of candidates' humanness and immunogenicity. this supports the development of safer, more effective therapeutic proteins and antibodies while greatly streamlining the drug development process. "ipa's smooth fusion of computer-driven humanization and immunogenicity testing paves the way for faster development and boosts the potential of new treatment methods," stated dr. ingrid brands, co-founder and general manager of biostrand. "our dedication to innovation and pushing the limits of ai-driven therapeutic discovery is represented in this collaboration and integration. we're all about setting new standards in medicine and driving value for our investors.” ipa has provided insights into its strategic approach for monetizing this breakthrough technology. the plan involves targeting their extensive existing client base, which includes 19 of the top 20 pharmaceutical companies and hundreds of biotechnology firms. these clients typically face substantial costs, when using transgenic animals, to progress a single therapeutic candidate through the commercialization process. these costs often reach tens to hundreds of millions of dollars per molecule, encompassing upfront payments, milestone payments, and commercial royalties. by introducing a more reliable, efficient, and cost-effective solution via ipa's ai-driven platform, the company is well-positioned to provide greater results and value for its clients, reducing their costs and accelerating their drug discovery timelines. this increase in quality, productivity, and value is expected to translate directly into increased revenue streams for ipa, fostering substantial financial growth for the company and its investors. ¹ https://www.gminsights.com/industry-analysis/animal-model-market about biostrand’s hyft technology biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensai in silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth . in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai in silico humanization platform with its hyft technology may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, british columbia may 30, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that its subsidiary, biostrand®, has successfully solved the information integration dilemma (iid) by developing a unique technology design that enables their patented hyft technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3d structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular, integrated framework. this breakthrough approach facilitates efficient data fusion, enabling a comprehensive analysis and interpretation of complex biological data. with hyfts, biostrand effectively addresses the iid, paving the way for quicker and more potent biological discoveries. this innovation has the potential to bring a paradigm shift in various domains including drug development, biomarker discovery, and the study of disease pathology, among others. the iid has long been a significant challenge for the biotechnology industry, as researchers and investors have grappled with the complexities of integrating various data types to gain meaningful insights. in the rapidly evolving field of biotechnology, data is generated from multiple sources such as scientific literature, experimental data, and genomic information. the integration of these different data types is critical for accelerating innovation and driving the discovery of novel therapeutics. however, traditional approaches have struggled to efficiently combine and analyze this diverse data, often leading to incomplete or inaccurate conclusions. biostrand's breakthrough approach leverages its patented hyft® technology and lensaitm platform, which together enable the efficient analysis and understanding of complex biological data. by solving the iid, biostrand has unlocked new possibilities for the discovery and development of novel therapeutics, which is expected to benefit both patients and the investor community. dirk van hyfte, co-founder and head of innovation of biostrand, said, "we are thrilled to have overcome the information integration dilemma, which has long been a major hurdle in our industry. our hyft technology and lensai platform are now poised to revolutionize the way researchers and ai-driven systems process and analyze complex biological data, ultimately leading to faster and more effective drug discovery and development." biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. the successful resolution of the information integration dilemma not only demonstrates the innovative nature of biostrand's technology but also highlights the company's dedication to improving the lives of patients worldwide. about immunoprecise antibodies ltd: immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

dr. dirk van hyfte, head of innovation and co-founder at biostrand, stated, “the integration of hyft technology into our llms marks a transformative moment in biotechnology." see full announcement

agreement focuses on in silico and de novo discovery and development of antibodies against tumor microenvironment targets. program will leverage biostrand’s (a talem affiliate) lensᵃⁱ® integrated intelligence technology®, built upon the proprietary hyft index®. victoria, british columbia march 30, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”) an ai-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with xyphos biosciences, inc. (a wholly owned subsidiary of astellas pharma inc., “astellas”). under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary lensᵃⁱ in silico generated antibodies, targeting an undisclosed target in the tumor microenvironment (tme), as potential therapeutic development candidates. targeting this molecule has the potential to markedly enhance anti-tumor immunity with other astellas therapies including chimeric antigen receptor-based (car) technologies. astellas will have the exclusive option to license any development candidates generated as part of the collaboration. ”we are proud to build upon the robust in silico antibody discovery capabilities developed by our team at biostrand. their lensᵃⁱ software and core hyft index are uniquely positioned to analyze targets and design antibodies directed at otherwise challenging oncological proteins, especially those that mediate immune suppression in the tme,” stated dr. jennifer bath, president and ceo of ipa. “third-party due diligence continues to support the industry’s excitement of recent biostrand developments and the potential of lensᵃⁱ to accelerate the discovery of more precise next-generation cancer therapies. we are excited to collaborate with astellas to advance our joint mission of bringing safer and more effective treatments to patients in need.” targeting this molecule in the tme with antibody therapeutics is a novel approach with no antibodies in clinical development. developing next-generation checkpoint inhibitor immunotherapies using new modalities is promising as an innovative healthcare solution. through this collaboration we expect to stimulate a highly specific and targeted attack on cancer cells by optimizing these development candidates and leveraging astellas' flexible convertiblecar™ cell therapy technology. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

company received official notice from the european patent office (epo) for the decision to grant its patent application on april 5th, 2023. the patent was initially filed february 7th, 2020. patent application covers a method to efficiently handle mass biological sequence information. related patents pending in other countries, favorable outcomes anticipated victoria, british colombia march 27, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), the parent company of biokey and affiliate of biostrand, announced today that the epo has issued a “decision to grant” for biokey’s patent application covering the company’s hyft® technology used to organize and analyze biological sequence information. the hyft technology and methodology provide a novel way to efficiently tap into sequence information, allowing the extraction and use the relevant information therein to address the current problems in omics data integration and analysis. the hyft technology serves as the core of the biostrand’s lensai integrated technologytm platform which provides cutting-edge data solutions and antibody discovery. the patent will provide biostrand’s lensai integrated technology with broad protection, further strengthening the company’s patent portfolio position and enabling exclusive access to the hyft technology. the company anticipates favorable outcomes in other countries as well, as many patent offices worldwide consider the status of related european cases to be highly relevant to the decision to grant patents. “this is a significant and exciting decision by the epo, and we view this announcement as a recognition of biostrand’s important contributions to the fields of omic data integration and analysis, fields paramount to the future of cancer research, precision medicine, biomarker identification, and novel drug discovery and development,” stated dr. jennifer bath, ceo of ipa. “this patent provides protection for biokey’s hyft technology, which will give scientists the ability to advance the development of safer and more effective therapies for the toughest medical challenges we face today.” the hyft technology hyft technology is a way of organizing information about the natural world by creating connections between patterns found in living things, called hyfts. these patterns can link genetic sequences to their structures and functions, as well as to other information such as scientific papers and medical records. the output, the hyft knowledge graph, contains over 660 million patterns and 25 billion connections, and is continuously updated with new information. this provides a powerful tool for exploring relationships in the natural world, which can be used for research and applications in medicine and other fields. the hyft graph is unique in its explicit representation of information from the whole biosphere, and it provides a transparent intermediate layer between sequences and predictions that allows for new knowledge to be extracted without the limitations of a black box. hyft-based technologies have numerous applications in various fields beyond just data integration, organization, and analysis, such as drug immunogenicity testing, drug discovery, and natural language processing (nlp). these applications have the potential to accelerate the drug development process and improve patient outcomes. in the field of immunogenicity, hyfts can help predict parts of a molecule that may trigger an immune response. this information is crucial in therapeutic and vaccine development, as it helps identify potential safety concerns before they become problematic. moreover, hyfts can predict off-target effects, which occur when a drug or therapy affects unintended targets in the body. early identification of potential off-target effects allows researchers to design safer and more effective treatments. in drug discovery, hyft-based technologies have multiple potential applications, including: toxicity prediction: by linking genetic sequences to toxicological data, hyfts can predict the toxicity of potential drug candidates, helping researchers identify compounds likely to cause adverse effects before entering clinical trials. drug repurposing: hyfts can identify existing drugs for repurposing by linking genetic sequences to known targets and functions, accelerating the drug discovery process by finding compounds already approved for other indications. clinical trial design: hyfts can optimize clinical trial design by linking genetic sequences to patient data and clinical outcomes, identifying patient subgroups more likely to benefit from specific treatments, and enabling personalized and efficient clinical trials. biomarker discovery: by linking genetic sequences to disease-specific phenotypes, hyfts can identify biomarkers of disease, helping to identify at-risk patients and enable earlier diagnosis and treatment. another application of hyft-based technologies is tied to nlp, which involves analyzing and extracting information from written or spoken language. hyfts can link text-based information, such as scientific papers or medical records, to specific genetic sequences or structures, facilitating more efficient and accurate analysis. this is particularly valuable in genomics and personalized medicine, where vast amounts of textual data must be processed and analyzed to identify potential therapies or treatments. the company believes that the utilization of hyft-based technologies in drug discovery and other fields shows great promise for expediting the drug development process and enhancing patient outcomes. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, biokey bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the potential applications of hyft-based technologies and the prediction capabilities and speed of the discovery processes. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above-mentioned hyfts may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

company to present at the upcoming 2023 annual meeting of the american association for cancer research (aacr) immunoprecise’s unique proprietary bispecific antibodies link cells expressing tumor-associated antigen tropomyosin receptor kinase b (trkb) with cd3-positive t cells, immune system cells that respond by recognizing and eliminating cancer cells. the company’s potential therapeutic, which is designed to bring trkb-expressing tumor cells in contact with engaged and activated t cells, may represent a novel first-in-class therapeutic for targeting trkb-associated tumors in such cancers as non-small cell lung, breast, colon, head, neck, and pancreatic. studies show most tumors from these cancers express high levels of trkb1, and the protein’s presence is associated with poor prognosis and low survival rates. the company has filed a provisional patent application to the united state patent and trademark office. victoria, british colombia march 23, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, talem therapeutics, will present a scientific poster with their latest data on the development of bispecific t-cell engagers targeting trkb at the annual aacr meeting in orlando, florida, which is held from april 14 to 19, 2023. with this advanced development to target trkb-expressing tumor cells, ipa differentiates itself from other organizations developing immunotherapeutics to treat malignant solid tumors. the (over)expression of trkb and (over)activation of the trkb-signaling pathway play a crucial role in various malignancies and are associated with poor disease outcomes. currently applied pharmaceuticals target trkb through interference with its tyrosine kinase activity, but they lack specificity and are therefore associated with many adverse effects. at the 2023 annual aacr meeting, ipa will present their novel therapeutic design, exhibiting high specificity to the tumor-associated protein trkb, shown to be associated with cancer cell survival, proliferation, migration, and resistance to chemotherapy. the company will share data demonstrating the evidence for the potential therapeutic’s ability to recruit and activate t cells to target trkb-specific tumors, in what they believe may be a safer, more effective, and more targeted cancer therapy. the importance of the invention was appreciated in a provisional patent application filed by talem therapeutics to the united state patent and trademark office. dr. jennifer bath, ipa’s ceo and president, stated: “for years, we have consistently demonstrated success in creating clinically relevant therapies for our clients and partners by utilizing our advanced drug discovery and analytical capabilities. we take pride in revealing the details of a pioneering bispecific therapy that aims to revolutionize the approach to targeting and treating various solid tumors. our continuous goal is to create safer and more precise therapies, as we collaborate with our partners to develop the future generation of cancer treatment options.” the poster presentation “bispecific t cell engagers targeting trkb” ipa will exhibit their poster number 29 in section 25 on monday april 17th, from 9.00 am to 12.30 pm. the session category is ‘immunology’, and the session is entitled ‘therapeutic antibodies 1’. an abstract of the poster is presented under number 1890. 1. meng, l.; liu, b.; ji, r.; jiang, x.; yan, x.; xin, y. targeting the bdnf/trkb pathway for the treatment of tumors (review). oncol lett 2018. https://doi.org/10.3892/ol.2018.9854. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the safe activation of t cells, regarding therapeutic potential of ipa’s trkb x cd3 bispecific antibodies to treat trkb-related tumors, and the company’s ability to complete the development of their tatx-200 program. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

ipa’s project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary b cell select® platform and protein manufacturing services. talem therapeutics has announced a collaboration with libera bio to develop multi-target antibodies including the use of artificial intelligence (ai) technology. the companies will use talem's ai platform to help discover and optimize antibodies for various diseases, including cancer. this collaboration is expected to generate antibodies against disease targets that have historically been undruggable. briacell’s ai-based drug discovery program, after a brief pause due to additional workflows added, is underway and going well. the program is using biostrand’s lensai to analyze and prioritize potential drug targets for cancer treatment. briacell aims to use this technology to accelerate the development of new cancer therapies. biostrand announces the first monetization of its natural language processing (nlp) and immunogenicity modules. these modules are now allowing pharmaceutical companies to extract and analyze data from scientific publications and identify potential immunogenicity issues with drug candidates. biostrand is ramping its efforts to use this technology to help pharmaceutical companies develop safer and more effective drugs. biostrand's saas-based data management platform has been awarded a first-round rfp (request for proposal) by an undisclosed pharmaceutical company. the platform allows researchers to store, manage, and analyze large amounts of genomic, transcriptomic, and proteomic data using ai and hyfts technology. if awarded, this program is expected to help the pharmaceutical company accelerate its drug discovery process and improve its r&d efficiency. minimally, this third-party validation marks the beginning of a new potential revenue stream of great interest and high conceivable revenues for biostrand. victoria, british columbia (canada), march 16, 2023 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended january 31, 2023. “we are thrilled to announce that this quarter has been a foundational one for our company. our project revenue has experienced a significant increase, thanks to our recognized best-in-class platform of function-first b cell. in addition, our clients have shown a noticeable trend of moving away from transgenic animals, which may limit genetic diversity of outputs, and towards animals with diverse b cell repertoires and rapid, cost-effective next-generation humanization technologies – capabilities that ipa is again unique positioned to provide”, stated dr. jennifer bath, ceo of ipa. she added, “in addition to our established success, we have ventured into the promising field of modern artificial intelligence, expanding our revenue streams, and providing the first revenue for our subsidiary, biostrand. our newest, unique ai-powered research collaboration may also allow us to tackle previously undruggable targets within the cellular context, and we are excited about the unparalleled value proposition that this could offer our investors. we are equally excited about our ongoing efforts to finalize another ai-driven research collaboration for a complex oncology program with a leading global oncology therapeutics company. these strategic initiatives have been critical in driving growth, innovation, and shareholder value, and we remain confident in our ability to continue to deliver exceptional results. as a company, we are proud of our achievements, and we look forward to the continued success that these initiatives will bring.” third quarter fiscal year 2023 financial summary* (all comparisons are to the period ended january 31, 2022) ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, an increase of 7.4% compared to the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year. for the nine months ended january 31, 2023, total revenue growth of 10.9% when adjusting for the effect of currency translations. gross profit increased 14.6% to $3.0 million for the three months ended january 31, 2023 as compared to the same period last year. ipa held cash of $11.4 million as of january 31, 2023. *expressed in canadian dollars, unless otherwise indicated. financial results revenue & gross profit ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, a 7.4% increase from the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year, driven by growth in the company’s b cell select® platform and protein manufacturing services. gross profit increased 14.6% to $3.0 million from the same period last year. liquidity and capital resources as of january 31, 2023, ipa held $11.4 million of cash, as compared to $30.0 million as of april 30, 2022, and had working capital of $12.2 million. ipa does not hold cash at silicon valley bank and has not seen any impact on our business from the collapse and subsequent take-over of the bank. polytope® taxt-03 antibody combination therapy talem, ipa's subsidiary, has experienced unanticipated delays in the production of its anti-covid therapeutic drug product, polytope, and has adjusted its milestones accordingly, having yet to receive the drug product from its cdmo partner, chempartner. talem is working closely with chempartner to negotiate a mutually beneficial outcome. due to these circumstances, the decision has been made to significantly reduce further investment in talem's covid program, while still recognizing the ongoing significance of covid-19 globally. ipa will continue to provide updates on talem's progress with chempartner and appreciates the support and patience of its investors during these discussions. conference call: date: thursday, march 16, 2023 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/683815668 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

the program will leverage biostrand’s lensai® full suite of integrated intelligence technology® with libera bio’s multifunctional polymeric nanocapsules (mpn technology®) the alliance has stipulated a minimum of upfront and downstream milestone payments of usd 155 million plus commercial royalties, per product developed victoria, canada and santiago de compostela, spain, march 15, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that talem therapeutics llc, an independently operating subsidiary of ipa, and libera bio s.l., have signed a collaboration agreement to jointly address intracellular targets. it is estimated that 75% of disease-causing targets are located inside cells1. some of the most elusive cancer targets are expressed inside tumor cells. because they are so difficult to address, they have sometimes been deemed “undruggable” and thus represent high unmet medical needs. numerous pathways intersect inside tumor cells, such as the mapk pathway or the “hedgehog pathway”, and may generate conditions for tumors to develop, grow and evade the immune system. disrupting signals at one or more points within these pathways may slow down the growth of the tumors and inhibit their proliferation. small molecules have been successfully developed to this end, but they often present a significant lack of specificity resulting in toxicity, leading to undesirable side effects for patients. engineering antibodies to force them inside tumor cells has also been attempted, but it is a complex process, often wrought with failure. the collaboration between talem and libera bio will leverage a nanotechnology that has been proven in vivo to deliver antibodies inside tumor cells and provides a potential solution to this medical challenge. libera bio’s multifunctional polymeric nanocapsules (mpn technology®) offer an elegant way to deliver antibodies inside tumor cells. the relevant antibodies are encapsulated in multi-layer nanocapsules of approximately 1/10,000th of a millimeter in diameter. the nanocapsules are specifically designed around the physicochemical properties of antibodies, to protect them from degradation in the blood stream. libera bio believes that this might be the only nanotechnology with in vivo proof of concept of delivering whole antibodies intracellularly. in addition, mpns can deliver other biologic modalities or combinations of a biologic and a small molecule in the same nanocapsule. passively or actively targeted, the mpns deliver these compounds through a cell membrane and to intracellular targets. whole antibodies, close to their natural form, can be delivered in this manner. talem will leverage its antibody discovery and development expertise and access, including without limitation, the lensai technology® from biostrand b.v., an independently operating subsidiary of ipa. biostrand has developed a proprietary, ai-driven platform to optimize the design of such antibodies. biostrand computationally generates and rapidly screens a large set of diverse antibody candidates against a prioritized list of targets, including intracellular targets. talem and libera bio will jointly develop novel antibodies for use with mpn delivery, with the goal of offering them to larger pharma companies to conduct late-stage development and commercialization. the work launches with the investigation of two intracellular targets with very high unmet patient needs to offer options to the oncologists treating them. “as we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the 'holy grail' in oncology. libera bio's ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously 'undruggable' targets is an exciting development that has the potential to transform the way we treat cancer,” said dr. jennifer bath, ceo and president of immunoprecise antibodies ltd. “the libera bio team has been very impressed with the combination of modern in silico tools and wet lab capabilities at the ipa family of companies. we are looking forward to this alliance that just may yield dozens of new options for cancer treatment,” added olivier jarry, co-founder and ceo of libera bio. 1. verdine gl, walensky ld. the challenge of drugging undruggable targets in cancer: lessons learned from targeting bcl-2 family members. clin cancer res. 2007;13(24):7264-70. doi:10.1158/1078-0432.ccr-07-2184. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com about libera bio. s.l. libera bio s.l. (www.liberabio.com) is a private spanish company, spun off from the university of santiago de compostela (galicia, spain). libera bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “holy grail” in oncology. it has conducted preclinical studies of antibodies addressing frequent mutations of kras, a protein involved in a large number of cancers, particularly pancreatic, colorectal and lung cancers. it is now preparing for the enabling studies aiming at a clinical trial authorization. visit http://liberabio.com contact: olivier jarry, ceo, contact@liberabio.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

biostrand completes integration of 20 million proprietary structural hyfts™ used as a navigational layer to parse over the protein predictive platforms alphafold-2 and evolutionary scale modeling (esm)-2 fold hyfts are now linked together by more than 25 billion relationships within the knowledge graph (kg) biostrand announces artificial intelligence collaboration and license agreement to discover and develop anti-cancer antibodies with briacell therapeutics ipa antibodies announced voluntary delisting from tsx venture exchange niaid confirms ipa’s polytope tatx-03 neutralizing activity against the currently spreading sars-cov-2 variant ba.2.75 victoria, british columbia (canada), december 15, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal year 2023, which ended october 31, 2022. “our focus on accelerated revenue development and the sales integration of our in silico capabilities using innovative and unique hyft-based technology was continued in the second quarter. with relevant outputs and advancements in drug discovery, ipa has quickly pushed the frontiers of cutting-edge innovation, building upon our already top-ranked global cro,” stated dr. jennifer bath, ceo of ipa. “along with continued corporate growth, we remain intently focused on maximizing shareholder value and we continue to swim against the tide of the downward market trend. however, we are not content. we have immense objectives, and we’re determined to work nonstop until we achieve them.” second quarter fiscal year 2023 financial summary* (all comparisons are to the period ended october 31, 2021) ipa achieved revenue of $5.2 million during the three months ended october 31, 2022, an increase of 9.8% compared to the three months ended october 31, 2021. during the three months ended october 31, 2022, research and development expense increased to $4.6 million from $3.0 million during the three months ended october 31, 2021. the increase in research and development costs is primarily attributable to spend associated with clinical manufacturing of the company’s polytope® antibody combination therapy. as of october 31, 2022, ipa held cash of $15.1 million. *expressed in canadian dollars, unless otherwise indicated. financial results revenue ipa achieved revenue of $5.2 million during the three months ended october 31, 2022, a 9.8% increase from the three months ended october 31, 2021. growth was primarily driven by increases in protein manufacturing and ipa’s b cell select® platform. research & development during the three months ended october 31, 2022, research and development expenses increased to $4.6 million, from $3.0 million during the three months ended october 31, 2021. the increase in research and development costs is primarily attributable to spend associated with clinical manufacturing of ipa’s polytope® antibody combination therapy. additional research and development expenses included salaries and benefits (including share-based compensation) of $0.3 million, and depreciation expense of $0.1 million. liquidity and capital resources as of october 31, 2022, ipa held cash of $15.1 million as compared to $30.0 million as of april 30, 2022, and had working capital of $15.4 million. conference call: date: thursday, december 15, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/662019205 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the speed and commercialization of discovery processes and integration of in silico models. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above mentioned hyfts and the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release.

structural hyft technology is used as a navigational layer to parse over the protein predictive platforms alphafold-2 and evolutionary scale modeling (esm)-2 fold hyft technology explores formal and explicit biologically relevant knowledge and connects information about sequence, structure, and function hyft technology is continuously enriched, e.g., by the structural models released by esm-2 fold and alphafold-2 hyfts are now linked together by more than 25 billion relationships within the knowledge graph (kg) victoria, british columbia (canada), december 8, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, today announced that its subsidiary, biostrand bv, has completed the full integration of 20 million structural hyfts with deepmind’s alphafold and meta’s esm-2 fold platforms. protein wars: alphafold-2 vs esm-2 fold recent efforts to predict the three-dimensional structure of a protein using ai are progressing as a solution to the protein folding challenge. a protein’s three-dimensional structure can be studied with the same level of accuracy as experimental methods, thanks to alphafold, a protein structure analysis ai created by deepmind, an alphabet business focused on artificial intelligence. in july 2021, alphafold became publicly available and is credited with revolutionizing biology. a searchable database containing the three-dimensional structures of more than 200 million proteins predicted by alphafold was released in july 2022. the esm metagenomic atlas, a database that predicted the structure of over 617 million metagenomic proteins, was then presented in november 2022 by meta ai, a facebook research team focused on generating knowledge for the ai community. the study of genomes that have been retrieved directly from environmental samples is known as metagenomics. esm is a ground-breaking approach developed by meta ai researchers to predict protein structure. this model is one of the closest alternatives to deepmind’s alphafold-2, which reportedly resolved the 50-year-old grand challenge of in silico protein folding. meta ai has introduced several models throughout the years, and the public can now see its most recent efforts. esm-2 fold inference is quicker at enabling the investigation of structural spaces of metagenomic proteins, even though alphafold-2 and rosettafold have higher accuracy. numerous protein structure prediction models exist in addition to esm-2 fold and alphafold-2, such as rosettafold, omegafold, intfold, raptorx, and others. the esm fold model from meta’s protein structure prediction ai translates the atoms and molecules that make up the protein into language and predicts the three-dimensional structure from the learning data. the group developed the esm-2 with 15 billion parameters by extending this model. esm-2, the largest protein language model to date, employs 2,000 gpus, and is able to predict the three-dimensional structure of more than 600 million proteins in the esm metagenomic atlas in just two weeks. meta ai’s research team claims that while esm-2’s structure prediction speed is up to 60 times faster than alphafold’s, its prediction accuracy is inferior to that of alphafold. this suggests that structure prediction can be scaled to considerably larger databases, according to meta. the hyft technology hyfts are universal fingerprinttm patterns mined throughout the whole biosphere. when linked together, they form a knowledge graph that constitutes over 660 million hyfts and more than 25 billion relations. the core characteristic is that these hyfts can connect sequence to structure and function, but also link sequence to all types of textual information such as scientific papers and medical records. recently, the company also added more than 20 million structural hyfts (s_hyfts) to this graph, and continuously adds metadata and relations. this strengthened the hyft-based platforms with the double compounded effect of harnessing the structural prediction capabilities of alphafold-2 and esm-2 as navigational layers for the hyfts to parse over, while integrating the associated knowledge and speeding up the discovery processes. continuously enriching and updating the hyft graph with the latest novelties is a core characteristic. this means that the number of relationships within the graph is exponentially growing. it provides the hyft-based lensai platforms with constantly updated and integrated knowledge relevant within a biological context. what makes this graph unique is the wealth of explicit information on the whole biosphere that is represented. since graphs hinge on relationships, they allow one to easily and efficiently determine and visualize the connectedness of different entities in this biosphere. furthermore, it equips the lensai platform with an extremely powerful starting point for further application of various ai and machine learning techniques in antibody discovery and precision medicine. the hyft graph provides a unique intermediate layer between sequences and predictions, allowing new knowledge and insights to be extracted without having the downside of operating in a black box. from knowledge graph to undiscovered knowledge why does it matter to have a huge knowledge graph covering the whole biosphere? the richness of a graph determines the depth and level of detail of new information and knowledge that can be extracted. having access to a wealth of 25 billion relationships empowers fine-grained levels of exploration that were not possible before. it opens a whole new world of undiscovered knowledge. in addition to the magnitude of relations, the biological relevance of the information is key. here, the hyft knowledge graph’s unique ability to connect sequence, structure, function, and literature is unprecedented. in silico and wet lab integrated biostrand’s ai-driven approach and ipa’s best-in-class laboratory capabilities are leveraging our target-agnostic antibody discovery platform to create the best possible drugs in a variety of therapeutic domains. supporting the wet lab with the most up-to-date and complete information and predictions using a wide range of in silico models accelerates wet-lab experiments, and generally makes them more efficient and insightful. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the effect of the integration of 20 million structural hyfts to the knowledge graph on structural prediction capabilities and speed of the discovery processes, as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above mentioned hyfts and the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, vancouver, british columbia (canada), and philadelphia, pa, november 30, 2022 – ipa (immunoprecise antibodies ltd.) ( “ipa”) (nasdaq: ipa), an advanced biotherapeutic research and technology company, today announced that biostrand bv (“biostrand”), an ai in silico discovery subsidiary of ipa, has entered into a research collaboration and license agreement (the “agreement”) with briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. the collaboration will leverage biostrand’s lensai™ software, built upon ipa’s proprietary hyft™ universal fingerprint™ technologies, and will focus on in silico antibody discovery to generate relevant clinical molecules for potential development. under the terms of the agreement, biostrand and briacell will collaborate on the design, discovery, and development of anti-cancer antibodies. upon successful antibody discovery, biostrand will receive an upfront payment of us$500,000, and will be eligible to receive future success-based development milestones, including those for the submission of investigational new drugs (inds), clinical milestone payments, and commercial royalties on net sales of products. further terms are not disclosed. “we are very excited to begin this program with briacell and apply our technology to the development of biologics that may have a huge clinical impact,” stated dr. ingrid brands, general manager and co-founder of biostrand. “shortening timelines, while also integrating as much information as possible upstream to improve the efficiency of the process, is extremely important in the development of highly targeted therapies. it is a step towards realizing our long-term vision of significantly advancing precision medicine.” “we believe that biostrand’s revolutionary ai-powered technology, combined with its cutting-edge protein engineering platform, will allow us to design and discover potent anti-cancer therapeutics,” stated miguel a. lopez-lago, phd, chief scientific officer of briacell. “this approach would complement briacell’s current immunotherapy pipeline of innovative anti-cancer therapeutics.” about briacell therapeutics corp. briacell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. more information is available at www. briacell.com immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements relating to the anticipated impact and results of ipa’s collaboration with briacell as well as statements relating to the amount and timing of payments and commercial royalties to be received by briacell. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the results of ipa’s collaboration with briacell may not be as benefical as expected, milestones leading to payments from briacell may not all be met or at all, the amount of global net sales leading to commercial royalties may be less than expected; as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. contact information contact (immunoprecise antibodies ltd.): investor contact: investors@ipatherapeutics.com contact (briacell therapeutics corp.) : william v. williams, md president & ceo 1-888-485-6340 info@briacell.com media relations: jules abraham director of public relations core ir 917-885-7378 julesa@coreir.com investor relations contact: core ir investors@briacell.com source immunoprecise antibodies

victoria, british columbia (canada), november 22, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) announces that it has applied and has received approval for a voluntary delisting of its common shares from the tsx venture exchange (“tsxv”). accordingly, it is anticipated that, effective as at the close of trading on friday, november 25, 2022, ipa’s common shares will no longer be listed and posted for trading on the tsxv. the delisting from the tsxv will not affect the company’s listing on the nasdaq global market (the “nasdaq”). the common shares will continue to trade on the nasdaq under the symbol “ipa”. the company believes that the trading volume of its shares on the tsxv no longer justifies the expenses and administrative efforts required to maintain a dual listing. the company also believes that delisting from the tsxv will create a central marketplace for its common shares on the nasdaq, and ultimately benefit the long-term liquidity and shareholder value of the company. following delisting from the tsxv, ipa’s shareholders can trade their common shares through their brokers on nasdaq. as most brokers in canada, including many discount and online brokers, have the ability to buy and sell securities listed on nasdaq, ipa’s nasdaq listing will continue to provide shareholders with the same accessibility to trade the company’s common shares. shareholders holding shares in canadian brokerage accounts should contact their brokers to confirm how to trade ipa’s shares on the nasdaq. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements with respect to the timing of the delisting of the common shares from the tsxv, the anticipated benefits of delisting from the tsxv as well as future results, the accessibility of and ability to trade the company’s common shares on the nasdaq, and the anticipated continued listing of the company’s common shares on the nasdaq. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, regulatory filings may not be filed or approved on a timely basis, or at all; ipa’s common shares may not be delisted from the tsxv on the expected date or at all; trading the company’s common shares on the nasdaq may not be as accessible as expected; as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. contacts investor contact: investors@ipatherapeutics.com

under strategic collaboration, talem, an ipa subsidiary, expands its relationship with ligand/omniab, inc., to develop three immuno-oncology programs targeting validated targets talem intends to leverage ipa’s broad range of advanced laboratory and in silico computational technologies, including lensai™ antibodies were discovered using omnichicken antibody discovery technology victoria, british columbia (canada), october 12, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), today announced that its subsidiary, talem therapeutics llc (“talem”), has entered into a multi-target license agreement with omniab, inc., a subsidiary of ligand pharmaceuticals incorporated. the agreement builds upon talem’s extensive antibody development expertise and its access to lensai™ in silico software technology to further the development and commercialization of omnichicken-derived antibody panels against b7h3, cd38 and tim3, which are immuno-oncology targets. the collaboration leverages antibodies from the omnichicken discovery technology, the industry’s first successfully engineered bird with an immune system that can efficiently generate human sequence antibody repertoires for the discovery of therapeutic antibodies, with talem’s advanced antibody development technologies aimed at optimizing clinical success. under the terms of the agreement, talem will oversee the development and optimization of the antibodies for each program. omniab and talem will share downstream economics upon potential out-licensing or commercialization of the programs. “this collaboration leverages talem’s unique strengths in optimizing and developing scientifically rigorous and clinically-relevant antibodies and provides an exceptional opportunity to apply ai-driven in silico technologies available to talem to rapidly develop antibodies derived from the omnichicken discovery technology,” stated dr. jennifer bath, ceo of ipa. dr. bath continued, “we believe that the expertise of the ipa family with a variety of antibody formats and broad range of powerful in silico and advanced wet lab technologies, will enable talem to meaningfully accelerate the development of these potential life-saving therapies faster and with more accuracy than ever before.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the anticipated developments resulting from the collaboration between talem and crystal. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in developing commercially viable products from the antibodies licensed from ligand pharmaceuticals’ subsidiary, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

victoria, british columbia (canada), september 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), announced today that its subsidiary, talem therapeutics llc (“talem”), has shared positive results of a new study conducted by the national institute of allergy and infectious disease (niaid), part of the national institutes of health (nih), that has shown the continued resilience of polytope® tatx-03 in broadly neutralizing sars-co-v-2 variants, including two omicron sublineages that had not been previously tested. this niaid-conducted pseudovirus-based study has reconfirmed the neutralizing activity of tatx-03 against the european variant (d614g mutant) of the parental virus and several previously tested variants, including delta (b.1.617.2), and omicron sublineages (ba.2, ba.4/5). importantly, tatx-03 has now demonstrated its neutralizing activity against the currently spreading ba.2.75 variant. maintained neutralizing potency was also confirmed for the omicron sublineage ba.2.12.1, sars-co-v-2 variant that had not yet been screened in virus neutralization studies. ipa’s chief scientific officer (cso), dr. ilse roodink, stated: “we appreciate that our interactions with the fda resulted in this collaboration with the niaid. this division of the nih is continuously screening clinical-stage antibody therapeutics for neutralizing potency towards emerging variants. we highly value this independent validation of the resilience of our polytope® tatx-03 product, further strengthening our position as we progress into clinical trials in humans.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic research and technology company that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to successfully submit a clinical use application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely submission of an application for regulatory approval, developing its polytope® tatx-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of polytope® tatx-03, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

structural hyfts fully indexed and integrated in structure-function workflow lensai® data management platform successfully launches hyper-scalable solution for partner access, integrating multiple data layers at once company shares biostrand case study demonstrating the complete in silico prediction of off-target effects from a top 10 pharma late-stage clinical antibody ipa successfully demonstrates t-cell engager strategy with tatx-112 bi-specific antibody tatx-22 program focus on the development of a novel, best-in-class bi-specific antibodies for acute myeloid leukemia ipa announces completion of in silico case studies as first sign of ability to address key antibody technologies without the use of wet lab assistance, results currently under in vitro company announces validation from niaid on polytope tatx-03 combination therapy neutralization of several variants, including the currently spreading subvariant, ba.2.75. victoria, british columbia (canada), september 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended july 31, 2022. “our biggest surprise this quarter was how rapidly our iterative-feedback ai software platform for antibody discovery advanced toward commercialization,” stated dr. jennifer bath, ipa’s chief executive officer. “we are clearly excited about the potential of our most recent acquisition, biostrand, and look forward to working together to leverage their elegant software and iterative ai platform with ipa’s clinically validated wet lab technologies, to realize the full potential of our capabilities to deliver the next generation of cancer and immunology therapies to modernize all aspects of antibody discovery and development,” dr. bath continued, “we aim to transform how we discover and develop novel therapeutics as we continue to shorten drug discovery timelines and to design safer, more targeted therapies for patients.” first quarter fiscal year 2023 financial summary* (all comparisons are to the period ended july 31, 2021) the company’s total revenue of $4.7 million was an increase of $0.1 million or 2.2% as compared to total revenue of $4.6 million from the same period last year. the company, primarily through its subsidiary talem therapeutics llc, invested $5.8 million in strategic research and development costs as compared to an investment of $1.1 million in the same period last year. the company recorded a net loss of $9.4 million, as compared to net loss of $3.2 million during the same period last year. as of july 31, 2022, the company held cash of $19.2 million. *expressed in canadian dollars, unless otherwise indicated. financial results revenue the company achieved revenue of $4.7 million during the three months ended july 31, 2022, a 2.2% increase from the three months ended july 31, 2021. growth was primarily driven by increases in protein manufacturing and cryostorage services. revenue during the three months ended july 31, 2022, was impacted by the weakening of the euro due to the effect of foreign currency translations. on a consolidated basis, total revenue was negatively impacted by $0.3 million as compared to the three months ended july 31, 2021. research & development r&d increased to $5.8 million from $1.1 million during the three months ended july 31, 2021, primarily due to strategic investment in the company’s sars-cov-2 polytope® antibody combination therapy. a total of $5.2 million in costs were incurred for gmp manufacturing of the therapy. net loss the company recorded a net loss of $9.4 million during the three months ended july 31, 2022, compared to a net loss of $3.2 million for the three months ended july 31, 2021. the increased net loss is primarily due to the company’s investment in r&d related to the sars cov-2 polytope® cocktail, increased salaries and benefits to support the company’s strategic plans, increased amortization from intangible assets recorded in connection with the biostrand acquisition, and increased consulting fees. liquidity and capital resources as of july 31, 2022, the company held cash of $19.2 million as compared to $30.0 million as of april 30, 2022, and had working capital of $21.7 million. the company’s internal forecast indicates the cash on hand will sustain its existing operations for at least 12 months. on october 13, 2021, an at-the-market (“atm”) equity offering facility was entered into with h.c. wainwright & co., llc as sole sales agent (“agent”). the company will be entitled, at its discretion and from time-to-time during the term of the atm agreement, to sell through the agent common shares of the company having an aggregate gross sales price of up to us $50 million. as of september 14, 2022, us $50 million of the company’s stock remained available for sale under the atm facility. conference call: date: wednesday, september 14, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/349012238 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company’s periodic reports on file with the toronto stock exchange and securities and exchange commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic research and technology company that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of ipa’s polytope monoclonal antibodies, including tatx-03, to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment, to retain efficacy over time, and to reduce or suppress the emergence of novel variants as well as its potential to prevent the spread of variants. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in developing its polytope monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. *non-ifrs financial measure readers are cautioned that “adjusted ebitda” is a measure not recognized under ifrs. adjusted ebitda is defined as operating earnings before interest, accretion, taxes, depreciation, amortization, share-based compensation, foreign exchange gain/loss, and asset impairment charges. management believes adjusted ebitda is a useful measure that facilitates period-to-period operating comparisons. readers are cautioned that “adjusted ebitda” is not an alternative to measures determined in accordance with ifrs and should not, on its own, be construed as indicator of performance, cash flow or profitability. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release.

victoria, british columbia (canada), august 29, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), a biotherapeutic research and technology company, today announced the continuing success of polytope® tatx-03 antibody combination therapy to neutralize variants of concern of the covid-19 causative virus, including the latest omicron ba.5 subvariant, validated by an independent research organization in an authentic virus assay. research was conducted by the max von pettenkofer institute, part of the medical faculty of the ludwig-maximilians-university (lmu, munich, germany), who is world-renowned for their research and diagnostic services on sars-cov-2. the blinded studies examined the efficacy of ipa’s polytope® tatx-03 antibody combination therapy alongside in-house derived formulations of several commercially approved antibodies. authentic isolates of virus variants tested in vitro by the lmu institute included 20e (eu1; b.1.177), alpha (b1.1.7), beta (b.1.351), delta (b.1.617.2), omicron lineages ba.1 (b.1.1.529.1), ba.1.1 (b.1.1.529.1.1), ba.2 (b.1.1.529.2), and ba.5 (b.1.1.529.5). whereas commercially licensed products had difficulty to protect the susceptible cells against some of the listed coronavirus (sub)variants, ipa’s polytope® tatx-03 was able to neutralize all (sub)variants tested, including the currently dominant omicron ba.5 subvariant, which has been described to display increased immune evasion compared to ba.1, ba.2 and pre-omicron variants. as the spike trimer of the ba.4 omicron variant is identical to ba.5 glycoprotein, the company anticipates that the consistent neutralizing potency of tatx-03 hold true for this variant. ipa’s chief scientific officer (cso), dr. ilse roodink, stated: “while underway to the first clinical trials of our polytope® in humans, this independent confirmation of the strength of our rationally designed combination therapy using authentic virus variants is very valuable for our ongoing discussion with the authorities. with the rapid evolution of omicron and its variants, the need for a sustainable therapy to sars-cov-2 infection becomes increasingly evident”. she continued, “while our first-generation tatx-03 therapy has proven its resilience in vitro, we are confident about the anticipated in vivo efficacy in humans, as some components of our cocktail are able to mediate anti-viral effects through mechanisms which may enhance the already proven performance in the prior in vitro neutralization assays.”. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic research and technology company that leverages network biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to successfully submit a clinical use application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely submission of an application for regulatory approval, developing its polytope® tatx-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of polytope® tatx-03, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f,dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

victoria, british columbia (canada), august 29, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), a biotherapeutic research and technology company, today announced the… lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet.

ipa_capabilitiesdeck_2022

the company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021 the company achieved record revenues of $5.2 million for the three months ended april 30, 2022, an increase of 7.4% over the same period last year. the company achieved an increase in cro revenue (total revenue minus talem asset out-licensing revenue) of 15.9% over the same period last year. victoria, british columbia (canada), july 29, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended april 30, 2022. fiscal 2022 financial summary* the company achieved record total revenues of $19.4 million during the year ended april 30, 2022, an 8.1% increase from the year ended april 30, 2021. project revenue of $17.4 million was $1.4 million, or 9.1%, higher than last year. growth is driven primarily by the company’s b cell select® platform, with expansion in both the number and size of projects under contract. the company, primarily through its subsidiary talem therapeutics llc, invested $6.7 million in strategic research and development costs as compared to $2.0 million in 2021. the company recorded a net loss of $16.7 million during the year ended april 30, 2022, compared to a net loss of $7.3 million for the year ended april 30, 2021. as of april 30, 2022, the company held cash of $30 million (april 30, 2021 – $41.8 million) *expressed in canadian dollars unless otherwise noted. “we delivered another year of strong performance in fiscal year 2022, demonstrating both our highest revenue quarter and fiscal year in the history of ipa,” said dr. jennifer l. bath, chief executive officer, ipa. “we are entering fiscal year 2023 with significant momentum and a strong focus and expectations on our new capabilities, robust pipeline, and excellent execution to deliver continued strong performance this year and over the long-term.” recent and fiscal 2022 operational highlights ipa seeks to rapidly and dramatically expand its ip portfolio with the addition of several us and international patent applications submitted by talem therapeutics llc and obtained through the recent biostrand acquisition ipa announces the retirement of lisa helbling, chief financial officer, and the appointment of her successor and current member of the ipa executive team, brad mcconn, effective august 5th. pre-clinical, ind-enabling histopathology data from toxicity study and ex vivo human tissue cross-reactivity (tcr) analysis support the safety of ipa’s polytope® tatx-03 cocktail ipa’s polytope® tatx-03 demonstrates protection against in vitro infection by omicron sublineage ba.2, in addition to all other variants of concern ipa completes acquisition of belgian group, biostrand, revolutionizing biotherapeutics with method to encode omics and power drug development with advanced artificial intelligence (ai) ipa’s newly acquired subsidiary, biostrand, awarded second round of grant funding from vlaio research grant ipa and chempartner biologics announce polytope® tatx-03 antibody cocktail manufacturing collaboration after program review by the department of defense (dod), ipa was selected to work with elektrofi on a deployment ready formulation of its polytope tatx-03 as well as future pandemic preparation under an sbir contract from defense health agency (dha) within the us dod ipa bolstered global senior leadership with barry duplantis, ph.d., promoted to vice president of client relations and the addition of ms. carla dahl, vice president of marketing ipa europe granted three-year approval for the “crédit d’impôt recherche” (cir) from the french ministry of higher education and research to provide research tax credits to eligible french companies the company established a multi-target research collaboration with pierre fabre in immuno-oncology ipa established a us $50 million at-the-market distribution agreement (the “atm”) ipa presented in vitro characterizations results from studies on tatx-21, a novel potential first-in-class antibody for atherosclerosis cardiovascular disease (acvd), at the 2021 bio convention ipa enters co-offering agreement with eurofins discovery, providing eurofin’s global clients’ integrated access to ipa’s end-to-end discovery service financial results revenue the company achieved record revenues of $19.4 million during the year ended april 30, 2022, compared to $17.9 million in fiscal year 2021, an 8.1% increase. the continued growth trend is primarily from project revenues in the company’s b cell select® platform with expansion in both the number and size of projects under contract. for the three months period ending april 30, 2022, the company achieved record revenues of $5.2 million compared to $4.9 million for the three months period ended april 30, 2021, a 7.4% increase. research & development research and development increased to $6.7 million from $2 million in 2021, due to the strategic investment in r&d the company is undertaking, including the company’s sarscov-2 polytope® cocktail and other research projects. net loss the company recorded a net loss of $16.7 million during the year ended april 30, 2022, compared to a net loss of $7.3 million for the year ended april 30, 2021. the $9.4 million increased net loss is primarily due to the company’s investment in r&d, increased professional and consulting fees, increased insurance costs, increased salaries, and benefits to support the company’s strategic plans and operations, and lower grant and subsidy income. liquidity and capital resources as of april 30, 2022, the company held cash of $30.0 million as compared to $41.8 million as of april 30, 2021, and had working capital of $28.2 million. the company’s internal forecast indicates the cash on hand will sustain its existing operations, support its nasdaq and tsxv on-going listing costs and satisfy its obligations for at least 12 months. on october 13, 2021, at at-the-market (“atm”) equity offering facility, was entered into with h.c. wainwright & co., llc, as sole sales agent (“agent”). the company will be entitled, at its discretion and from time-to-time during the term of the atm agreement, to sell through the agent common shares of the company having an aggregate gross sales price of up to us $50 million. as of july 29, 2022, us $50 million of the company’s stock remained available for sale under the atm facility. conference call: date: friday, july 29, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/831812822 the conference call will be webcast live and available for replay via the same link found on the main page of the company’s investors section at: https://www.immunoprecise.com/investors. if you are dialing into the call, please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company’s periodic reports on file with the toronto stock exchange and securities and exchange commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.immunoprecise.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of ipa’s polytope monoclonal antibodies, including tatx-03, to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment, to retain efficacy over time, and to reduce or suppress the emergence of novel variants as well as its potential to prevent the spread of variants. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in developing its polytope monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 29, 2022 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. *non-ifrs financial measure readers are cautioned that “adjusted ebitda” is a measure not recognized under ifrs. adjusted ebitda is defined as operating earnings before interest, accretion, taxes, depreciation, amortization, share-based compensation, foreign exchange gain/loss, and asset impairment charges. management believes adjusted ebitda is a useful measure that facilitates period-to-period operating comparisons. readers are cautioned that “adjusted ebitda” is not an alternative to measures determined in accordance with ifrs and should not, on its own, be construed as indicator of performance, cash flow or profitability. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release.

the company to host an earnings conference call via webcast victoria, british columbia (canada), july 26, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa)… lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet. lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. at vero eos et accusam et justo duo dolores et ea rebum. stet clita kasd gubergren, no sea takimata sanctus est lorem ipsum dolor sit amet.

the company to host an earnings conference call via webcast victoria, british columbia (canada), july 26, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on friday, july 29, 2022, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. immunoprecise management will host the conference call followed by a pre-submitted question-and-answer period. investors interested in submitting questions ahead of the call are encouraged to email the company’s investor relations contact. conference call: date: friday, july 29, 2022 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/831812822 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. anyone listening to the call is encouraged to read the company’s periodic reports on file with the toronto stock exchange and securities and exchange commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.immunoprecise.com. investor contact: investors@immunoprecise.com

milestone ipa toxicity study supports the safety of polytope® tatx-03 antibody cocktail against covid-19 ind-enabling safety evaluations of polytope® tatx-03, executed under good laboratory practice (glp) standards and regulatory guidelines, revealed no in vivo adverse effects during histopathological examination nor any undesirable off-target binding to human biomaterials. victoria, british columbia (canada), july 12, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa), an advanced biotherapeutic research and technology company, reports the critical third-party findings of two ind-enabling pre-clinical safety studies, de-risking the clinical development of the company’s polytope® tatx-03 antibody cocktail and its potential to prevent and treat covid-19. a summary of the positive findings indicates that, through ex vivo screenings, no non-specific binding of tatx-03 components to human tissues was identified. in addition, an extended pre-clinical in vivo toxicology study did not reveal any tissue or organ changes following exposure to the antibody cocktail, even when administered at over three times the highest anticipated dose in humans. in the current landscape of “not if, but when” people will contract covid-19, the debilitating post-covid “long-haul” effects, and the ongoing life-threatening risks for immunocompromised individuals, this long-awaited safety data illustrates the company’s reputation for uncompromising scientific standards and dedication to sustainable biotherapeutic solutions. the toxicology study was carried out under regulatory-compliant glp conditions with animals receiving three intravenous injections at one-week intervals with either polytope® tatx-03 or placebo. no mortality was observed and, importantly, no macro- or microscopic morphological or histopathological impact was detected on any of the examined organs and tissues even after an extended observation period, as recommended by the fda. in parallel, a full tissue cross-reactivity (tcr) study was performed according to regulatory guidelines and involved colorimetric immunohistochemical analysis of 37 tissue and blood materials from five unrelated humans to cover a broad array of various human tissues, organs and expressed proteins. these screenings did not show cross-reactivity of the individual tatx-03 antibodies, an outcome that supports the specificity of the antibodies to its intended target and suggests that no unintended binding is expected in humans. the toxicology and tcr study results are in line and compliant with the outcomes and conclusions from the previous in vivo pharmacokinetic study, and the dose-escalation study as reported in the company’s march 9, 2022, news release. the positive results reported here will be included in the regulatory filing for approval of clinical studies in humans. “this is another significant milestone for ipa and a leading contribution in efforts to protect against the present and future threat that covid-19 and its variants still pose. these data support the safety of tatx-03 on top of its already demonstrated, and we believe, unprecedented, resilience, reflected by its potency to neutralize all sars-cov-2 variants of concern tested so far,” stated dr. ilse roodink, cso of ipa. “we are confident about the next steps in the program and are compiling the data for sharing with the health authorities for clinical approval,” she continued, “these excellent data readouts on safety and pharmacokinetics tremendously support our ambition to start the first-in-human clinical phase trial which is expected to commence later this year.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.immunoprecise.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete its pre-regulatory approval studies, the ability of the company to successfully submit a clinical use application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time, and statements regarding the commencement date of first-in-human clinical phase trial. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely submission of an application for regulatory approval, developing its polytope® tatx-03 through the successful and timely completion of clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of polytope® tatx-03, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

ipa subsidiary biostrand receives grant to expand lensai platform by linking hyfts™ with 3d protein structure and function diepenbeek, (belgium), may 9, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to share that ipa’s subsidiary biostrand, a belgian end-to-end multi-omics analysis platform provider, has received a €460,000 round of grant funding from vlaio (flanders innovation & entrepreneurship), the research fund of the flemish regional government in belgium. conditionally awarded in january this year, biostrand recently satisfied the remaining criteria for the award, which follows an original grant from vlaio of €235,000 in 2020. commenting on the latest grant, dr. ingrid brands, general manager and co-founder of biostrand, stated, “thus far, our patented hyft™-based methodology has been applied predominantly to streamline analysis at the syntactic level and combines sequence information with natural language processing. using the presence, occurrence, and distribution of hyft™ patterns, the focus has been on analysis and integration of sequence-based ‘syntactical’ information. we are now extending the methodology to combine syntactical and structural information and to expand our services portfolio with hyft™-based structural and functional modelling functionalities. by linking hyfts™ with the 3d structure (and function) of proteins and expanding platform capabilities for ai discovery, we will be able to support an even wider array of applications, including assay development, biomarker discovery, and computer-aided drug design.” the strategic objective driving this hyft™-based synthesis of syntactical and structural information is to extend biostrand’s technology to encompass the structure of proteins. a key advantage of this blended approach is the detection of protein sequences with similar structures (and function) but without high sequence similarity (distant homologs). a primary application for this approach will be in protein structure prediction, with a particular first focus on antibodies as well as g protein coupled receptors (gpcrs). this will be extended to cover protein-protein interaction prediction (ppi) at a later stage. biostrand is also working on an ai discovery platform that will leverage advanced ai techniques to facilitate integrated protein structure and function analysis. combined with existing r&r and variant analyzer modules, natural language analysis capabilities and the hyft™-based unified syntactical plus structural methodology, biostrand’s ai discovery platform will empower researchers to fully analyse their data and gain insights across the entire analysis pipeline, from raw sequencing data to biologically relevant aspects such as diagnostics and drug discovery. the expansion of biostrand’s omics platform with these advanced functionalities is crucial to become an ambitious market player and position biostrand as a one-stop-shop for omics analysis,” said dr. brands. “we believe that integrating sequence and 3d structure analysis in combination with natural language processing will revolutionize protein structure and function prediction and boost developments in biotechnology and precision medicine. providing a powerful, integrated, and user-friendly data analysis platform for life sciences researchers is our contribution to ramping up the effectiveness of r&d cycles and enabling the real-time analysis of actionable patient data that will bring precision medicine to the next level. it also takes us one step further in our mission to create a truly effective omics data analysis solution.” the company also announces the departure of stefan lang, chief business officer of ipa, effective immediately, and wishes him the best in his future endeavors. immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. investor contact: email: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified using words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete the studies proposed for the grant award. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). furthermore, there can be no assurance that the pending patent applications will issue as patents and that challenges will not be instituted against the validity or enforceability of such patents. should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

• ipa’s polytope® tatx-03 shows continuous validation of potent in vitro neutralizing activity against sars-cov-2 variants of concern, as further demonstrated against the omicron sublineage ba.2 • neutralization potency of the tatx-03 cocktail towards ba.2-pseudotyped viral particles is comparable to its previously reported neutralizing activity against omicron ba.1 •in addition to retained potent neutralization by the cocktail as a whole, all four individual therapeutic antibodies in ipa’s tatx-03 retained binding to the ba.2 spike trimer, with reactivity profiles similar to ba.1 victoria, british columbia (canada), april 20, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to share the outcome of recent laboratory data on their polytope® tatx-03 antibody cocktail, which demonstrates strong neutralizing activity toward the omicron subvariant ba.2. the ba.2 pseudovirus was neutralized with a potency comparable to the previously analyzed omicron ba.1, demonstrating ongoing and continued consistency of the cocktail to potently neutralize sars-cov-2 variants of concern (voc). this functional outcome was supported by demonstrated binding of each individual antibody constituent to spike-protein trimer ba.2, data which is also highly comparable with the binding observed against ba.1. various sublineages were identified relatively soon after the sars-cov-2 omicron variant was designated as a voc. of the sublineages classified, ba.2 and ba.3 have higher transmission potential than, for example, ba.1. given the global prevalence and exceptional transmissibility of ba.2, as well as the reality that most antibody therapies authorized by the fda under emergency use authorization have lost neutralizing potency against the omicron variants, recent conversations with the food and drug administration led to prioritizing potency screening of ipa’s tatx-03 product toward ba.2. in line with recent in silico modelling predictions at ipa, the in vitro experimental data showed no significant difference in tatx-03 antibody binding to omicron and the ba.2 sublineage. as anticipated, ipa’s rationally designed anti-sars-cov-2 cocktail potently prevented cell infection by omicron sublineage ba.2 pseudovirus particles at similar antibody concentrations compared to ba.1, resulting in complete neutralization of this dominant subvariant. “in our news release on january 31st, we announced data demonstrating the potent neutralization of the omicron ba.1 subvariant by ipa’s polytope® tatx-03. once again, the remarkable and unprecedented endurance of our first-generation tatx-03 antibody cocktail demonstrates a unique ability to maintain neutralization potency against all concerning viral mutants, this time against the currently dominant omicron sublineage ba.2 containing, yet again, unique mutations,” stated dr. ilse roodink, cso of ipa. “with the new results on the ba.2 subvariant, the vast data package on ipa’s tatx-03 pharmaceutical continues to mount, demonstrating limited variation in its powerful and consistent neutralization potency against all virus variants, giving great confidence to the significance of this resilient product. this is, again, a wonderful confirmation of the sustainability and long-term value of our tatx-03 therapy.” immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. investor contact: lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the company’s ability to complete its pre-ind studies, the ability of the company to successfully submit an ind application with respect to polytope® tatx-03, statements regarding regulatory approvals, statements regarding the potential of ipa’s polytope® tatx-03 to provide strong anti-viral effects against sars-cov-2/covid-19 disease or any variant of the virus as either a prophylactic (preventative) or treatment (therapeutic), or to retain efficacy over time. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely completing its pre-ind studies or submitting an ind application to the fda, developing its polytope® monoclonal antibodies, including tatx-03, or other vaccines or therapeutics against covid-19 through the successful and timely completion of preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, including polytope® tatx-03 and, be successful in partnering or commercializing its products related to covid-19, the coverage and applicability of the company’s intellectual property rights to its polytope® antibody cocktails, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no, 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). furthermore, there can be no assurance that the pending patent applications will issue as patents and that challenges will not be instituted against the validity or enforceability of such patents. should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies

victoria, british columbia (canada), april 14, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to announce that it has completed its previously announced acquisition of control over biostrand bv, biokey bv, and bioclue bv (hereinafter collectively referred to as “biostrand“), a group of belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary immunoprecise netherlands bv. “uniting biostrand and ipa reflects the company’s commitment to acquiring truly transformative technologies that leapfrog traditional competencies driving the development of safe and effective antibody therapies. for several years ipa’s team has scrutinized artificial intelligence (ai) and machine learning technologies, in search of capabilities that don’t simply give a nod to an opaque use of computationally-driven analyses, nor incremental and limited additions to currently existing research tools, but instead change the trajectory of personalized medicines and the philosophy behind what is truly meaningful for the future of ai in the life sciences,” commented dr. jennifer bath, ceo of ipa. “with biostrand joining the ipa family, we rewrite the future of biotherapeutic discovery, providing access to unique and rapid in silico technologies that unequivocally improve the specificity and design of biotherapeutics,” dr. bath continued. “this is achieved, in part, using patent-pending technologies that identify, define, and code finite and unique fingerprints representing structures and functions present in all omic data. together, we share a common vision and unique strengths using the power of rapidly analyzed genomic, transcriptomic, and proteomic data, combined with natural language processing, to understand the structural and functional basis of diseases, and to develop life-saving precision medicines. our combined capabilities move us closer to more precise and powerful individualized therapies with an aim of changing the way therapies are designed, approved, and prescribed.“ details of the transaction immunoprecise netherlands bv acquired all of the issued and outstanding shares of idea family bv, a private limited liability company holding 75.01% of the issued and outstanding shares of biostrand, as well as the remaining 24.99% of the issued and outstanding shares of biostrand. at closing, the company paid a consideration of approximately € 20 million to the vendors, namely charmquark een, a partnership (maatschap) controlled by dirk van hyfte, charmquark twee, a partnership (maatschap) controlled by ingrid brands, and k&e bv, a private limited liability company (besloten vennootschap) controlled by koen quaghebeur and els paesmans. the consideration consisted of an aggregate of 4,077,774 common shares of ipa, representing approximately € 16,265,500 based on the thirty-day volume-weighted average price of the common shares ending on the trading day immediately prior to the closing; and a cash payment of approximately € 3,734,500 the consideration also includes a contingent earnout payment based on the profitability of biostrand over a 7-year period, which shall not exceed in total €12 million. an investment consideration will also be provided by ipa to biostrand in an aggregate amount of € 6 million over a period of 3 years, for operation expenses, development of biostrand’s platform, and correction of deficiencies. the common shares issued are subject to a statutory resale restriction pursuant to canadian securities laws, as well as a contractual escrow agreement entered into on closing between the vendors, ipa, and an escrow agent, providing for the gradual release of the common shares over a 3-year period. each of biostrand and its securityholders are arm’s length parties to the company. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. about biostrand bv, biokey bv, and bioclue bv\ biostrand, biokey, and bioclue are private limited liability companies, incorporated under the laws of belgium, and are active in the field of bioinformatics and biotechnology. biostrand’s focus is on handling of biological sequences, and generating biological sequence information, software development, algorithms, data visualization and visual analytics. potential applications are in the field of molecular diagnostics, point of care testing, in depth analysis for drug development, prediction, construction and adaptation of biopolymer sequences as well as a product, service, or tool which stores this information in a database. the business of biokey is related to the identification of characteristic biological sequences in proteins, rna and dna, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences. bioclue focuses on technology for performing secondary analysis, consisting of read mapping / assembly and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, rna and dna, including through mass spectrometry, sequencing, microarray or hybrid microarray system technologies. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the launch of sequencing technologies and in silico discovery platforms and expectations regarding the impacts thereof, the contingent earn-out consideration, the form and use of the investment consideration provided by ipa to biostrand, expectations regarding synergies from the transaction and the ability to integrate biostrand into the company’s business, and the projected impact of completion of the transaction on the company’s business, financial conditions and results. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no. 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies investor contact lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com

new platform integrates sequence data and information from entire biosphere • acquisition includes wholly owned subsidiary businesses biokey bv and bioclue bv. • platform is based on a proprietary biological discovery called hyft™ patterns, signature sequences in dna, rna, and amino acids. • the hyfts information model combined with advanced artificial intelligence (ai) creates new comprehensive high speed analysis capabilities while maintaining high accuracy and reducing computational footprint. • novel ai-powered protein-protein interactions prediction platform. victoria, british columbia (canada), march 29th, 2022 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa) (tsxv: ipa) is pleased to announce that it has entered into a definitive share purchase agreement (spa) to acquire, through its wholly-owned subsidiary immunoprecise netherlands bv, control over biostrand bv, biokey bv, and bioclue bv (hereinafter collectively referred to as “biostrand”), a group of belgian biotech entities and pioneers in the field of bioinformatics and biotechnology. this transaction is expected to create short and long-term commercialization opportunities with clients and partners by introducing a novel ai-powered protein-protein interactions prediction platform and fortifying ipa’s sequencing with massive throughput capabilities in omics (genomics, transcriptomics, proteomics, and metabolomics) interrogation. the company anticipates that the transaction will not only attract new clients and partners but will also enable its subsidiary, talem therapeutics, to access unparalleled ai technologies to help power each stage of its therapeutic antibody development. transaction highlights • biostrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis. • the acquisition enhances ipa’s position as a leader in the field of biotherapeutics – biostrand’s software and ai capabilities complement every sector of ipa’s business. • biostrand’s semantically driven natural language process (nlp) approach makes omics data research truly effective and differentiates ipa’s offerings to provide a powerful and unique opportunity for ipa’s clients. • total consideration of € 20 million, of which € 2 million will be paid in cash, subject to adjustments, and € 18 million will be paid in equity. • management and board of directors unanimously approved the transaction. differentiating technologies biostrand offers an ai-powered revolutionary methodology for rapidly analyzing and mining a broad range of biological data to identify patterns and variations in multi-omics data and detect structural anchor points that will drive innovation in numerous fields including precision medicine, drug and vaccine development, and target discovery. by detecting hyfts™, which are proprietary biological signature sequences, multiple layers of information in sequence and structural data are automatically integrated, resulting in a systems approach to omic analyses. these hyfttm fingerprints connect sequences and literature analysis through a bottom-up nlp approach, by providing a universal syntax for the language of biology. this revolutionizing pattern and profile detection is critical in understanding diseases and biological processes. multi-omics data integration typically requires quite considerable expertise in computational techniques with additional challenges in accuracy and reliability. with biostrand’s revolutionary hyft™ framework, all biological data is instantly computable. company synergies the acquisition of biostrand expands ipa’s scientific capabilities to excel far beyond antibody discovery, expanding from the earliest stages of target identification to late-stage therapies. the transaction combines biostrand’s computer-aided drug discovery capabilities with ipa’s best-in-class antibody discovery and development expertise to create an integrated, next-generation, end-to-end platform for target and therapeutic antibody discovery and development. dr. jennifer bath, president and chief executive officer of immunoprecise antibodies, commented, “the addition of biostrand’s next-generation capabilities in systems omics analysis further enhances ipa’s unique ability to serve as a single-source partner to support our clients’ in silico, in vitro and in vivo research, further solidifying our position as the leading, early-stage antibody discovery contract research organization. a previously undisclosed collaboration with biostrand has already generated unique and intriguing data and we are confident that our clients and partners will find the addition of biostrand’s offerings both advantageous and transformational for their research programs. we believe the acquisition of biostrand, recently referred to as the “google of genomics”, is a blockbuster move, brings together a revolutionary combination that will change the way researchers approach and complete target and antibody discovery, and that our combined platforms, once integrated, will attract new business opportunities at an accelerated rate. we are excited to add biostrand to the ipa family.” the transaction pursuant to the spa, immunoprecise netherlands b.v. will acquire i) all of the issued and outstanding shares of idea family bv, a private limited liability company holding 75.01% of the issued and outstanding shares of biostrand and ii) the remaining 24.99% of the issued and outstanding shares of biostrand, the whole for a total consideration of approximately € 20 million, plus a potential earnout consideration. the purchase price will be satisfied as follows: • approximately € 2 million payable in cash, of which € 1 million will be subject to holdback. a sum of € 500,000 will be held back for a period of 90 days after closing of the transaction for adjustment purposes and € 500,000 of the cash consideration will be held back and progressively released over a 3-year period to guarantee the obligations of the vendors under the spa; • a number of common shares of ipa to be issued at closing, the value per common share to be determined based on the 30-day volume-weighted average price of the common shares (vwap) ending on the trading day immediately prior to the date of closing, representing no greater than 19.99% of the issued and outstanding common shares of ipa immediately prior to closing, for an aggregate deemed value of € 18 million. in the event the issuance cap is reached, ipa will make a cash payment to the vendors equal to the value of the common shares that were not issued as a result of the issuance cap, based on the vwap of the common shares as of the closing date; and • a contingent earnout payment based on the profitability of biostrand over a 7-year period, which shall not exceed in total € 12 million. other key deal terms • biostrand is being acquired on a debt-free, cash-free basis; • investment consideration provided by ipa to biostrand of aggregate amount of € 6 million in the form of a loan or in the form of equity over a period of 3 years for operation expenses, development of biostrand’s platform, and correction of deficiencies; • customary representations and warranties in the spa; • customary indemnities for breaches of representations and warranties and breaches of covenants in the spa; • the equity consideration will be subject to a 4-month statutory resale restriction period pursuant to canadian securities laws, as well as a contractual escrow agreement to be entered into at closing between the vendors, ipa, and an escrow agent, providing for the gradual release of the common shares over a 3-year period. • key personnel, including the founders of biostrand and other members of the executive team of biostrand, will continue their employment with updated management agreements; • non-competition and non-solicitation agreements will be entered into, as a condition of closing, with certain principals of biostrand; • each of biostrand and the biostrand shareholders are arm’s length parties to the company; • the purchase price is subject to working capital and other adjustments; • closing of the transaction is expected to occur on or before april 15, 2022, subject to receipt of all applicable approvals and the satisfaction of applicable conditions to closing; • the other closing conditions in the spa are customary, including, but not limited to, the receipt of all necessary regulatory approvals and the required notifications to nasdaq with respect to the issuance of ipa’s common shares; and • the transaction is an “expedited acquisition” under policy 5.3 of the tsx venture exchange. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. the company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development, against rare and/or challenging epitopes. for further information, visit www.ipatherapeutics.com. about biostrand bv biostrand bv is a private limited liability company, incorporated under the laws of belgium. the business of biostrand bv focuses on technology, in the field of bioinformatics and biotechnology, for handling of biological sequences including for example processing, storing and comparing biological sequence information, and for generating biological sequence information, software development, algorithms, data visualisation and visual analytics, which can for example be applied in the field of molecular diagnostics, point of care testing, in depth analysis for drug development, prediction, construction and adaptation of biopolymer sequences as well as a product, service, or tool which stores this information in a database. about biokey bv biokey bv is a private limited liability company, incorporated under the laws of belgium. the business of biokey bv focuses on technology, in the field of bioinformatics and biotechnology, related to the identification of characteristic biological sequences in proteins, rna and dna, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences. about bioclue bv bioclue bv is a private limited liability company, incorporated under the laws of belgium. the business of bioclue bv focuses on technology, in the field of bioinformatics and biotechnology, for performing, inherently linked with a microarray process and possible primary analysis, a secondary analysis, whether or not performed simultaneously with the primary analysis, consisting of read mapping, read assembly – de novo or reference based – and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, rna and dna, including through mass spectrometry, sequencing, micro array or hybrid microarray system technologies. investor contact: lifesci advisors john mullaly email: jmullaly@lifesciadvisors.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release include, but are not limited to, statements regarding the transaction, expectations regarding synergies from the transaction and the ability to integrate biostrand into the company’s business, pro forma financial estimates, including revenue, the opportunities presented by the transaction, synergies and expansion opportunities, the expansion of the company’s knowledge lifecycle, the expected closing of the transaction, the receipt of all necessary regulatory approvals and satisfaction of all other closing conditions and the projected impact of completion of the transaction on the company’s business, financial conditions and results. in respect of the forward-looking information contained herein, the company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the company may not be successful in timely completing the transaction, the necessary approvals are not obtained or some other condition to the closing of the transaction is not satisfied, as well as those risks discussed in the company’s annual information form dated july 27, 2021 (which may be viewed on the company’s profile at www.sedar.com) and the company’s form 40-f, amendment no. 1 dated september 28, 2021 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. there is no guarantee that the transaction will close at all, or in the time frame anticipated, or on the terms as originally negotiated. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. neither the tsx venture exchange nor its regulation services provider (as that term is defined in policies of the tsx venture exchange) accepts responsibility for the adequacy or accuracy of this release. source immunoprecise antibodies